<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.1 20151215//EN"  "JATS-archivearticle1.dtd"><article article-type="research-article" dtd-version="1.1" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink"><front><journal-meta><journal-id journal-id-type="nlm-ta">elife</journal-id><journal-id journal-id-type="publisher-id">eLife</journal-id><journal-title-group><journal-title>eLife</journal-title></journal-title-group><issn pub-type="epub" publication-format="electronic">2050-084X</issn><publisher><publisher-name>eLife Sciences Publications, Ltd</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">59616</article-id><article-id pub-id-type="doi">10.7554/eLife.59616</article-id><article-categories><subj-group subj-group-type="display-channel"><subject>Research Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Medicine</subject></subj-group></article-categories><title-group><article-title>Health benefits attributed to 17α-estradiol, a lifespan-extending compound, are mediated through estrogen receptor α</article-title></title-group><contrib-group><contrib contrib-type="author" id="author-195925"><name><surname>Mann</surname><given-names>Shivani N</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="other" rid="fund8"/><xref ref-type="other" rid="fund2"/><xref ref-type="fn" rid="con1"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-195926"><name><surname>Hadad</surname><given-names>Niran</given-names></name><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="fn" rid="con2"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-86581"><name><surname>Nelson Holte</surname><given-names>Molly</given-names></name><xref ref-type="aff" rid="aff5">5</xref><xref ref-type="fn" rid="con3"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-195927"><name><surname>Rothman</surname><given-names>Alicia R</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con4"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-195928"><name><surname>Sathiaseelan</surname><given-names>Roshini</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con5"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-195929"><name><surname>Ali Mondal</surname><given-names>Samim</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con6"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-195930"><name><surname>Agbaga</surname><given-names>Martin-Paul</given-names></name><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="aff" rid="aff6">6</xref><xref ref-type="aff" rid="aff7">7</xref><xref ref-type="other" rid="fund7"/><xref ref-type="fn" rid="con7"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-195931"><name><surname>Unnikrishnan</surname><given-names>Archana</given-names></name><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="aff" rid="aff8">8</xref><xref ref-type="fn" rid="con8"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-185228"><name><surname>Subramaniam</surname><given-names>Malayannan</given-names></name><xref ref-type="aff" rid="aff5">5</xref><xref ref-type="other" rid="fund6"/><xref ref-type="fn" rid="con9"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-195932"><name><surname>Hawse</surname><given-names>John</given-names></name><xref ref-type="aff" rid="aff5">5</xref><xref ref-type="fn" rid="con10"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-171987"><name><surname>Huffman</surname><given-names>Derek M</given-names></name><xref ref-type="aff" rid="aff9">9</xref><xref ref-type="fn" rid="con11"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-54050"><name><surname>Freeman</surname><given-names>Willard M</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">http://orcid.org/0000-0001-7027-999X</contrib-id><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="aff" rid="aff10">10</xref><xref ref-type="aff" rid="aff11">11</xref><xref ref-type="other" rid="fund4"/><xref ref-type="other" rid="fund5"/><xref ref-type="fn" rid="con12"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" corresp="yes" id="author-191020"><name><surname>Stout</surname><given-names>Michael B</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-9996-9123</contrib-id><email>michael-stout@ouhsc.edu</email><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="other" rid="fund1"/><xref ref-type="other" rid="fund2"/><xref ref-type="other" rid="fund9"/><xref ref-type="other" rid="fund3"/><xref ref-type="fn" rid="con13"/><xref ref-type="fn" rid="conf1"/></contrib><aff id="aff1"><label>1</label><institution>Department of Nutritional Sciences, University of Oklahoma Health Sciences Center</institution><addr-line><named-content content-type="city">Oklahoma City</named-content></addr-line><country>United States</country></aff><aff id="aff2"><label>2</label><institution>Oklahoma Center for Geroscience, University of Oklahoma Health Sciences Center</institution><addr-line><named-content content-type="city">Oklahoma City</named-content></addr-line><country>United States</country></aff><aff id="aff3"><label>3</label><institution>Harold Hamm Diabetes Center, University of Oklahoma Health Sciences Center</institution><addr-line><named-content content-type="city">Oklahoma City</named-content></addr-line><country>United States</country></aff><aff id="aff4"><label>4</label><institution>The Jackson Laboratory</institution><addr-line><named-content content-type="city">Bar Harbor</named-content></addr-line><country>United States</country></aff><aff id="aff5"><label>5</label><institution>Department of Biochemistry and Molecular Biology, Mayo Clinic</institution><addr-line><named-content content-type="city">Rochester</named-content></addr-line><country>United States</country></aff><aff id="aff6"><label>6</label><institution>Department of Cell Biology, University of Oklahoma Health Sciences Center</institution><addr-line><named-content content-type="city">Oklahoma City</named-content></addr-line><country>United States</country></aff><aff id="aff7"><label>7</label><institution>Dean McGee Eye Institute, University of Oklahoma Health Sciences Center</institution><addr-line><named-content content-type="city">Oklahoma City</named-content></addr-line><country>United States</country></aff><aff id="aff8"><label>8</label><institution>Department of Biochemistry and Molecular Biology, University of Oklahoma Health Sciences Center</institution><addr-line><named-content content-type="city">Oklahoma City</named-content></addr-line><country>United States</country></aff><aff id="aff9"><label>9</label><institution>Department of Molecular Pharmacology, Albert Einstein College of Medicine</institution><addr-line><named-content content-type="city">New York</named-content></addr-line><country>United States</country></aff><aff id="aff10"><label>10</label><institution>Genes &amp; Human Disease Research Program, Oklahoma Medical Research Foundation</institution><addr-line><named-content content-type="city">Oklahoma City</named-content></addr-line><country>United States</country></aff><aff id="aff11"><label>11</label><institution>Oklahoma City Veterans Affairs Medical Center</institution><addr-line><named-content content-type="city">Oklahoma City</named-content></addr-line><country>United States</country></aff></contrib-group><contrib-group content-type="section"><contrib contrib-type="senior_editor"><name><surname>Tyler</surname><given-names>Jessica K</given-names></name><role>Senior Editor</role><aff><institution>Weill Cornell Medicine</institution><country>United States</country></aff></contrib><contrib contrib-type="editor"><name><surname>Buffenstein</surname><given-names>Rochelle</given-names></name><role>Reviewing Editor</role><aff><institution>Calico Life Sciences, LLC</institution><country>United States</country></aff></contrib></contrib-group><pub-date date-type="publication" publication-format="electronic"><day>08</day><month>12</month><year>2020</year></pub-date><pub-date pub-type="collection"><year>2020</year></pub-date><volume>9</volume><elocation-id>e59616</elocation-id><history><date date-type="received" iso-8601-date="2020-06-03"><day>03</day><month>06</month><year>2020</year></date><date date-type="accepted" iso-8601-date="2020-12-07"><day>07</day><month>12</month><year>2020</year></date></history><permissions><copyright-statement>© 2020, Mann et al</copyright-statement><copyright-year>2020</copyright-year><copyright-holder>Mann et al</copyright-holder><ali:free_to_read/><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><ali:license_ref>http://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This article is distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use and redistribution provided that the original author and source are credited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="elife-59616-v2.pdf"/><abstract><p>Metabolic dysfunction underlies several chronic diseases, many of which are exacerbated by obesity. Dietary interventions can reverse metabolic declines and slow aging, although compliance issues remain paramount. 17α-estradiol treatment improves metabolic parameters and slows aging in male mice. The mechanisms by which 17α-estradiol elicits these benefits remain unresolved. Herein, we show that 17α-estradiol elicits similar genomic binding and transcriptional activation through estrogen receptor α (ERα) to that of 17β-estradiol. In addition, we show that the ablation of ERα completely attenuates the beneficial metabolic effects of 17α-E2 in male mice. Our findings suggest that 17α-E2 may act through the liver and hypothalamus to improve metabolic parameters in male mice. Lastly, we also determined that 17α-E2 improves metabolic parameters in male rats, thereby proving that the beneficial effects of 17α-E2 are not limited to mice. Collectively, these studies suggest ERα may be a drug target for mitigating chronic diseases in male mammals.</p></abstract><kwd-group kwd-group-type="author-keywords"><kwd>17α-estradiol</kwd><kwd>aging</kwd><kwd>estrogen receptor</kwd><kwd>hypothalamus</kwd><kwd>metabolism</kwd><kwd>obesity</kwd></kwd-group><kwd-group kwd-group-type="research-organism"><title>Research organism</title><kwd>Mouse</kwd><kwd>Rat</kwd></kwd-group><funding-group><award-group id="fund1"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000002</institution-id><institution>National Institutes of Health</institution></institution-wrap></funding-source><award-id>R00 AG51661</award-id><principal-award-recipient><name><surname>Stout</surname><given-names>Michael B</given-names></name></principal-award-recipient></award-group><award-group id="fund2"><funding-source><institution-wrap><institution>Harold Hamm Diabetes Center</institution></institution-wrap></funding-source><award-id>Pilot Research Funding</award-id><principal-award-recipient><name><surname>Mann</surname><given-names>Shivani N</given-names></name><name><surname>Stout</surname><given-names>Michael B</given-names></name></principal-award-recipient></award-group><award-group id="fund3"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000002</institution-id><institution>National Institutes of Health</institution></institution-wrap></funding-source><award-id>R01 AG069742</award-id><principal-award-recipient><name><surname>Stout</surname><given-names>Michael B</given-names></name></principal-award-recipient></award-group><award-group id="fund4"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000002</institution-id><institution>National Institutes of Health</institution></institution-wrap></funding-source><award-id>R01 AG059430</award-id><principal-award-recipient><name><surname>Freeman</surname><given-names>Willard M</given-names></name></principal-award-recipient></award-group><award-group id="fund5"><funding-source><institution-wrap><institution>Veterans Affairs Oklahoma City</institution></institution-wrap></funding-source><award-id>I01BX003906</award-id><principal-award-recipient><name><surname>Freeman</surname><given-names>Willard M</given-names></name></principal-award-recipient></award-group><award-group id="fund6"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100007927</institution-id><institution>University of Oklahoma Health Sciences Center</institution></institution-wrap></funding-source><award-id>P30 EY012190</award-id><principal-award-recipient><name><surname>Agbaga</surname><given-names>Martin-Paul</given-names></name></principal-award-recipient></award-group><award-group id="fund7"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000002</institution-id><institution>National Institutes of Health</institution></institution-wrap></funding-source><award-id>R01 EY030513</award-id><principal-award-recipient><name><surname>Agbaga</surname><given-names>Martin-Paul</given-names></name></principal-award-recipient></award-group><award-group id="fund8"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000002</institution-id><institution>National Institutes of Health</institution></institution-wrap></funding-source><award-id>T32 AG052363</award-id><principal-award-recipient><name><surname>Mann</surname><given-names>Shivani N</given-names></name></principal-award-recipient></award-group><award-group id="fund9"><funding-source><institution-wrap><institution>Einstein Nathan Shock Center</institution></institution-wrap></funding-source><award-id>P30 AG038072</award-id><principal-award-recipient><name><surname>Stout</surname><given-names>Michael B</given-names></name></principal-award-recipient></award-group><funding-statement>The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.</funding-statement></funding-group><custom-meta-group><custom-meta specific-use="meta-only"><meta-name>Author impact statement</meta-name><meta-value>17α-Estradiol, a life-span extending compound, signals through estrogen receptor α (ERα) in the liver and hypothalamus to elicit health benefits in a sex-specific manner.</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="s1" sec-type="intro"><title>Introduction</title><p>Aging is the leading risk factor for most chronic diseases, many of which are associated with declines in metabolic homeostasis (<xref ref-type="bibr" rid="bib73">López-Otín et al., 2013</xref>). Metabolic detriments associated with advancing age are further exacerbated by obesity (<xref ref-type="bibr" rid="bib135">Villareal et al., 2005</xref>; <xref ref-type="bibr" rid="bib137">Waters et al., 2013</xref>), which has risen substantially in the older population (&gt;65 years) over the past several decades (<xref ref-type="bibr" rid="bib28">Flegal et al., 2010</xref>; <xref ref-type="bibr" rid="bib29">Flegal et al., 2016</xref>). Moreover, obesity in mid-life has been shown to accelerate aging mechanisms and induce phenotypes more commonly observed in older mammals (<xref ref-type="bibr" rid="bib9">Bischof and Park, 2015</xref>; <xref ref-type="bibr" rid="bib47">Horvath et al., 2014</xref>; <xref ref-type="bibr" rid="bib88">Nevalainen et al., 2017</xref>; <xref ref-type="bibr" rid="bib144">Yang et al., 2009</xref>; <xref ref-type="bibr" rid="bib139">Whitmer et al., 2005a</xref>; <xref ref-type="bibr" rid="bib140">Whitmer et al., 2005b</xref>; <xref ref-type="bibr" rid="bib24">Dye et al., 2017</xref>). These observations have led many to postulate that obesity may represent a mild progeria syndrome (<xref ref-type="bibr" rid="bib106">Salvestrini et al., 2019</xref>; <xref ref-type="bibr" rid="bib132">Tzanetakou et al., 2012</xref>; <xref ref-type="bibr" rid="bib94">Pérez et al., 2016</xref>; <xref ref-type="bibr" rid="bib125">Tchkonia et al., 2010</xref>; <xref ref-type="bibr" rid="bib118">Stout et al., 2017a</xref>). Although it is well established that dietary interventions, including calorie restriction, can reverse obesity-related metabolic sequelae, many of these strategies are not well tolerated in older patients due to concomitant comorbidities (<xref ref-type="bibr" rid="bib135">Villareal et al., 2005</xref>; <xref ref-type="bibr" rid="bib52">Jensen et al., 2014</xref>). Compliance issues across all age groups also remain a paramount hurdle due to calorie restriction adversely affecting mood, thermoregulation, and musculoskeletal mass (<xref ref-type="bibr" rid="bib20">Dirks and Leeuwenburgh, 2006</xref>). These adverse health outcomes demonstrate the need for pharmacological approaches aimed at curtailing metabolic perturbations associated with obesity and aging.</p><p>17α-estradiol (17α-E2) is one of the more recently studied compounds to demonstrate efficacy for beneficially modulating obesity- and age-related health outcomes. The NIA Interventions Testing Program (ITP) found that long-term administration of 17α-E2 extends median lifespan of male mice in a dose-dependent manner (<xref ref-type="bibr" rid="bib120">Strong et al., 2016</xref>; <xref ref-type="bibr" rid="bib44">Harrison et al., 2014</xref>). Our group has been exploring potential mechanisms by which 17α-E2 may improve healthspan and extend lifespan in a sex-specific manner. We have found that 17α-E2 administration reduces calorie intake and regional adiposity in combination with significant improvements in a multitude of systemic metabolic parameters in both middle-aged obese and old male mice without inducing deleterious effects (<xref ref-type="bibr" rid="bib119">Stout et al., 2017b</xref>; <xref ref-type="bibr" rid="bib115">Steyn et al., 2018</xref>; <xref ref-type="bibr" rid="bib82">Miller, 2020</xref>). Other groups have also determined that lifelong administration of 17α-E2 beneficially modulates metabolic outcomes, including glucose tolerance, mTORC2 signaling, and hepatic amino acid composition and markers of urea cycling, which were reported to be dependent upon the presence of endogenous androgens (<xref ref-type="bibr" rid="bib32">Garratt et al., 2017</xref>; <xref ref-type="bibr" rid="bib33">Garratt et al., 2018</xref>). Additionally, multiple lifespan extending compounds, including 17α-E2, exhibit similar modifications in liver function (<xref ref-type="bibr" rid="bib131">Tyshkovskiy et al., 2019</xref>). In all, recent studies by several independent laboratories strongly indicate that the lifespan-extending effects of 17α-E2 are at least associated with, if not dependent on, metabolic improvements.</p><p>Despite the mounting evidence demonstrating that 17α-E2 improves numerous health parameters, the signaling mechanism(s) and primary tissues through which 17α-E2 elicits these benefits remain unknown. Although 17α-E2 is a naturally occurring enantiomer to 17β-estradiol (17β-E2), it has been postulated that 17α-E2 signals through a novel uncharacterized receptor (<xref ref-type="bibr" rid="bib128">Toran-Allerand, 2005</xref>; <xref ref-type="bibr" rid="bib127">Toran-Allerand et al., 2002</xref>; <xref ref-type="bibr" rid="bib129">Toran-Allerand et al., 2005</xref>; <xref ref-type="bibr" rid="bib40">Green and Simpkins, 2000</xref>) as opposed to classical estrogen receptors α (ERα) and β (ERβ), which is due to 17α-E2 having significantly reduced binding affinity for ERα and ERβ as compared to 17β-E2 (<xref ref-type="bibr" rid="bib25">Edwards and McGUIRE, 1980</xref>; <xref ref-type="bibr" rid="bib61">Korenman, 1969</xref>; <xref ref-type="bibr" rid="bib69">Littlefield et al., 1990</xref>; <xref ref-type="bibr" rid="bib4">Anstead et al., 1997</xref>). For this reason, 17α-E2 is often referred to as a non-feminizing estrogen (<xref ref-type="bibr" rid="bib40">Green and Simpkins, 2000</xref>; <xref ref-type="bibr" rid="bib27">Engler-Chiurazzi et al., 2017</xref>; <xref ref-type="bibr" rid="bib53">Kaur et al., 2015</xref>). A few studies have suggested that a novel but uncharacterized estrogen receptor, termed ER-X, may mediate 17α-E2 actions in the brain (<xref ref-type="bibr" rid="bib128">Toran-Allerand, 2005</xref>; <xref ref-type="bibr" rid="bib127">Toran-Allerand et al., 2002</xref>; <xref ref-type="bibr" rid="bib129">Toran-Allerand et al., 2005</xref>; <xref ref-type="bibr" rid="bib40">Green and Simpkins, 2000</xref>), although more recent studies supporting this hypothesis are lacking in the literature. Similarly, no reports to date have directly tested whether the doses of 17α-E2 shown to improve healthspan and lifespan in mice are mediated through ERα and/or ERβ.</p><p>There is a multitude of data in the diabetes and metabolism literature demonstrating that ERα is a regulator of systemic metabolic parameters. Although most of these studies have historically been performed in female mammals, more recent studies have demonstrated that ERα also plays a critical role in modulating metabolism in male mammals. For instance, Allard and colleagues recently demonstrated that genomic actions of ERα regulate systemic glucose homeostasis in mice of both sexes and insulin production and release in males (<xref ref-type="bibr" rid="bib3">Allard et al., 2019</xref>). Other studies have also determined that hepatic steatosis and insulin sensitivity, and therefore the control of gluconeogenesis, are regulated through FOXO1 in an ERα-dependent manner in male mice (<xref ref-type="bibr" rid="bib143">Yan et al., 2019</xref>). Furthermore, hepatocyte-specific deletion of ERα was sufficient to abrogate similar estrogen-mediated metabolic benefits (<xref ref-type="bibr" rid="bib41">Guillaume et al., 2019</xref>; <xref ref-type="bibr" rid="bib98">Qiu et al., 2017</xref>; <xref ref-type="bibr" rid="bib80">Meda et al., 2020</xref>). Given that several reports have linked the administration of 17α-E2 to improvements in metabolic homeostasis, we hypothesized that 17α-E2 signals through ERα to modulate hepatic function and systemic metabolism, thereby potentially contributing to the lifespan-extending effects of 17α-E2.</p><p>The work outlined in this report sought to determine if ERα is the primary receptor by 17α-E2 signals and modulates health parameters in mice. We initially determined that 17α-E2 and 17β-E2 elicit similar genomic actions through ERα. Given that no studies to date have tested the potential role of ERα in modulating 17α-E2-mediated effects in vivo, we treated obese wild type (WT) and ERα knockout (ERα KO) littermate mice with 17α-E2 to determine if the ablation of ERα could attenuate 17α-E2-induced benefits on adiposity, metabolic homeostasis, and hepatic function. We found that the ablation of ERα completely attenuated all beneficial metabolic effects of 17α-E2. Follow-up studies in male WT rats undergoing hyperinsulinemic-euglycemic clamps revealed that 17α-E2 modulates hepatic insulin sensitivity following acute exposure. Given the established connection between the hypothalamus and liver in the modulation of hepatic insulin sensitivity (<xref ref-type="bibr" rid="bib59">Könner et al., 2007</xref>; <xref ref-type="bibr" rid="bib105">Ruud et al., 2017</xref>; <xref ref-type="bibr" rid="bib96">Pocai et al., 2005a</xref>; <xref ref-type="bibr" rid="bib97">Pocai et al., 2005b</xref>; <xref ref-type="bibr" rid="bib22">Dodd et al., 2018</xref>), coupled with our data demonstrating ERα-dependency of 17α-E2 actions on metabolic parameters, we speculate that 17α-E2 acts through ERα in the liver and/or hypothalamus to improve metabolic homeostasis in male mammals.</p></sec><sec id="s2" sec-type="results"><title>Results</title><sec id="s2-1"><title>17α-E2 and 17β-E2 similarly modulate genomic binding and transcriptional activity of ERα</title><p>Ligand-mediated ERα dimerization leads to nuclear translocation and transcriptional activity. Previous work has shown that 17α-E2 and 17β-E2 can bind to ERα with different affinities (<xref ref-type="bibr" rid="bib25">Edwards and McGUIRE, 1980</xref>; <xref ref-type="bibr" rid="bib61">Korenman, 1969</xref>; <xref ref-type="bibr" rid="bib69">Littlefield et al., 1990</xref>; <xref ref-type="bibr" rid="bib4">Anstead et al., 1997</xref>), yet potential differences in resultant genomic binding and transcriptional activity between the two ligands remains unexplored. We assessed ERα DNA binding and transcriptional induction following exposure to 17β-E2 (10 nM) or 17α-E2 (10 nM or 100 nM) in U2OS cells that stably express ERα following doxycycline induction. We chose to use these cells because they do not endogenously express any form of ERα or ERβ and have been extensively utilized to elucidate the effects of ERα and ERβ agonists and antagonists on gene expression (<xref ref-type="bibr" rid="bib83">Monroe et al., 2003</xref>; <xref ref-type="bibr" rid="bib84">Monroe et al., 2005</xref>). ChIP-sequencing revealed peaks of ERα genomic binding in all conditions, that when compared, are qualitatively similar across treatments (<xref ref-type="fig" rid="fig1">Figure 1A</xref>). Statistically significant differences in ERα binding were determined by negative binomial regression with a Wald’s pairwise post-hoc comparison (false discovery rate correction, FDR &lt; 0.05). A total of 21,443 peaks were found to have a significant pairwise post-hoc comparison between vehicle and 17α-E2 and/or 17β-E2 treated cells. No statistically significant differences between 17α-E2 and 17β-E2-treated groups were observed. 17α-E2 and 17β-E2 not only induced ERα binding at the same genomic locations but also to similar magnitudes. Comparing the levels of increased or decreased ERα binding (as compared to vehicle control) between treatments demonstrates the consistency of ERα genomic binding regardless of the agonist (<xref ref-type="fig" rid="fig1">Figure 1B</xref>, <xref ref-type="supplementary-material" rid="supp1">Supplementary file 1</xref>). The degree of increased or decreased ERα binding was highly similar between 10 nM 17α-E2 and 10 nM 17β-E2, (Pearson’s r = 0.95, p&lt;0.001) and 100 nM 17α-E2 and 10 nM 17β-E2 (Pearson’s r = 0.96, p&lt;0.001). As expected, ERα-binding sites were enriched for estrogen response elements (ERE), estrogen-related receptor beta (Esrrb), and estrogen-related receptor alpha (Erra). Other common motifs found within ER elements, including steroidogenic factor-1 (SF1) (<xref ref-type="bibr" rid="bib67">Lin et al., 2007</xref>), and motif elements of known interacting partners, including retinoid acid receptor:retinoid X receptor (RAR:RXR) (<xref ref-type="bibr" rid="bib63">Lee et al., 1998</xref>), were also enriched (<xref ref-type="fig" rid="fig1">Figure 1C</xref>). In addition, we observed enrichment of androgen response elements (ARE) in ERα peaks (<xref ref-type="fig" rid="fig1">Figure 1C</xref>). Of particular relevance, many of the top enriched motifs identified contained the ERE consensus sequence TTGAC (<xref ref-type="supplementary-material" rid="supp2">Supplementary file 2</xref>). Following motif enrichment, we performed pairwise differential motif enrichment across all groups to determine if a specific agonist or agonist concentration caused a differential enrichment of any motifs, as would be suggestive of differential genomic binding. No differential motif binding was observed across treatment groups indicating that both 17α-E2 and 17β-E2 cause ERα to bind to the same types of genomic elements (Hypergeometric test, FDR &lt; 0.05).</p><fig-group><fig id="fig1" position="float"><label>Figure 1.</label><caption><title>17α-E2 and 17β-E2 elicit similar genomic binding and transcriptional profiles through ERα.</title><p>(<bold>A</bold>) Heatmap representing normalized genome-wide DNA binding by ERα via ChIP sequencing analyses centered according to peak summits for each treatment group and compared to each other group. (<bold>B</bold>) Differential binding was identified between vehicle and 17α-E2 or 17β-E2 treatment groups, but no differences were identified between 17α-E2 and 17β-E2-treated groups (negative binomial regression, followed by Wald test for pairwise comparisons, FDR &lt; 0.05). Fold change in binding relative to vehicle control was compared between 17α-E2 treatments and 17β-E2. (<bold>C</bold>) Motif enrichment analysis, filtered for mammalian and non-overlapping motif groups, showing the top 10 non-redundant enriched sequence motifs across treatment groups (hypergeometric test, FDR &lt; 0.05), (<bold>D</bold>) PCA plot of transcriptional profiles by RNA sequencing analyses demonstrating clustering of 17α-E2 and 17β-E2 treatment groups together, opposite from Vehicle-treated group along the first principle component, and (<bold>E</bold>) Heatmap representing differentially expressed genes (negative binomial regression, followed by Wald test for pairwise comparisons, FDR &lt; 0.05) by RNA sequencing analyses (left) and ERα binding patterns within the gene body ±5 kb flanking regions of these genes via ChIP sequencing (right). Significant differential pairwise expression was observed only between 17α-E2 and 17β-E2 treatment groups and vehicle-treated control. These studies utilized U2OS-ERα cells treated with low dose (10 nM) 17α-E2, high dose (100 nM) 17α-E2, 17β-E2 (10 nM), or vehicle (EtOH). n = 3/group.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-59616-fig1-v2.tif"/></fig><fig id="fig1s1" position="float" specific-use="child-fig"><label>Figure 1—figure supplement 1.</label><caption><title>17α-E2 and 17β-E2 elicit similar ERα binding profile.</title><p>PCA plot of genome-wide ERα binding profiles by ChIP sequencing analyses. U2OS-ERα cells treated with low dose (10 nM) 17α-E2, high dose (100 nM) 17α-E2, or 17β-E2 (10 nM) induced binding in common genomic locations and differed from vehicle (EtOH) treated cells. n = 3/group.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-59616-fig1-figsupp1-v2.tif"/></fig></fig-group><p>Next, we examined potential differences in transcriptional responses between treatment groups using RNA-sequencing. Principle component analysis based on the entire transcriptome revealed that all samples exposed to either 17α-E2 or 17β-E2 clustered together, whereas vehicle-treated cells remained distinctly separated from treated cells on the first principle component, which explains the majority of the variance in transcription (70.6%) (<xref ref-type="fig" rid="fig1">Figure 1D</xref>). These data suggest that treatment vs vehicle is the primary covariate explaining variance in transcriptional profiles, not the specific agonist. Next, differential expression was assessed between all groups using a negative binomial regression model with a Wald pairwise post-hoc test. No genes were found to be differentially regulated (FDR &lt; 0.05) between the estrogen treatments. Yet, compared to vehicle-treated cells, treatment of U2OS cells with either 10 nM or 100 nM 17α-E2 or 10 nM 17β-E2 resulted in nearly identical gene suppression and activation signatures (<xref ref-type="fig" rid="fig1">Figure 1E</xref>, left). Additionally, both 17α-E2 or 17β-E2 treatment conditions resulted in higher ERα DNA binding affinity to gene bodies of these differentially expressed transcripts compared to vehicle treatment, and no differences were observed between 17α-E2 and 17β-E2 conditions (<xref ref-type="fig" rid="fig1">Figure 1E</xref>, right) (negative binomial regression with Wald pairwise post-hoc). These findings led us to postulate that 17α-E2 may be the signaling through ERα to modulate health parameters in male mice. As such, we subsequently sought to determine if the ablation of ERα in vivo would mitigate the effects of 17α-E2.</p></sec><sec id="s2-2"><title>ERα ablation attenuates 17α-E2-mediated benefits on metabolic parameters in male mice in vivo</title><p>To induce obesity and metabolic perturbations in male mice, we administered high-fat diet (HFD) for several months prior to initiating 17α-E2 treatment. Control mice remained on HFD, whereas 17α-E2-treated mice were switched to an identical HFD containing 17α-E2. Almost immediately after 17α-E2 treatment began, male WT mice displayed significant reductions in mass (<xref ref-type="fig" rid="fig2">Figure 2A–B</xref>) and adiposity (<xref ref-type="fig" rid="fig2">Figure 2C–D</xref>). This is aligned with our previous reports demonstrating that 17α-E2 administration quickly reduces body mass and adiposity (<xref ref-type="bibr" rid="bib119">Stout et al., 2017b</xref>; <xref ref-type="bibr" rid="bib115">Steyn et al., 2018</xref>; <xref ref-type="bibr" rid="bib82">Miller, 2020</xref>), which we have linked to hypothalamic regulation of anorexigenic signaling pathways (<xref ref-type="bibr" rid="bib115">Steyn et al., 2018</xref>). Indeed, male WT mice in the current study also displayed robust declines in calorie consumption during the first 4 weeks of treatment (<xref ref-type="fig" rid="fig2">Figure 2E</xref>). Conversely, all these benefits were completely abolished in male mice lacking ERα (ERα KO), thereby confirming that 17α-E2 definitively acts through ERα to modulate feeding behaviors, mass, and adiposity in male mice. Given the close association between adiposity and metabolic homeostasis, coupled with our previous work demonstrating the ability of 17α-E2 to improve metabolic parameters (<xref ref-type="bibr" rid="bib119">Stout et al., 2017b</xref>; <xref ref-type="bibr" rid="bib115">Steyn et al., 2018</xref>), we also assessed several metabolic variables in these studies. Similar to the mass and adiposity data described above, male WT mice receiving 17α-E2 displayed significant improvements in fasting insulin (<xref ref-type="fig" rid="fig3">Figure 3B</xref>), HbA1C (<xref ref-type="fig" rid="fig3">Figure 3C</xref>), and glucose tolerance (<xref ref-type="fig" rid="fig3">Figure 3D–E</xref>, <xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1</xref>), whereas male ERα KO mice receiving 17α-E2 failed to recapitulate these findings. Interestingly, despite the masses of the male WT 17α-E2 treatment group being nearly 15 grams greater than those of the male WT chow-fed controls, glucose tolerance was essentially identical between these groups, thereby indicating that 17α-E2 restores metabolic flexibility in the presence of obesity in male mice (<xref ref-type="fig" rid="fig3">Figure 3D–E</xref>, <xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1</xref>). We also evaluated the effects of 17α-E2 on metabolic parameters in female WT and ERα KO mice provided a standard chow diet. In contrast to the males, we chose not to subject female WT and ERα KO mice to HFD because female ERα KO mice spontaneously develop obesity due to the ablation of ERα (<xref ref-type="bibr" rid="bib79">Manrique et al., 2012</xref>; <xref ref-type="bibr" rid="bib134">Vidal et al., 1999</xref>). Given that the female ERα KO mice are already in a challenged state, HFD would further exacerbate mass and adiposity differences between ERα KO and WT female mice. We found that 17α-E2 failed to elicit improvements in mass, adiposity, calorie consumption, or metabolic parameters in female mice of either genotype (<xref ref-type="fig" rid="fig3s2">Figure 3—figure supplement 2</xref>). The positive effects of 17α-E2 in male mice led us to speculate that the liver may play a key role in modulating 17α-E2-mediated effects on systemic metabolic homeostasis. Importantly, several studies have implicated hepatic ERα in the regulation of glucose homeostasis, insulin sensitivity, and crosstalk with hypothalamic neurons that modulate metabolism and feeding behavior (<xref ref-type="bibr" rid="bib80">Meda et al., 2020</xref>; <xref ref-type="bibr" rid="bib130">Torre et al., 2017</xref>; <xref ref-type="bibr" rid="bib7">Barros and Gustafsson, 2011</xref>).</p><fig id="fig2" position="float"><label>Figure 2.</label><caption><title>ERα is required for 17α-E2 to reduce mass, adiposity, and calorie intake in male mice.</title><p>(<bold>A</bold>) Percent change in mass (mean ± SEM, two-way repeated measures ANOVA with Holm-Sidak post-hoc; *p&lt;0.05, **p&lt;0.005 between WT HFD and WT HFD+17α), (<bold>B</bold>) Mass at baseline (week 0; solid) and week 14 (striped) (mean ± SEM, two-way repeated measures ANOVA with Holm-Sidak post-hoc; *p&lt;0.05, **p&lt;0.005), (<bold>C</bold>) Percent change in fat mass (mean ± SEM, two-way repeated measures ANOVA with Holm-Sidak post-hoc; *p&lt;0.05, **p&lt;0.005), (<bold>D</bold>) Fat mass at baseline (week 0; solid) and week 14 (striped) (mean ± SEM, two-way repeated measures ANOVA with Holm-Sidak post-hoc; *p&lt;0.05, **p&lt;0.005), and (<bold>E</bold>) Average daily calorie intake per week in WT and ERα KO mice provided 45% HFD (TestDiet 58V8)±17α-E2 (14.4ppm) (mean ± SEM, two-way repeated measures ANOVA with Holm-Sidak post-hoc; *p&lt;0.05, **p&lt;0.005). Age-matched, male WT, chow-fed (TestDiet 58YP) mice were also evaluated as a normal-weight reference group and the corresponding means are depicted as dashed gray lines. n = 10 (WT HFD), 10 (WT HFD+17α), 9 (KO HFD), 10 (KO HFD+17α), 12–15 (WT Chow).</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-59616-fig2-v2.tif"/></fig><fig-group><fig id="fig3" position="float"><label>Figure 3.</label><caption><title>17α-E2 reverses obesity-related metabolic dysfunction in male WT, but not ERα KO, mice.</title><p>(<bold>A</bold>) Fasting glucose (mean ± SEM, two-way repeated measures ANOVA), (<bold>B</bold>) Fasting insulin (mean ± SEM, two-way repeated measures ANOVA with Holm-Sidak post-hoc; *p&lt;0.05, **p&lt;0.005), and (<bold>C</bold>) glycosylated hemoglobin (HbA1c) at baseline (week 0; solid) and week 14 (striped) in WT and ERα KO mice provided 45% HFD (TestDiet 58V8)±17α-E2 (14.4 ppm) (mean ± SEM, two-way repeated measures ANOVA with Holm-Sidak post-hoc; **p&lt;0.005). (<bold>D</bold>) Glucose tolerance testing (GTT; 1 mg/kg) (mean ± SEM, two-way repeated measures ANOVA with Holm-Sidak post-hoc; *p&lt;0.05 between WT HFD and WT HFD+17α), and (<bold>E</bold>) GTT AUC during week 10 of the study (mean ± SEM, two-way ANOVA with Holm-Sidak post-hoc; *p&lt;0.05). Age-matched, male WT, chow-fed (TestDiet 58YP) mice were also evaluated as a normal-weight reference group and the corresponding means are depicted as dashed gray lines. n = 9–10 (WT HFD), 8–10 (WT HFD+17α), 9–10 (KO HFD), 8–10 (KO HFD+17α), 12–15 (WT Chow).</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-59616-fig3-v2.tif"/></fig><fig id="fig3s1" position="float" specific-use="child-fig"><label>Figure 3—figure supplement 1.</label><caption><title>17α-E2 reverses obesity-related metabolic dysfunction in male WT, but not ERα KO, mice.</title><p>(<bold>A</bold>) Glucose tolerance testing (GTT; 1 mg/kg), normalized to baseline (min 0) (mean ± SEM, two-way repeated measures ANOVA with Holm-Sidak post-hoc; *p&lt;0.05 between WT HFD and WT HFD+17α), and (<bold>B</bold>) Normalized GTT AUC in WT and ERα KO mice provided 45% HFD (TestDiet 58V8)±17α-E2 (14.4ppm) for 10 weeks (mean ± SEM, two-way ANOVA with Holm-Sidak post-hoc; *p&lt;0.05). Age-matched, male WT, chow-fed (TestDiet 58YP) mice were also evaluated as a normal-weight reference group and the corresponding means are depicted as dashed gray lines. n = 10 (WT HFD), 8 (WT HFD+17α), 9 (KO HFD), 8 (KO HFD+17α), 12 (WT Chow).</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-59616-fig3-figsupp1-v2.tif"/></fig><fig id="fig3s2" position="float" specific-use="child-fig"><label>Figure 3—figure supplement 2.</label><caption><title>17α-E2 fails to alter metabolic parameters in WT or ERα KO female mice.</title><p>(<bold>A</bold>) Mass at baseline (week 0; solid) and week 4 (striped) (mean ± SEM, two-way repeated measures ANOVA), (<bold>B</bold>) Fat mass at baseline (week 0; solid) and week 4 (striped) (mean ± SEM, two-way repeated measures ANOVA), (<bold>C</bold>) Average daily calorie intake per week (mean ± SEM, two-way repeated measures ANOVA), (<bold>D</bold>) Fasting glucose during week 4 (mean ± SEM, two-way repeated measures ANOVA), and (<bold>E</bold>) Fasting insulin during week 4 in WT and ERα KO female mice provided chow (TestDiet 58YP)±17α-E2 (14.4ppm) (mean ± SEM, two-way repeated measures ANOVA). n = 9 (WT Chow), 9 (WT 17α), 11 (KO Chow), 9 (KO 17α).</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-59616-fig3-figsupp2-v2.tif"/></fig></fig-group></sec><sec id="s2-3"><title>17α-E2 improves liver disease pathology in an ERα-dependent manner in male mice</title><p>We previously reported that 17α-E2 alters hepatic lipid deposition and DNA damage responses in male mice through unknown mechanisms (<xref ref-type="bibr" rid="bib119">Stout et al., 2017b</xref>). In the current study, we sought to determine if these findings are mediated through ERα. We found that 17α-E2 significantly reduced liver mass and steatosis in male WT, but not ERα KO mice, as evidenced by reductions in oil-red-O positivity, fatty acid content, and triglyceride accumulation (<xref ref-type="fig" rid="fig4">Figure 4</xref>, <xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1</xref>). These observations were accompanied by significant alterations in gene expression associated with de novo lipogenesis (fatty acid synthase [<italic>Fasn</italic>]) and β-oxidation (peroxisome proliferator-activated receptor alpha [<italic>Pparα</italic>]; sterol regulatory element binding transcription factor 1 [<italic>Srebf1</italic>]) (<xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1</xref>). These findings are similar to previous reports showing that 17β-E2 acts through ERα to modulate the expression and activity of genes that regulate hepatic lipid metabolism (<xref ref-type="bibr" rid="bib19">Della Torre et al., 2016</xref>; <xref ref-type="bibr" rid="bib121">Stubbins et al., 2012</xref>; <xref ref-type="bibr" rid="bib149">Zhang et al., 2013</xref>). Interestingly, despite seeing overall reductions in hepatic fatty acid content with 17α-E2 treatment in male WT mice (<xref ref-type="fig" rid="fig4">Figure 4C</xref>), we also observed elevations in specific fatty acids in these mice as compared to WT HFD controls. Notably, arachidonic acid (AA, 20:4n6) and docosahexaenoic acid (DHA, 22:6n3), both of which are precursors for eicosanoid, resolvin, and protectin production (<xref ref-type="bibr" rid="bib122">Szefel et al., 2015</xref>; <xref ref-type="bibr" rid="bib58">Kohli and Levy, 2009</xref>), were found to be increased by 17α-E2 treatment in male WT mice (<xref ref-type="fig" rid="fig4s2">Figure 4—figure supplement 2</xref>). Our findings are aligned with a previous report by Garratt et al. showing that 17α-E2 increases AA and DHA in liver (<xref ref-type="bibr" rid="bib33">Garratt et al., 2018</xref>). None of the 17α-E2-mediated changes in fatty acid profiles were observed in male ERα KO mice receiving 17α-E2. In response to the elevations in AA and DHA with 17α-E2 treatment, we also assessed circulating eicosanoids. We found that 17α-E2 treatment also mildly altered several circulating eicosanoid concentrations in male WT mice (<xref ref-type="supplementary-material" rid="supp3">Supplementary file 3</xref>). Many of these have been linked to changes in inflammatory signaling (<xref ref-type="bibr" rid="bib57">Kiss et al., 2010</xref>; <xref ref-type="bibr" rid="bib36">Gilroy et al., 2016</xref>), although the role they are playing in 17α-E2-mediated effects of on metabolism and/or aging remain unclear.</p><fig-group><fig id="fig4" position="float"><label>Figure 4.</label><caption><title>17α-E2 reverses obesity-related hepatic steatosis in an ERα-dependent manner in male mice.</title><p>(<bold>A</bold>) Liver mass (mean ± SEM, two-way ANOVA with Holm-Sidak post-hoc; *p&lt;0.05), (<bold>B</bold>) Representative liver oil-red-O staining, (<bold>C</bold>) Liver fatty acids (mean ± SEM, two-way ANOVA with Holm-Sidak post-hoc; **p&lt;0.005), and (<bold>D</bold>) Liver triglycerides in WT and ERα KO mice provided 45% HFD (TestDiet 58V8)±17α-E2 (14.4ppm) for 14 weeks (mean ± SEM, two-way ANOVA with Holm-Sidak post-hoc; **p&lt;0.005). Age-matched, male WT, chow-fed (TestDiet 58YP) mice were also evaluated as a normal-weight reference group and the corresponding means are depicted as dashed gray lines. n = 4–10 (WT HFD), 4–9 (WT HFD+17α), 4–9 (KO HFD), 4–10 (KO HFD+17α), 4–15 (WT Chow).</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-59616-fig4-v2.tif"/></fig><fig id="fig4s1" position="float" specific-use="child-fig"><label>Figure 4—figure supplement 1.</label><caption><title>17α-E2 alters markers of lipid and glucose homeostasis predominantly through ERα in male mice.</title><p>(<bold>A</bold>) Quantification of oil-red-O lipid staining in liver sections from WT and ERα KO mice provided 45% HFD (TestDiet 58V8)±17α-E2 (14.4ppm) for 14 weeks (mean ± SEM, two-way ANOVA with Holm-Sidak post-hoc; *p&lt;0.05). Hepatic gene expression related to (<bold>B</bold>) Lipid metabolism (box plots depict total range of fold changes in gene expression with mean shown as a horizontal black line, Benjamini–Hochberg multiple testing correction, two-way ANOVA with Holm-Sidak post-hoc; *p&lt;0.05, **p&lt;0.005), (<bold>C</bold>) Hepatic insulin resistance (box plots depict total range of fold changes in gene expression with mean shown as a horizontal black line, Benjamini–Hochberg multiple testing correction, two-way ANOVA with Holm-Sidak post-hoc; *p&lt;0.05, **p&lt;0.005), and (<bold>D</bold>) Glucose homeostasis from WT and ERα KO mice provided 45% HFD (TestDiet 58V8)±17α-E2 (14.4ppm) for 14 weeks (box plots depict total range of fold changes in gene expression with mean shown as a horizontal black line, Benjamini–Hochberg multiple testing correction, two-way ANOVA with Holm-Sidak post-hoc; *p&lt;0.05, **p&lt;0.005). Age-matched, male WT, chow-fed (TestDiet 58YP) mice were also evaluated as a normal-weight reference group and the corresponding means are depicted as dashed gray lines. n = 5–10 (WT HFD), 5–9 (WT HFD+17α), 5–7 (KO HFD), 5–10 (KO HFD+17α), 8–11 (WT Chow).</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-59616-fig4-figsupp1-v2.tif"/></fig><fig id="fig4s2" position="float" specific-use="child-fig"><label>Figure 4—figure supplement 2.</label><caption><title>17α-E2 alters the hepatic fatty acid profile in male WT, but not ERα KO, mice.</title><p>Relative molar % of fatty acids in the liver from WT and ERα KO mice provided 45% HFD (TestDiet 58V8)±17α-E2 (14.4ppm) for 14 weeks (mean ± SEM, Benjamini–Hochberg multiple testing correction, two-way ANOVA with Holm-Sidak post-hoc; *p&lt;0.05, **p&lt;0.005). Age-matched, male WT, chow-fed (TestDiet 58YP) mice were also evaluated as a normal-weight reference group and the corresponding means are depicted as dashed gray lines. n = 4.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-59616-fig4-figsupp2-v2.tif"/></fig></fig-group><p>Due to the association between obesity-related hepatic steatosis and the onset of fibrosis, we assessed collagen deposition by trichrome staining and found that 17α-E2 reduced this in male WT, but not ERα KO, mice (<xref ref-type="fig" rid="fig5">Figure 5A</xref>). We also observed significant suppression of several transcripts associated with liver fibrosis in male WT mice receiving 17α-E2, including collagen type 1 alpha 1 (<italic>Col1a1</italic>) (<xref ref-type="bibr" rid="bib45">Hayashi et al., 2014</xref>; <xref ref-type="bibr" rid="bib76">Lua et al., 2016</xref>), cyclin-dependent kinase inhibitor 1A (<italic>Cdkn1a</italic>) (<xref ref-type="bibr" rid="bib16">Crary and Albrecht, 1998</xref>; <xref ref-type="bibr" rid="bib146">Yang et al., 2020</xref>), matrix metallopeptidase 1 (<italic>Mmp1</italic>) (<xref ref-type="bibr" rid="bib66">Lichtinghagen et al., 2003</xref>), matrix metallopeptidase 12 (<italic>Mmp12</italic>) (<xref ref-type="bibr" rid="bib77">Madala et al., 2010</xref>), monocyte chemoattractant protein 1 (<italic>Ccl2</italic>) (<xref ref-type="bibr" rid="bib37">Glass et al., 2018</xref>; <xref ref-type="bibr" rid="bib6">Baeck et al., 2012</xref>), C-X-C motif chemokine ligand 1 (<italic>Cxcl1</italic>) (<xref ref-type="bibr" rid="bib145">Yang et al., 2017</xref>), growth differentiation factor 15 (<italic>Gdf15</italic>) (<xref ref-type="bibr" rid="bib60">Koo et al., 2018</xref>), and TNF receptor superfamily member 1A (<italic>Tnfrsf1a</italic>) (<xref ref-type="bibr" rid="bib39">Grattagliano et al., 2019</xref>; <xref ref-type="fig" rid="fig5">Figure 5B</xref>). Transcripts shown to be predicative of hepatic insulin resistance (follistatin [<italic>Fst</italic>], inhibin subunit beta E [<italic>Inhbe</italic>], insulin receptor substrate 2 [<italic>Irs2</italic>]) (<xref ref-type="bibr" rid="bib123">Tao et al., 2018</xref>; <xref ref-type="bibr" rid="bib92">Parks et al., 2015</xref>) and gluconeogenic plasticity (phosphoenolpyruvate carboxykinase 1 [<italic>Pck1</italic>], pyruvate kinase [<italic>Pkm</italic>]) (<xref ref-type="bibr" rid="bib141">Xiong et al., 2011</xref>) were also beneficially modulated by 17α-E2 in male WT mice (<xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1</xref>). To confirm that 17α-E2 improves hepatic insulin sensitivity, we also evaluated phosphorylation status of AKT and FOXO1 in livers from male WT and ERα KO mice following the administration of an insulin bolus (<xref ref-type="fig" rid="fig5">Figure 5C</xref>). We found dramatic improvements in phosphorylated AKT (pS473) and FOXO1 (pS256) in male WT mice treated with 17α-E2 (<xref ref-type="fig" rid="fig5">Figure 5D–E</xref>), whereas these benefits were not observed in male ERα KO mice. Our findings are aligned with previous reports demonstrating that hepatic ERα plays a critical role in regulating insulin sensitivity in the liver of male mice (<xref ref-type="bibr" rid="bib143">Yan et al., 2019</xref>; <xref ref-type="bibr" rid="bib41">Guillaume et al., 2019</xref>; <xref ref-type="bibr" rid="bib98">Qiu et al., 2017</xref>; <xref ref-type="bibr" rid="bib153">Zhu et al., 2014</xref>). Collectively, these findings suggest that the liver is highly responsive to 17α-E2 and that hepatic ERα is likely the signaling mechanism by which 17α-E2 prevents and/or reverses steatosis, fibrosis, and insulin resistance.</p><fig id="fig5" position="float"><label>Figure 5.</label><caption><title>17α-E2 reverses obesity-related liver fibrosis and insulin resistance in an ERα-dependent manner in male mice.</title><p>(<bold>A</bold>) Representative liver Masson’s trichrome staining for collagen and (<bold>B</bold>) Liver transcriptional markers of fibrosis in WT and ERα KO mice provided 45% HFD (TestDiet 58V8)±17α-E2 (14.4ppm) for 14 weeks (box plots depict total range of fold changes in gene expression with mean shown as a horizontal black line, Benjamini–Hochberg multiple testing correction, two-way ANOVA with Holm-Sidak post-hoc; *p&lt;0.05, **p&lt;0.005). (<bold>C</bold>) Schematic of in vivo insulin stimulation (2mU/g) in fasting mice, (<bold>D</bold>) Representative liver immunoblots, and (<bold>E</bold>) Quantification of phospho/total (p/t) AKT (pS473) and FOXO1 (pS256) in WT and ERα KO mice provided 60% HFD (TestDiet 58Y1)±17α-E2 (14.4ppm) for 12 weeks (mean ± SEM, Benjamini–Hochberg multiple testing correction, two-way ANOVA with Holm-Sidak post-hoc; **p&lt;0.005). Age-matched, male WT, chow-fed (TestDiet 58YP) mice were also evaluated as a normal-weight reference group and the corresponding means are depicted as dashed gray lines. n = 7–10 (WT HFD), 8–9 (WT HFD+17α), 7–10 (KO HFD), 10 (KO HFD+17α), 7–11 (WT Chow).</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-59616-fig5-v2.tif"/></fig><p>Despite our findings demonstrating that 17α-E2 reduces calorie intake and improves liver disease parameters in male mice in an ERα-dependent manner, it has historically been unclear if the benefits attributed to 17α-E2 occur primarily due to long-term reductions in calorie intake. Moreover, it remains unclear if 17α-E2 acts in a tissue-specific manner and if these observations would also occur in other mammalian species. To address these questions, we subsequently evaluated the effects of acute 17α-E2 administration during hyperinsulinemic-euglycemic clamps in male WT outbred rats. These experiments allowed us to evaluate tissue-specific insulin-sensitivity following acute 17α-E2 exposure, thereby circumventing long-term effects of the compound including reductions in calorie intake.</p></sec><sec id="s2-4"><title>Acute 17α-E2 administration improves hepatic insulin sensitivity in male rats</title><p>The hyperinsulinemic-euglycemic clamp is the gold-standard for assessing insulin action in vivo (<xref ref-type="bibr" rid="bib5">Ayala et al., 2010</xref>). Animals are fasted overnight prior to receiving a constant infusion of insulin and a variable infusion of [3-<sup>3</sup>H] glucose to maintain a euglycemia throughout the clamping period. Blood samples are frequently obtained to assess glucose concentration and adjust glucose infusion rates (GIRs) to maintain euglycemia, thereby allowing the calculation of insulin sensitivity to be done. Our first set of experiments in male rats sought to determine if acute peripheral infusions of 17α-E2 modulates metabolic parameters during hyperinsulinemic-euglycemic clamps (<xref ref-type="fig" rid="fig6">Figure 6A</xref>). We found that acute peripheral administration of 17α-E2 significantly increased systemic insulin responsiveness as compared to vehicle controls, which is indicated by increased GIRs (<xref ref-type="fig" rid="fig6">Figure 6B</xref>). These studies also determined that peripheral 17α-E2 administration robustly suppressed hepatic gluconeogenesis as compared to vehicle controls (<italic>R</italic><sub>a</sub>; <xref ref-type="fig" rid="fig6">Figure 6C–D</xref>), whereas glucose disposal rates (<italic>R</italic><sub>d</sub>; <xref ref-type="fig" rid="fig6">Figure 6E</xref>) were essentially identical between groups under clamped conditions. These data indicate that 17α-E2 beneficially modulates metabolic parameters independent of reductions in calorie intake and adiposity. Furthermore, these findings strongly suggest that the liver is a primary site where 17α-E2 acts to improve metabolic homeostasis due to gluconeogenesis being tightly controlled by hormonal actions on hepatocytes (<xref ref-type="bibr" rid="bib151">Zhang et al., 2018</xref>). However, it also well established that the hypothalamus can directly modulate gluconeogenesis in the liver through hepatic innervation (<xref ref-type="bibr" rid="bib126">Timper and Brüning, 2017</xref>); therefore, we sought to determine if acute intracerebroventricular (ICV) delivery of 17α-E2 (<xref ref-type="fig" rid="fig6">Figure 6F</xref>) could modulate metabolic parameters similarly to that observed during peripheral 17α-E2 administration. Interestingly, we found that central administration of 17α-E2 essentially phenocopied the effects of peripheral 17α-E2 infusion with regard to GIRs and suppression of hepatic gluconeogenesis (<xref ref-type="fig" rid="fig6">Figure 6G–I</xref>). These findings suggest that 17α-E2 likely acts through hypothalamic neurons to regulate hepatic gluconeogenesis. Indeed, agouti-related peptide/neuropeptide Y (AgRP/NPY) and pro-opiomelanocortin (Pomc) neurons are known to regulate hepatic glucose production (<xref ref-type="bibr" rid="bib59">Könner et al., 2007</xref>; <xref ref-type="bibr" rid="bib105">Ruud et al., 2017</xref>; <xref ref-type="bibr" rid="bib96">Pocai et al., 2005a</xref>; <xref ref-type="bibr" rid="bib97">Pocai et al., 2005b</xref>; <xref ref-type="bibr" rid="bib22">Dodd et al., 2018</xref>) and both neuronal populations express ERα (<xref ref-type="bibr" rid="bib112">Smith et al., 2013</xref>; <xref ref-type="bibr" rid="bib111">Skinner and Herbison, 1997</xref>; <xref ref-type="bibr" rid="bib142">Xu et al., 2011</xref>; <xref ref-type="bibr" rid="bib1">Acosta-Martinez et al., 2007</xref>; <xref ref-type="bibr" rid="bib116">Stincic et al., 2018</xref>; <xref ref-type="bibr" rid="bib54">Kelly and Rønnekleiv, 2015</xref>; <xref ref-type="bibr" rid="bib113">Smith et al., 2014</xref>). Collectively, the hyperinsulinemic-euglycemic clamp studies revealed that 17α-E2 definitively modulates metabolic homeostasis in an acute manner and suggests that the liver and hypothalamus are two primary sites of action for the regulation of metabolic parameters by 17α-E2.</p><fig id="fig6" position="float"><label>Figure 6.</label><caption><title>Acute delivery of 17α-E2 improves hepatic insulin sensitivity.</title><p>(<bold>A</bold>) Schematic of peripheral 17α-E2 infusions (or vehicle) during hyperinsulinemic-euglycemic clamps, (<bold>B</bold>) glucose infusion rates (GIR) (mean ± SEM, unpaired Student’s t-test; **p&lt;0.005), (<bold>C</bold>) rate of glucose appearance (<italic>R</italic><sub>a</sub>; hepatic glucose production) (mean ± SEM, unpaired Student’s t-test on Clamp; **p&lt;0.005), (<bold>D</bold>) % suppression of hepatic glucose production (mean ± SEM, unpaired Student’s t-test; **p&lt;0.005), and (<bold>E</bold>) rate of glucose disappearance (<italic>R</italic><sub>d</sub>; peripheral glucose disposal) in 6 month old, male, FBN-F1 hybrid rats (mean ± SEM, unpaired Student’s t-test on Clamp). (<bold>F</bold>) Schematic of ICV (central) 17α-E2 infusions (or vehicle) during hyperinsulinemic-euglycemic clamps, (<bold>G</bold>) GIR (mean ± SEM, unpaired Student’s t-test; *p&lt;0.05), (<bold>H</bold>) <italic>R</italic><sub>a</sub> (mean ± SEM, unpaired Student’s t-test on Clamp; **p&lt;0.005), (<bold>I</bold>) % suppression glucose production (mean ± SEM, unpaired Student’s t-test; *p&lt;0.05), and (<bold>J</bold>) <italic>R</italic><sub>d</sub> in 6-month-old, male, FBN-F1 hybrid rats (mean ± SEM, unpaired Student’s t-test on Clamp). n = 5–9 (Veh.), 7–8 (17α).</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-59616-fig6-v2.tif"/></fig></sec></sec><sec id="s3" sec-type="discussion"><title>Discussion</title><p>17α-E2 has recently been found to increase median lifespan in male mice through uncharacterized mechanisms (<xref ref-type="bibr" rid="bib120">Strong et al., 2016</xref>; <xref ref-type="bibr" rid="bib44">Harrison et al., 2014</xref>). We and others have shown that metabolic improvements by 17α-E2 may underlie the lifespan extending effects. In these studies, we sought to determine the role of ERα in 17α-E2-mediated transcriptional effects in vitro and metabolic effects in vivo. Although previous studies have shown that 17α-E2 has limited binding affinity for ERα, it remains unclear if 17α-E2 can induce transcriptional and physiological alterations in this manner. Given the close association between metabolic improvements and ERα activity, we hypothesized that 17α-E2 signals through ERα to elicit beneficial health outcomes. In these studies, we utilized U2OS cells stably expressing ERα and ERα global knockout mice to assess the involvement of this receptor in mediating 17α-E2 effects. Results from these studies demonstrate that ERα plays a pivotal role in 17α-E2-mediated effects on genomic activity and metabolism. Moreover, these data suggest that ERα may be a target for the treatment of aging and chronic diseases in males.</p><p>Given the similarities between the metabolic benefits observed in vivo with 17α-E2 treatment and the established body of literature linking ERα activity to systemic metabolic regulation (<xref ref-type="bibr" rid="bib7">Barros and Gustafsson, 2011</xref>), we utilized a well-established cell line model to globally assess the ERα cistrome and transcriptome following 17α-E2 and 17β-E2 treatment. We found that, regardless of dose, 17α-E2 and 17β-E2 elicited the same pattern of ERα genomic binding loci and these loci shared the same DNA motif enrichments. Additionally, activation and suppression of gene expression were similar with both 17α-E2 and 17β-E2 exposure and were independent of dosage. This provides strong evidence that 17α-E2 is signaling through ERα to elicit beneficial outcomes, which is contrary to what other reports have suggested (<xref ref-type="bibr" rid="bib44">Harrison et al., 2014</xref>; <xref ref-type="bibr" rid="bib32">Garratt et al., 2017</xref>; <xref ref-type="bibr" rid="bib33">Garratt et al., 2018</xref>; <xref ref-type="bibr" rid="bib127">Toran-Allerand et al., 2002</xref>; <xref ref-type="bibr" rid="bib129">Toran-Allerand et al., 2005</xref>; <xref ref-type="bibr" rid="bib128">Toran-Allerand, 2005</xref>). Toran-Allerand et al. reported that 17α-E2 signals through a novel receptor in the brain, which they termed ER-X (<xref ref-type="bibr" rid="bib127">Toran-Allerand et al., 2002</xref>; <xref ref-type="bibr" rid="bib128">Toran-Allerand, 2005</xref>). Although our findings appear to dispute this notion, several reports have shown that ERα exists and functions as multiple alternatively spliced variants (<xref ref-type="bibr" rid="bib30">Flouriot et al., 1998</xref>; <xref ref-type="bibr" rid="bib136">Wang et al., 2005</xref>; <xref ref-type="bibr" rid="bib124">Taylor et al., 2010</xref>; <xref ref-type="bibr" rid="bib150">Zhang et al., 2016</xref>; <xref ref-type="bibr" rid="bib68">Lin et al., 2013</xref>). Therefore, we speculate that ER-X may have been a truncated, alternatively spliced, form of ERα, which nonetheless causes the same genomic and transcriptomic effects. These findings led us to investigate how ERα may modulate 17α-E2-induced benefits in vivo using ERα global KO mice.</p><p>In alignment with our previous reports (<xref ref-type="bibr" rid="bib119">Stout et al., 2017b</xref>; <xref ref-type="bibr" rid="bib115">Steyn et al., 2018</xref>), 17α-E2 reduced calorie intake, body mass, adiposity, and obesity-related metabolic perturbations in male WT mice. Conversely, 17α-E2 failed to elicit these beneficial effects in ERα KO mice, further supporting our hypothesis that ERα is the receptor by which 17α-E2 signals to induce beneficial metabolic outcomes. These observations are similar to how ERα is known to mediate the actions of endogenous estrogens on metabolic parameters in females (<xref ref-type="bibr" rid="bib7">Barros and Gustafsson, 2011</xref>). In particular, 17β-E2 acts through ERα to regulate systemic insulin sensitivity, lipid distribution, thermogenesis, and hypothalamic anorexigenic pathways (<xref ref-type="bibr" rid="bib7">Barros and Gustafsson, 2011</xref>; <xref ref-type="bibr" rid="bib116">Stincic et al., 2018</xref>; <xref ref-type="bibr" rid="bib72">López and Tena-Sempere, 2015</xref>). The loss of endogenous estrogen action due to menopause in humans or ovariectomy (OVX) in rodents eliminates these beneficial effects and elicits metabolic perturbations (<xref ref-type="bibr" rid="bib114">Stefanska et al., 2015</xref>). Moreover, OVX following sexual maturation has also been shown to reduce lifespan in female mice (<xref ref-type="bibr" rid="bib8">Benedusi et al., 2015</xref>), indicating that endogenous estrogens regulate lifespan in females; which we surmise is at least partially mediated through ERα.</p><p>In the current study, 17α-E2 failed to induce beneficial metabolic effects in female mice of either genotype, which we postulate is due to endogenous 17β-E2 saturating ERα in female WT mice, thereby limiting the potential benefits of 17α-E2 treatment. This interpretation is supported by our recent report showing that OVX renders WT female mice responsive to the beneficial effects of 17α-E2 on adiposity and bone mass (<xref ref-type="bibr" rid="bib78">Mann et al., 2020</xref>), both of which are regulated by ERα activity (<xref ref-type="bibr" rid="bib46">Heine et al., 2000</xref>; <xref ref-type="bibr" rid="bib55">Khosla and Monroe, 2018</xref>). In males, very few studies have evaluated the role of ERα in metabolism, although a few recent reports have suggested that ERα plays tissue-specific roles, particularly in the liver, by regulating glucoregulatory pathways (<xref ref-type="bibr" rid="bib3">Allard et al., 2019</xref>; <xref ref-type="bibr" rid="bib143">Yan et al., 2019</xref>; <xref ref-type="bibr" rid="bib41">Guillaume et al., 2019</xref>; <xref ref-type="bibr" rid="bib98">Qiu et al., 2017</xref>; <xref ref-type="bibr" rid="bib80">Meda et al., 2020</xref>; <xref ref-type="bibr" rid="bib153">Zhu et al., 2014</xref>). These studies, coupled with our current findings, led us to speculate that 17α-E2 may be signaling through ERα in the liver to reverse metabolic disease and potentially extend healthspan and/or lifespan in males.</p><p>The liver is a major regulator of systemic metabolic homeostasis. Obesity and advancing age often promote a variety of liver conditions, including steatosis, fibrosis, and insulin resistance; all of which are associated with hallmarks of aging (<xref ref-type="bibr" rid="bib50">Hunt et al., 2019</xref>), including cellular senescence (<xref ref-type="bibr" rid="bib89">Ogrodnik et al., 2017</xref>), epigenetic alterations (<xref ref-type="bibr" rid="bib47">Horvath et al., 2014</xref>), and dysregulated nutrient-sensing (<xref ref-type="bibr" rid="bib73">López-Otín et al., 2013</xref>). We have previously shown that 17α-E2 can reduce hepatic steatosis, hepatic insulin resistance, and hepatocyte DNA damage through unknown mechanisms (<xref ref-type="bibr" rid="bib119">Stout et al., 2017b</xref>). In the present study, we sought to determine if these findings are mediated through ERα. We found that 17α-E2 dramatically reduced liver mass and lipid content. As expected, these observations were not seen in ERα KO mice, providing further support for the hypothesis that 17α-E2 regulates systemic metabolic parameters through ERα. Interestingly, our findings suggest that 17α-E2 suppresses de novo lipogenesis and increases β-oxidation, predominantly in an ERα-dependent manner. This is aligned with previous reports showing that 17β-E2 can modulate hepatic lipid dynamics through both genomic and non-genomic actions (<xref ref-type="bibr" rid="bib93">Pedram et al., 2016</xref>), leading to altered expression of rate limiting enzymes that control de novo lipogenesis (<xref ref-type="bibr" rid="bib149">Zhang et al., 2013</xref>) and β-oxidation (<xref ref-type="bibr" rid="bib14">Camporez et al., 2013</xref>). Reports have also shown that 17β-E2 can increase triglyceride export, thereby decreasing hepatic lipid deposition (<xref ref-type="bibr" rid="bib152">Zhu et al., 2013</xref>). Although we did not directly assess cholesterol profiles in these studies, we speculate that 17α-E2 may partially reduce hepatic steatosis by increasing VLDL synthesis and/or triglyceride incorporation into VLDL. Additional studies will be needed to confirm how 17α-E2 alters hepatic lipoprotein dynamics.</p><p>Hepatic steatosis promotes liver fibrosis, which exacerbates hepatic insulin resistance (<xref ref-type="bibr" rid="bib56">Kim et al., 2015</xref>). Endogenous estrogens and hormone replacement therapies in post-menopausal women have been shown to serve a protective role on liver function (<xref ref-type="bibr" rid="bib121">Stubbins et al., 2012</xref>; <xref ref-type="bibr" rid="bib14">Camporez et al., 2013</xref>; <xref ref-type="bibr" rid="bib152">Zhu et al., 2013</xref>; <xref ref-type="bibr" rid="bib103">Rossi et al., 2004</xref>; <xref ref-type="bibr" rid="bib13">Brussaard et al., 1997</xref>). Additionally, male humans are at a higher risk of developing hepatic steatosis and fibrosis as compared to age-matched females (<xref ref-type="bibr" rid="bib42">Guy and Peters, 2013</xref>; <xref ref-type="bibr" rid="bib35">GBD 2017 Cirrhosis Collaborators and Collaborators, 2020</xref>). In addition to reducing hepatic lipid deposition in male WT mice in the current studies, 17α-E2 also dramatically suppressed transcriptional and histological markers of hepatic fibrosis in an ERα-dependent manner. We also determined that 17α-E2 improved hepatic insulin sensitivity in male WT, but not ERα KO, mice. Several transcriptional markers associated with hepatic insulin resistance were suppressed in male WT mice receiving 17α-E2, whereas this suppression was almost entirely absent in ERα KO mice. Subsequent studies employing insulin stimulation prior to euthanasia also revealed that 17α-E2 robustly increased liver AKT and FOXO1 phosphorylation in male WT mice, indicating a reversal of obesity-related hepatic insulin resistance and increased control of gluconeogenesis. These findings clearly demonstrate that 17α-E2 modulates hepatic insulin sensitivity in an ERα-dependent manner. These observations are aligned with previous reports showing that 17β-E2 acts through ERα to improve glucoregulation (<xref ref-type="bibr" rid="bib80">Meda et al., 2020</xref>; <xref ref-type="bibr" rid="bib152">Zhu et al., 2013</xref>). This provides further support that 17α-E2 is eliciting metabolic improvements through ERα that are specific to the liver. Therefore, hepatic ERα may be a promising target for the development of therapeutics to alleviate metabolic disease in males. Future studies utilizing cell-type-specific ablation of ERα in the liver will be needed to unravel these possibilities.</p><p>Despite the robust effects of 17α-E2 on liver function, it remained unclear if 17α-E2 directly modulates hepatic insulin sensitivity or if these benefits were a secondary response to prolonged reductions in calorie intake, adiposity, and lipid redistribution. To test this, we performed hyperinsulinemic-euglycemic clamps, in conjunction with acute infusions of 17α-E2 in male WT rats. We found that peripheral infusions of 17α-E2 improved hepatic insulin sensitivity almost immediately, as evidenced by a greater suppression of hepatic glucose production in rats receiving 17α-E2 as compared to vehicle controls. Additionally, we did not observe improvements in glucose disposal, thereby indicating that 17α-E2 does not acutely increase systemic insulin-stimulated glucose uptake. This observation is aligned with recent literature demonstrating limited involvement of ERα in skeletal muscle insulin sensitivity (<xref ref-type="bibr" rid="bib51">Iñigo et al., 2020</xref>). These data indicate that 17α-E2 primarily alters systemic metabolic homeostasis through the modulation of hepatic gluconeogenesis, which is known to account for 76–87% of glucose production in the body (<xref ref-type="bibr" rid="bib15">Cherrington et al., 1994</xref>). Although these studies are suggestive of direct actions in the liver, 17α-E2 also has the ability to cross the blood brain barrier and elicit responses in the hypothalamus (<xref ref-type="bibr" rid="bib115">Steyn et al., 2018</xref>). Given that the hypothalamus can regulate hepatic glucose production (<xref ref-type="bibr" rid="bib59">Könner et al., 2007</xref>; <xref ref-type="bibr" rid="bib105">Ruud et al., 2017</xref>; <xref ref-type="bibr" rid="bib96">Pocai et al., 2005a</xref>; <xref ref-type="bibr" rid="bib97">Pocai et al., 2005b</xref>; <xref ref-type="bibr" rid="bib22">Dodd et al., 2018</xref>; <xref ref-type="bibr" rid="bib126">Timper and Brüning, 2017</xref>), we also evaluated systemic insulin sensitivity following central administration of 17α-E2. These experiments essentially phenocopied the results of the peripheral 17α-E2 infusions, suggesting that the suppression of hepatic gluconeogenesis by 17α-E2 is at least partially mediated by the hypothalamus. A multitude of studies have shown that the arcuate nucleus (ARC) of the hypothalamus plays a critical role in the regulation of hepatic gluconeogenesis through autonomic regulation and vagus nerve activity (<xref ref-type="bibr" rid="bib105">Ruud et al., 2017</xref>; <xref ref-type="bibr" rid="bib96">Pocai et al., 2005a</xref>; <xref ref-type="bibr" rid="bib151">Zhang et al., 2018</xref>; <xref ref-type="bibr" rid="bib12">Brandt et al., 2018</xref>). Multiple neuronal populations within the ARC are known to be involved in the regulation of hepatic glucose production, including Pomc (<xref ref-type="bibr" rid="bib22">Dodd et al., 2018</xref>) and AgRP/NPY (<xref ref-type="bibr" rid="bib59">Könner et al., 2007</xref>; <xref ref-type="bibr" rid="bib105">Ruud et al., 2017</xref>; <xref ref-type="bibr" rid="bib96">Pocai et al., 2005a</xref>; <xref ref-type="bibr" rid="bib97">Pocai et al., 2005b</xref>). Similarly, we have previously shown that the effects of 17α-E2 on calorie intake and adiposity are dependent upon functional Pomc neurons, thereby providing evidence that 17α-E2 can act through the hypothalamus to mediate systemic metabolic parameters (<xref ref-type="bibr" rid="bib115">Steyn et al., 2018</xref>). However, in the absence of functional Pomc neurons, 17α-E2 was still able to reduce fasting glucose and insulin, suggesting that 17α-E2 modulates peripheral metabolism through multiple mechanisms, which may include alternative neuronal populations. Given that both Pomc (<xref ref-type="bibr" rid="bib142">Xu et al., 2011</xref>) and AgRP/NPY (<xref ref-type="bibr" rid="bib112">Smith et al., 2013</xref>; <xref ref-type="bibr" rid="bib111">Skinner and Herbison, 1997</xref>; <xref ref-type="bibr" rid="bib1">Acosta-Martinez et al., 2007</xref>; <xref ref-type="bibr" rid="bib116">Stincic et al., 2018</xref>; <xref ref-type="bibr" rid="bib54">Kelly and Rønnekleiv, 2015</xref>; <xref ref-type="bibr" rid="bib113">Smith et al., 2014</xref>; <xref ref-type="bibr" rid="bib108">Sar et al., 1990</xref>) neurons express ERα, regulate systemic metabolic parameters, and modulate feeding circuitry in a coordinated counter-regulatory fashion, it remains unclear whether 17α-E2 is altering hepatic and systemic metabolic parameters through Pomc and/or AgRP/NPY neurons. Interestingly, a recent report from Debarba et al. demonstrated that 17α-E2 increased hypothalamic ERα expression in the ARC (<xref ref-type="bibr" rid="bib18">Debarba, 2020</xref>), which further suggests that 17α-E2 signals through ERα in the hypothalamus. Future studies utilizing hypothalamic cell-type-specific ERα KO models will be needed to disentangle which populations of neurons are required for 17α-E2 to control food intake, peripheral glucose homeostasis, and insulin sensitivity.</p><p>Collectively, our findings strongly suggest that 17α-E2 acts through ERα in the liver and/or hypothalamus to modulate metabolic parameters. However, our findings are in contrast to other reports suggesting that 17α-E2 elicits health benefits by modulating androgen metabolism (<xref ref-type="bibr" rid="bib32">Garratt et al., 2017</xref>; <xref ref-type="bibr" rid="bib33">Garratt et al., 2018</xref>; <xref ref-type="bibr" rid="bib34">Garratt and Stout, 2018</xref>). Garratt et al. reported that responsiveness to 17α-E2 was significantly attenuated in castrated male mice (<xref ref-type="bibr" rid="bib33">Garratt et al., 2018</xref>), which the authors proposed may indicate 17α-E2 acts as a 5α-reductase inhibitor (<xref ref-type="bibr" rid="bib109">Schriefers et al., 1991</xref>) to prevent the conversion of testosterone into dihydrotestosterone (DHT). 17α-E2 is known to be a mild 5α-reductase inhibitor that is prescribed as a topical treatment for androgenetic alopecia (<xref ref-type="bibr" rid="bib90">Orfanos and Vogels, 1980</xref>). 5α-Reductase inhibition could conceivably elicit beneficial metabolic effects by either reducing the concentration of DHT, which has been shown to decrease adiposity (<xref ref-type="bibr" rid="bib85">Movérare-Skrtic et al., 2006</xref>; <xref ref-type="bibr" rid="bib11">Bolduc et al., 2004</xref>), or by promoting greater aromatization of testosterone to 17β-E2 (<xref ref-type="bibr" rid="bib133">Veldhuis et al., 2009</xref>), which has been linked to improvements in metabolic parameters (<xref ref-type="bibr" rid="bib104">Rubinow, 2017</xref>). If true, this would imply that the benefits of 17α-E2 are occurring in an indirect manner. However, the dose of 17α-E2 used in the vast majority of these studies, does not induce dramatic feminization of the sex hormone profiles in male mice (<xref ref-type="bibr" rid="bib119">Stout et al., 2017b</xref>), which leads us to speculate that 17a-E2 is acting in a direct manner through ERα rather than indirectly through androgen modulation. Furthermore, studies in male rodents (<xref ref-type="bibr" rid="bib71">Livingstone et al., 2015</xref>; <xref ref-type="bibr" rid="bib23">Dowman et al., 2013</xref>) and humans <xref ref-type="bibr" rid="bib138">Wei et al., 2019</xref> demonstrate that 5α-reductase inhibition or deficiency increases insulin resistance and hepatic steatosis and fibrosis, which are contradictory to the effects of 17α-E2 treatment in all of our studies utilizing male mice (<xref ref-type="bibr" rid="bib119">Stout et al., 2017b</xref>; <xref ref-type="bibr" rid="bib115">Steyn et al., 2018</xref>; <xref ref-type="bibr" rid="bib82">Miller, 2020</xref>; <xref ref-type="bibr" rid="bib110">Sidhom et al., 2020</xref>). Despite these contrasting observations, the studies by Garratt et al. do provide important insights into the interconnected and underappreciated relationship between androgen- and estrogen-signaling pathways and their roles in metabolism and aging. For instance, several recent reports have demonstrated interactions between the androgen receptor (AR) and ERα (<xref ref-type="bibr" rid="bib17">D'Amato et al., 2016</xref>; <xref ref-type="bibr" rid="bib91">Panet-Raymond et al., 2000</xref>; <xref ref-type="bibr" rid="bib95">Peters et al., 2009</xref>), which suggests that modulation of one may affect function of the other. Additional factors to consider when comparing and contrasting our studies from those of Garratt et al. are differences in the length of study, age, and obesity status of the mice, and counterregulatory and/or compensatory effects of castration. Notably, it is plausible that 17α-E2 could be inducing metabolic benefits and lifespan-extending effects through several distinct mechanisms, including direct actions through ERα, suppression of DHT production, and/or aromatization of testosterone. Future studies will be needed to discern the potentially interdependent nature of 17α-E2 actions on ERα and androgen metabolism in metabolic improvement and lifespan extension.</p><p>There are a few notable caveats to our studies. First, we utilized constitutive global ERα KO mice, which have been shown to display varying degrees of compensatory ERβ activity due to the absence of ERα during development (<xref ref-type="bibr" rid="bib107">Sánchez-Criado et al., 2012</xref>; <xref ref-type="bibr" rid="bib101">Rosenfeld et al., 1998</xref>). However, if compensatory ERβ expression was playing a role in our study, we likely would not see a complete attenuation of 17α-E2-mediated effects. As such, the results of our studies clearly indicate that ERα is the primary receptor by which 17α-E2 signals. Another potential concern of the model is that ERα KO mice are known to have elevated endogenous testosterone levels (<xref ref-type="bibr" rid="bib38">Gould et al., 2007</xref>), although the studies by Garratt et al. would suggest that higher testosterone levels could potentially render the male mice more responsive to 17α-E2, whereas we observed the opposite. Future studies utilizing inducible Cre models to knockdown ERα post-sexual development may be considered if it is determined that Cre induction and subsequent ERα ablation is consistent throughout multiple organ systems, which has been shown to be inconsistent in other reports (<xref ref-type="bibr" rid="bib86">Murray et al., 2012</xref>). Despite these minor concerns related to the model, the use of the constitutive global ERα KO was undoubtedly the best option for these studies. However, it must also be noted that female mice present a greater phenotypic response than males to the ablation of ERα, thereby exacerbating obesity and metabolic dysfunction which makes comparisons to female WT mice as well as their male littermates problematic (<xref ref-type="bibr" rid="bib79">Manrique et al., 2012</xref>; <xref ref-type="bibr" rid="bib134">Vidal et al., 1999</xref>). For this reason, we chose not to provide HFD to female mice in these studies. Regardless, 17α-E2 still failed to elicit beneficial responses in female mice of either genotype (WT or ERα KO), which is aligned with previous reports demonstrating a lack of effect of 17α-E2 in intact females (<xref ref-type="bibr" rid="bib32">Garratt et al., 2017</xref>; <xref ref-type="bibr" rid="bib33">Garratt et al., 2018</xref>). We also recently reported that OVX renders female mice responsive to several of the benefits conferred by 17α-E2 treatment in male mice (<xref ref-type="bibr" rid="bib78">Mann et al., 2020</xref>). These observations, coupled with the genomic data presented herein, support the hypothesis that endogenous 17β-E2 actions on ERα diminishes potential benefits of 17α-E2 in intact female mice. However, future studies will be needed to definitively determine if female mice subjected to diet-induced obesity will display responsiveness to 17α-E2 once severe metabolic dysfunction has emerged. Lastly, the current studies were relatively short in duration and it remains unclear if metabolic improvements with 17α-E2 treatment are required for the lifespan extension effects of the compound. Although several other studies have evaluated the long-term effects of 17α-E2 (<xref ref-type="bibr" rid="bib120">Strong et al., 2016</xref>; <xref ref-type="bibr" rid="bib44">Harrison et al., 2014</xref>; <xref ref-type="bibr" rid="bib32">Garratt et al., 2017</xref>; <xref ref-type="bibr" rid="bib33">Garratt et al., 2018</xref>), a shorter treatment duration was effective for testing our hypothesis in these studies. Similarly, given the close relationship between metabolic homeostasis, sex hormones, and longevity (<xref ref-type="bibr" rid="bib73">López-Otín et al., 2013</xref>; <xref ref-type="bibr" rid="bib7">Barros and Gustafsson, 2011</xref>), we surmise that future studies evaluating the effects of ERα on male lifespan in the presence or absence of 17α-E2 will be needed. Although our current report does not provide direct evidence that ERα modulates the lifespan extending effects of 17α-E2, it does provide insight into the involvement of hepatic and/or hypothalamic ERα on 17α-E2-mediated metabolic effects in male mice.</p><p>In summary, the data presented herein are the first to show that 17α-E2 and 17β-E2 induce nearly identical ERα chromatin association patterns and transcriptional activity. Moreover, we demonstrate that the metabolic benefits of 17α-E2 in male mice are ERα-dependent. We also provide evidence that strongly suggests 17α-E2 acts through the liver and hypothalamus to regulate metabolic homeostasis in male mice. These effects were mirrored by studies in male WT rats receiving 17α-E2, indicating that 17α-E2 can modulate metabolism almost instantaneously and that these effects are not limited to a single mammalian species. Future studies will be needed to confirm that 17α-E2 acts predominantly through ERα in a cell-type-specific manner in the liver and hypothalamus to modulate systemic metabolic homeostasis. It is also imperative that we determine if ERα exclusively modulates the lifespan-extending effects of 17α-E2 in male mice. Another potential avenue of investigation that remains unresolved is whether 17α-E2 acts through ERα in a genomic or non-genomic manner to modulate health parameters. Potential interactions between androgen and estrogen signaling must also be considered when evaluating the effects of 17α-E2 on metabolism and lifespan. These studies will provide additional insight into mechanisms of metabolic improvement and lifespan extension by 17α-E2. Our studies provide critical insight into the molecular mechanisms by which 17α-E2 elicits metabolic benefits in males, which were previously unknown and may underlie its lifespan-extending effects.</p></sec><sec id="s4" sec-type="materials|methods"><title>Materials and methods</title><table-wrap id="keyresource" position="anchor"><label>Key resources table</label><table frame="hsides" rules="groups"><thead><tr><th>Reagent type (species) <break/>or resource</th><th>Designation</th><th>Source or reference</th><th>Identifiers</th><th>Additional information</th></tr></thead><tbody><tr><td>Genetic reagent (<italic>M. musculus</italic>)</td><td>B6N(Cg)-Esr1tm4.2Ksk/J</td><td>The Jackson Laboratory</td><td>Stock No:026176; <break/>RRID:<ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/IMSR_JAX:026176">IMSR_JAX:026176</ext-link></td><td>ERα (<italic>Esr1</italic>) KO mice</td></tr><tr><td>Cell line (<italic>Homo sapien</italic>)</td><td>U2OS Cells</td><td>ATCC</td><td>HTB-96; <break/>RRID:<ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/CVCL_0042">CVCL_0042</ext-link></td><td>PMID:<ext-link ext-link-type="uri" xlink:href="https://www.ncbi.nlm.nih.gov/pubmed/15802376">15802376</ext-link> <break/>PMID:<ext-link ext-link-type="uri" xlink:href="https://www.ncbi.nlm.nih.gov/pubmed/14505348">14505348</ext-link></td></tr><tr><td>Antibody</td><td>anti-FLAG M2 (Mouse monoclonal)</td><td>Sigma-Aldrich</td><td>F1804</td><td>IP: 1 uL per pull-down (1 mg/mL)</td></tr><tr><td>Commercial assay or kit</td><td>Protein G Dynabeads</td><td>Applied Biosystems/Thermofisher Scientific</td><td>10003D</td><td>IP: 30 uL per IP</td></tr><tr><td>Chemical compound, drug</td><td>17α-E2</td><td>Steraloids, Inc</td><td>E0870-000</td><td/></tr><tr><td>Chemical compound, drug</td><td>Novolin R 100 U/ml</td><td>Novolin</td><td/><td>2mU/g</td></tr><tr><td>Other (diet)</td><td>Chow; TestDiet 58YP</td><td>TestDiet</td><td>TestDiet 58YP</td><td/></tr><tr><td>Other (diet)</td><td>HFD; TestDiet 58V8</td><td>TestDiet</td><td>TestDiet 58V8</td><td>HFD 45% by kcal</td></tr><tr><td>Other (diet)</td><td>HFD; TestDiet 58Y1</td><td>TestDiet</td><td>TestDiet 58Y1</td><td>HFD 60% by kcal</td></tr><tr><td>Commercial assay or kit</td><td>Mouse Ultrasensitive Insulin ELISA</td><td>ALPCO</td><td>Cat# 80-INSMSU-E01; RRID:<ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/AB_2792981">AB_2792981</ext-link></td><td/></tr><tr><td>Commercial assay or kit</td><td>Free Glycerol Agent</td><td>Sigma-Aldrich</td><td>Sigma F6428</td><td/></tr><tr><td>Commercial assay or kit</td><td>Triglyceride Reagent</td><td>Sigma-Aldrich</td><td>Sigma F6428</td><td/></tr><tr><td>Commercial assay or kit</td><td>Glycerol Standard</td><td>Sigma-Aldrich</td><td>Sigma G1394</td><td/></tr><tr><td>Antibody</td><td>anti-pS473 AKT (Rabbit polyclonal)</td><td>Abcam</td><td>Cat# ab81283; RRID:<ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/AB_2224551">AB_2224551</ext-link></td><td>WB: (1:3000)</td></tr><tr><td>Antibody</td><td>Anti-pan-AKT (Rabbit polyclonal)</td><td>Abcam</td><td>Cat# ab179463; RRID:<ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/AB_2810977">AB_2810977</ext-link></td><td>WB (1:10000)</td></tr><tr><td>Antibody</td><td>Anti-pS256 FOX01 (Rabbit polyclonal)</td><td>Abcam</td><td>Cat# ab131339; RRID:<ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/AB_11159015">AB_11159015</ext-link></td><td>WB (1:1000)</td></tr><tr><td>Antibody</td><td>Anti-FOX01a (Rabbit polyclonal)</td><td>Abcam</td><td>Cat# ab52857; RRID:<ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/AB_869817">AB_869817</ext-link></td><td>WB (1:1000)</td></tr><tr><td>Antibody</td><td>Anti-GAPDH (Rabbit polyclonal)</td><td>Abcam</td><td>Cat# ab9485; RRID:<ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/AB_307275">AB_307275</ext-link></td><td>WB (1:2500)</td></tr><tr><td>Antibody</td><td>Anti-Rabbit IgG, IRDye 800 CW</td><td>LI-COR</td><td>Cat# 926–32211; RRID:<ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/AB_621843">AB_621843</ext-link></td><td>WB (1:15000)</td></tr><tr><td>Commercial assay or kit</td><td>TaqMan Gene Expression Master Mix</td><td>Applied Biosystems/Thermofisher Scientific</td><td>4369542</td><td/></tr><tr><td>Sequenced-based reagent</td><td>qPCR primer <italic>Mmp1</italic></td><td>Integrated DNA Technologies</td><td>Mm.PT.58.42286812 <break/>Ref Seq: NM_008607(1)</td><td>Exon 5–6</td></tr><tr><td>Sequenced-based reagent</td><td>qPCR primer <italic>Mmp12</italic></td><td>Integrated DNA Technologies</td><td>Mm.PT.58.31615472 <break/>Ref Seq: NM_008605(1)</td><td>Exon 8–9</td></tr><tr><td>Sequenced-based reagent</td><td>qPCR primer <italic>Ccl2</italic></td><td>Integrated DNA Technologies</td><td>Mm.PT.58.42151692 <break/>Ref Seq: NM_011333(1)</td><td>Exon 1–3</td></tr><tr><td>Sequenced-based reagent</td><td>qPCR primer <italic>Srebf1</italic></td><td>Integrated DNA Technologies</td><td>Mm.PT.58.8508227 <break/>Ref Seq: NM_011480(1)</td><td>Exon 1–2</td></tr><tr><td>Sequenced-based reagent</td><td>qPCR primer <italic>Pck1</italic></td><td>Integrated DNA Technologies</td><td>Mm.PT.58.11992693 <break/>Ref Seq: NM_011044(1)</td><td>Exon 3–4</td></tr><tr><td>Sequenced-based reagent</td><td>qPCR primer <italic>Cdkn1a</italic></td><td>Integrated DNA Technologies</td><td>Mm.PT.58.17125846 <break/>Ref Seq: NM_007669(1)</td><td>Exon 2–3</td></tr><tr><td>Sequenced-based reagent</td><td>qPCR primer <italic>Pparα</italic></td><td>Integrated DNA Technologies</td><td>Mm.PT.58.9374886 <break/>Ref Seq: NM_001113418(2)</td><td>Exon 8–9</td></tr><tr><td>Sequenced-based reagent</td><td>qPCR primer <italic>Cxcl1</italic></td><td>Integrated DNA Technologies</td><td>Mm.PT.58.42076891 <break/>Ref Seq: NM_008176(1)</td><td>Exon 2–4</td></tr><tr><td>Sequenced-based reagent</td><td>qPCR primer <italic>Col1a1</italic></td><td>Integrated DNA Technologies</td><td>Mm.PT.58.7562513 <break/>Ref Seq: M_007742(1)</td><td>Exon 1–2</td></tr><tr><td>Sequenced-based reagent</td><td>qPCR primer <italic>Tnfrsf1a</italic></td><td>Integrated DNA Technologies</td><td>Mm.PT.58.28810479 <break/>Ref Seq: NM_011609(1)</td><td>Exon 5–7</td></tr><tr><td>Software, algorithm</td><td>SigmaPlot 12.5</td><td>Systat Software</td><td>RRID:<ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/SCR_003210">SCR_003210</ext-link></td><td>statistical analyses</td></tr><tr><td>Software, algorithm</td><td>ImageJ</td><td>ImageJ</td><td>RRID:<ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/SCR_003070">SCR_003070</ext-link></td><td>histological quantification</td></tr><tr><td>Software, algorithm</td><td>Image Studio</td><td>LI-COR</td><td>RRID:<ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/SCR_015795">SCR_015795</ext-link></td><td>western blot quantification</td></tr><tr><td>Software, algorithm</td><td>RStudio</td><td>GenomicAlignments <break/>DiffBind <break/>DESeq2 <break/>GenomicRanges</td><td>RRID:<ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/SCR_000432">SCR_000432</ext-link></td><td>Peak Calling <break/>Differential expression <break/>Differential binding</td></tr><tr><td>Software, algorithm</td><td>Bowtie2 <break/>MACS2 <break/>Bedtools <break/>Samtools <break/>Picard-tools <break/>Trimmomatic</td><td>Bowtie2 <break/>MACS2 <break/>Bedtools <break/>Samtools <break/>Picard-tools <break/>Trimmomatic</td><td/><td>Alignment, Peak Calling, trimming, duplicate identification</td></tr></tbody></table></table-wrap><sec id="s4-1"><title>U2OS cells</title><p>U2OS osteosarcoma cells stably expressing flag-tagged ERα (U2OS-ERα) under the control of doxycycline (dox)-inducible promoter (<xref ref-type="bibr" rid="bib83">Monroe et al., 2003</xref>) were utilized for the studies described here. U2OS cells were originally purchased from ATTC and were authenticated using IDEXX BioAnalytics (Westbrook, ME). Cells were also regularly checked for mycoplasma contamination using a PCR-based mycoplasma detection kit from SouthernBiotech (Birmingham, AL) and were confirmed to be negative. U2OS-ERα cells were cultured in phenol-free αMEM medium supplemented with 10% HyCloneTM charcoal/dextran stripped FBS (GE Healthcare Life Sciences, Pittsburgh, PA), 1% antibiotic/antimycotic, 5 mg/L blasticidin S, and 500 mg/L zeocin in a humidified 37°C incubator with 5% CO<sub>2</sub>. Cells were plated in 12-well plates in the presence of doxycycline to induce ERα expression. The following day, cells were treated for 24 hr with 17β-E2 (10 nM) or 17α-E2 (10 nM and 100 nM) (Steraloids, Newport, RI) in charcoal-stripped FBS-containing media.</p></sec><sec id="s4-2"><title>ChIP-sequencing</title><p>To evaluate patterns of ERα binding agonized by 17α-E2 vs 17β-E2, we performed ChIP-Sequencing. U2OS-ERα cells were harvested 24 hr post-treatment and chromatin immunoprecipitation was performed as previously described (<xref ref-type="bibr" rid="bib100">Reese et al., 2018</xref>; <xref ref-type="bibr" rid="bib87">Nelson et al., 2006</xref>). Briefly, ERα was immunoprecipitated overnight at 4°C using 10 µg of Flag antibody (clone M2, Sigma-Aldrich, St. Louis, MO). Complexes bound to the antibody were captured with protein G Dynabeads (Thermo Fisher Scientific, Waltham, MA), extensively washed, and reverse cross-linked at 65°C overnight. DNA isolation was performed by phenol/chloroform extraction and was used for ChIP-sequencing library preparation. Libraries were sequenced using paired-end 100 bp reads on the Illumina HiSeq 4000 (GSE151039). Reads were aligned to the human genome (hg19, <ext-link ext-link-type="uri" xlink:href="https://genome.ucsc.edu/cgi-bin/hgGateway">https://genome.ucsc.edu/cgi-bin/hgGateway</ext-link>) using bowtie2 (<xref ref-type="bibr" rid="bib62">Langmead and Salzberg, 2012</xref>) and duplicated reads were flagged with Picard-tools (<ext-link ext-link-type="uri" xlink:href="http://broadinstitute.github.io/picard/">http://broadinstitute.github.io/picard/</ext-link>). ERα-binding peaks were called using MACS2 (<xref ref-type="bibr" rid="bib148">Zhang et al., 2008</xref>) with recommended settings. Peak genomic location, breadth of coverage, and peak summit location were determined using MACS2. NarrowPeak files containing peak information were used to determine differential ERα binding. First, peaks were centralized around the summit and 250 bp flanking regions were added to the summit location to generate equal 500 bp regions across all experimental groups. Peak files were then used to extract read counts from the aligned de-duplicated BAM file using samtools (<xref ref-type="bibr" rid="bib65">Li et al., 2009</xref>), read counts were then normalized to total library sequencing depth. To determine differential binding, the R package diffbind was utilized (<xref ref-type="bibr" rid="bib102">Ross-Innes et al., 2012</xref>). Normalized read counts were log2 transformed and normalized across all experimental groups. Differential binding between treatment groups was determined using negative binomial regression models utilized in the R package DESeq2, statistical significance for pairwise comparisons between experimental groups was determined using Wald test. To account for multiple comparisons, we used Benjamini-Hochberg multiple testing correction (False-discovery rate, FDR). Motif analysis was performed using HOMER with standard settings to identified motifs. Peak regions called for each treatment group were analyzed to identify enriched motifs relative to the entire genome. For pairwise differential motif enrichment or depletion between experimental groups, we utilized a hypergeometric test with the number of sequences with a motif from each group and total number of peaks as total sample size. Motifs that appeared in less than five sequences between both pairwise test groups were removed. Benjamini-Hochberg multiple testing correction was utilized to control for multiple testing (FDR &lt; 0.05).</p></sec><sec id="s4-3"><title>RNA-sequencing</title><p>U2OS-ERα cells were harvested 24 hr post-treatment and RNA was extracted using Trizol and DNase cleanup. RNA libraries were prepared with Illumina’s TrueSeq RNA-seq library prep according to manufacturer protocol. Libraries were sequenced with 150 bp paired-end reads on the Illumina 4000 platform (Illumina, San Diego, CA) (GSE151039). Sequence quality control was performed with fastQC, Paired reads were trimmed using trimmomatic, and were aligned to the hg19 genome using STAR (<xref ref-type="bibr" rid="bib21">Dobin et al., 2013</xref>). Differential expression was determined using previously described methods (<xref ref-type="bibr" rid="bib43">Hadad et al., 2019</xref>). In brief, gene counts were determined with the R package GenomicAlignments ‘summarizeOverlap’ function. Gene counts were then transformed using regularized log transformation and normalized relative to library size using the DESeq2 (<xref ref-type="bibr" rid="bib74">Love et al., 2014</xref>) R package. Differential expression was determined using negative binomial generalized linear model using <italic>counts ~ treatment</italic> model. We performed pairwise differential expression between all experimental groups using Wald test. All comparisons were corrected for multiple testing using Benjamini-Hochberg multiple testing correction method. Differential expression significance threshold was set to FDR corrected p&lt;0.05.</p></sec><sec id="s4-4"><title>Animal study 1</title><p>To determine if ERα is the primary receptor by which 17α-E2 signals to elicit metabolic benefits in vivo, we utilized male global ERα KO and WT littermate mice. Mice were acquired from Dr. Kenneth Korach (National Institute of Environmental Health Sciences [NIEHS]) and were also bred at OUHSC by pairing ERα heterozygous KO mice (JAX; strain #026176). Mice were fed a 45% high-fat diet (HFD) (TestDiet 58V8, 35.5% CHO, 18.3% PRO, 45.7% FAT) from TestDiet (Richmond, IN) for 4 months prior to study initiation to induce obesity and metabolic perturbations. Additionally, age-matched, male WT, chow-fed mice were maintained on TestDiet 58YP (66.6% CHO, 20.4% PRO, 13.0% FAT) throughout the entire study as a healthy-weight reference group. Mice were individually housed with ISO cotton pad bedding, cardboard enrichment tubes, and nestlets at 22 ± 0.5°C on a 12:12 hr light-dark cycle. Unless otherwise noted, all mice had ad libitum access to food and water throughout the experimental timeframe. At the conclusion of the fattening period, all mice (age: 6–8 months) receiving HFD were randomized within genotype by age, body mass, fat mass, calorie intake, fasting glucose, fasting insulin, and glycosylated hemoglobin (HbA1C) into HFD or HFD+17α (TestDiet 58V8 + 17α-E2, 14.4ppm; Steraloids, Newport, RI) treatment groups for a 14-week intervention. Body mass and calorie intake were assessed daily for the first 4 weeks, followed by body mass and body composition (EchoMRI, Houston, TX) on a weekly basis. At 10 weeks post-treatment, mice were fasted for 5–6 hr and fasting glucose, fasting insulin, HbA1C, and glucose tolerance were assessed. At the conclusion of the study (14 weeks post treatment), mice were euthanized with isoflurane in the fasted state (5–6 hr). Blood was collected into EDTA-lined tubes by cardiac puncture, and plasma was collected and frozen. Tissues were excised, weighed, flash frozen, and stored at −80°C unless otherwise noted. Small sections of liver were fixed in 4% paraformaldehyde in preparation for paraffin- or cryo-embedding for future analyses. All animal procedures were reviewed and approved by the Institutional Animal Care and Use Committee at OUHSC.</p></sec><sec id="s4-5"><title>Animal study 2</title><p>Although previous studies [<xref ref-type="bibr" rid="bib120">Strong et al., 2016</xref>; <xref ref-type="bibr" rid="bib44">Harrison et al., 2014</xref>; <xref ref-type="bibr" rid="bib32">Garratt et al., 2017</xref>; <xref ref-type="bibr" rid="bib33">Garratt et al., 2018</xref>] have demonstrated minimal effects of 17α-E2 in female mice, we thought it prudent to determine if the ablation of ERα would alter female responsiveness to 17α-E2. Female WT and ERα KO mice were acquired from Dr. Kenneth Korach (National Institute of Environmental Health Sciences [NIEHS]). Female mice were maintained on Chow TestDiet 58YP (66.6% CHO, 20.4% PRO, 13.0% FAT) and were not subject to HFD feeding due to ERα KO female mice naturally displaying an obesity phenotype. Mice were individually housed with ISO cotton pad bedding, cardboard enrichment tubes, and nestlets at 22 ± 0.5°C on a 12:12 hr light-dark cycle. Unless otherwise noted, all mice had ad libitum access to food and water throughout the experimental timeframe. At age 9–11 months, female mice were randomized within genotype by age, body mass, fat mass, calorie intake, fasting glucose, fasting insulin, and glycosylated hemoglobin (HbA1C) into Chow or Chow+17α-E2 (TestDiet 58YP + 17α-E2,14.4ppm; Steraloids, Newport, RI) treatment groups. The study was terminated following a 4-week intervention due to a lack of responsiveness to 17α-E2. At the conclusion of the study, mice were euthanized with isoflurane in the fasted state (5–6 hr). Blood was collected into EDTA-lined tubes by cardiac puncture, and plasma was collected and frozen. Tissues were excised, weighed, flash frozen, and stored at −80°C. All animal procedures were reviewed and approved by the Institutional Animal Care and Use Committee at OUHSC.</p></sec><sec id="s4-6"><title>Animal study 3</title><p>To assess insulin sensitivity within the liver, an additional cohort of ERα KO and WT littermate mice were bred from mice acquired from Jackson Laboratory (JAX; strain #026176), which were generated from identical founder strains in the laboratory of Dr. Korach at NIEHS. Male ERα KO and WT mice were fed a 60% high-fat diet (HFD; TestDiet 58Y1, 20.3% CHO, 18.1% PRO, 61.6% FAT) for 4 months prior to study initiation to induce obesity and metabolic perturbations. Additionally, as was done in Animal Study 1, age-matched, male WT, chow-fed mice were maintained on TestDiet 58YP (66.6% CHO, 20.4% PRO, 13.0% FAT) throughout the entire study as a healthy-weight reference group. Mice were group housed with corncob bedding, cardboard enrichment tubes, and nestlets at 22 ± 0.5°C on a 12:12 hr light-dark cycle. Unless otherwise noted, all mice had ad libitum access to food and water throughout the experimental timeframe. At the conclusion of the fatting period, all mice (age: 6 months) receiving HFD were randomized within genotype by body mass, fat mass, calorie intake, fasting glucose, and fasting insulin into HFD or HFD+17α (TestDiet 58Y1 + 17α-E2, 14.4ppm; Steraloids, Newport, RI) treatment groups for a 12-week intervention. Prior to being euthanized, mice were fasted (5–6 hr) and IP injected with insulin (Novolin R 100 U/ml; 2mU/g) to assess insulin activity and sensitivity in tissue as previously described (<xref ref-type="bibr" rid="bib75">Lu et al., 2012</xref>). Each mouse was euthanized with isoflurane 15 min following their insulin injection. Blood was collected into EDTA-lined tubes by cardiac puncture, and plasma was collected and frozen. Tissues were excised, weighed, flash frozen, and stored at −80°C unless otherwise noted. All animal procedures were reviewed and approved by the Institutional Animal Care and Use Committee at OUHSC.</p></sec><sec id="s4-7"><title>Animal study 4</title><p>Hyperinsulinemic-euglycemic clamp experiments, the gold-standard for assessing insulin sensitivity, were performed in male rats to determine if 17α-E2 can acutely modulate insulin sensitivity and glucose homeostasis. FBN-F1 hybrid male rats were acclimated to the animal facilities within the Einstein Nathan Shock Center for 2 weeks prior to undergoing surgeries in preparation for hyperinsulinemic-euglycemic clamp studies. Rats were fed Purina 5001 (58.0% CHO, 28.5% PRO, 13.5% FAT) and were individually housed with corncob bedding at 22 ± 0.5°C on a 14:10 hr light-dark cycle with ad libitum access to food and water. All surgeries were conducted under 2% isoflurane. For clamp studies incorporating central infusions, rats underwent two surgical procedures. First, stereotactic placement of a steel-guide cannula (Plastics One, Roanoke, VA) reaching the 3rd ventricle was performed. The implant was secured in place with dental cement and animals were treated with analgesic as needed. Approximately 14 days later, animals underwent a second surgical procedure to place indwelling catheters into the right internal jugular vein and the left carotid artery, which was also performed for animals undergoing only peripheral clamp studies. Hyperinsulinemic-euglycemic clamp studies incorporating peripheral 17α-E2 infusions were performed as previously described (<xref ref-type="bibr" rid="bib26">Einstein et al., 2010</xref>). For studies employing peripheral infusions of 17α-E2, 17α-E2 was diluted in sterile saline to a final concentration of 30 ng/µl. Beginning at t = 0 min animals received a primed-continuous infusion of saline or 30 ng/µl 17α-E2 provided as a 3 µg bolus at a rate of 20 ul/min over 5 min, followed by a continuous infusion at a rate of 0.06 ml/hr over 235 min (9.4 ng/hr) for a maintenance dose of 7 µg (total dose 10 µg). Hyperinsulinemic-euglycemic clamp studies with intracerebroventricular (ICV) infusions were performed as previously described (<xref ref-type="bibr" rid="bib48">Huffman et al., 2016a</xref>). 17α-E2 powder (Steraloids, Newport, RI) was dissolved in DMSO at a concentration of 10 mg/ml and stored at −80°C. For ICV infusions, 17α-E2 was diluted in artificial cerebral spinal fluid (ACSF) to a final concentration of 2 ng/µl. Beginning at t = 0 min, animals received a primed-continuous ICV infusion of ACSF (Veh.) or 17α-E2 (17α) provided as a 15 ng bolus at a rate of 1 µl/min over 7.5 min, followed by a continuous infusion of 56.5 ng at a rate of 0.08 µl/hr over 6 hr (9.4 ng/hr) and a total dose of 71.5 ng. All animal procedures were reviewed and approved by the Institutional Animal Care and Use Committee at the Einstein College of Medicine.</p></sec><sec id="s4-8"><title>In vivo metabolic analyses in mice</title><p>To evaluate the effects of 17α-E2 on metabolic parameters in vivo, we performed several assessments of glucose homeostasis. Unless otherwise noted, all experiments requiring fasting conditions were performed in the afternoon, 5–6 hr following the removal of food at the beginning of the light-cycle as outlined elsewhere (<xref ref-type="bibr" rid="bib5">Ayala et al., 2010</xref>). To ensure fasting conditions, mice were transferred to clean cages containing ISO cotton padding and clean cardboard enrichment tubes. Non-terminal blood was collected via tail snip. Fasting glucose was evaluated using a Bayer Breeze 2 Blood Glucose Monitoring System (Bayer Global, Leverkusen, Germany). Fasting insulin was evaluated using a Mouse Ultrasensitive Insulin ELISA from Alpco (Salem, NH). HbA1c was assessed by A1C-Now Monitoring kits (Bayer, Whippany, NJ). Glucose tolerance tests were performed following a 5 hr fast using an intraperitoneal filtered dextrose injection of 1 g/kg body mass (<xref ref-type="bibr" rid="bib49">Huffman et al., 2016b</xref>). Blood glucose was measured immediately pre-injection (time 0) and at 15, 30, 60, 90, and 120 min post-injection.</p></sec><sec id="s4-9"><title>Liver histology</title><p>To evaluate the effects of 17α-E2 treatment on lipid accumulation and fibrosis, we evaluated fixed liver tissue. Tissues were fixed in 4% PFA for 24 hr, cryo-embedding samples were transferred to 30% sucrose for 72 hr and embedded in OCT, paraffin-embedding samples were transferred to 1X PBS for 48 hr, then to 70% ethanol until embedding. Liver oil-red-O and Masson’s trichrome staining were performed by the Oklahoma Medical Research Foundation Imaging Core Facility using previously reported methodology (<xref ref-type="bibr" rid="bib64">Leonard et al., 2018</xref>; <xref ref-type="bibr" rid="bib81">Mehlem et al., 2013</xref>). Oil-red-O (ORO, Sigma-Aldrich, St. Louis, MO) and H and E counterstaining were performed on cryo-embedded tissues, and were imaged within 6 hr of staining. Red lipid stain was blindly quantified from 10 images per animal using ImageJ software and presented as a lipid to total tissue ratio. Masson’s trichrome staining was performed on paraffin embedded liver tissue and was used for qualitative purposes. In brief, slides were stained with Weigert’s Iron Hematoxylin (Sigma-Aldrich, St. Louis, MO), washed, stained with Biebrich Scarlet-Acid Fusion (Sigma-Aldrich, St. Louis, MO), washed, stained with Phosphomolybdic Acid-Phosphotunsctic Acid, and then stained with Aniline Blue (Sigma-Aldrich, St. Louis, MO).</p></sec><sec id="s4-10"><title>Liver triglycerides</title><p>We evaluated the effects of 17α-E2 treatment on triglyceride accumulation in the liver. Liver samples (∼100 mg) were homogenized on ice for 60 s in 10X (v/w) Cell Signaling Lysis Buffer (Cell Signaling, Danvers, MA) with protease and phosphatase inhibitors (Boston BioProducts, Boston, MA). Total lipid was extracted from the homogenate using the Folch method with a 2:1 chloroform-methanol mixture (<xref ref-type="bibr" rid="bib31">Folch et al., 1957</xref>). Lipid was dried down using a nitrogen drier at room temperature, and resuspended in 100 µl of 3:1:1 tert-butyl alcohol-methanol-Triton X-100 solution. Final triglyceride concentrations were determined using a spectrophotometric assay with a 4:1 Free Glycerol Agent/Triglyceride Agent solution (Sigma Triglyceride and Free-Glycerol reagents, St. Louis, MO) as previously described (<xref ref-type="bibr" rid="bib117">Stout et al., 2011</xref>).</p></sec><sec id="s4-11"><title>Liver fatty acids</title><p>We evaluated the effects of 17α-E2 on hepatic fatty acid content. Liver samples (∼50 mg) were homogenized and on ice for 60 s in 10X (v/w) Cell Signaling Lysis Buffer (Cell Signaling, Danvers, MA) with protease and phosphatase inhibitors (Boston BioProducts, Boston, MA). Total lipid was extracted using a modified Bligh and Dyer method (<xref ref-type="bibr" rid="bib10">Bligh and Dyer, 1959</xref>) (Sigma-Aldrich, St. Louis, MO). Of 15:0 and 17:0 internal standards, 50 nmol were added and acid hydrolysis/methanolysis was done to generate fatty acid methyl esters (FAMEs) (<xref ref-type="bibr" rid="bib2">Agbaga et al., 2018</xref>). FAMEs were identified as previously described by GC-MS (<xref ref-type="bibr" rid="bib2">Agbaga et al., 2018</xref>). A 6890N gas chromatograph with flame ionization detector (GC-FID) (Agilent Technologies) was used to quantify FAMEs (<xref ref-type="bibr" rid="bib147">Yu et al., 2012</xref>). Standards 15:0 and 17:0 were used to compare and determine sample concentrations. Data is represented as the relative mole percent of each fatty acid.</p></sec><sec id="s4-12"><title>Plasma eicosanoids</title><p>We evaluated the effects of 17α-E2 treatment on circulating eicosanoids (<xref ref-type="supplementary-material" rid="supp3">Supplementary file 3</xref>). Plasma eicosanoid analyses were performed by the UCSD Lipidomics Core as described previously (<xref ref-type="bibr" rid="bib99">Quehenberger et al., 2010</xref>). Eicosanoids were isolated from plasma, extracted, separated using liquid chromatography, and analyzed with mass spectrometry (MDS SCIEX 4000 Q Trap; Applied Biosystems, Foster City, CA) (<xref ref-type="bibr" rid="bib99">Quehenberger et al., 2010</xref>).</p></sec><sec id="s4-13"><title>Real-time PCR</title><p>To evaluate alterations in gene expression following 17α-E2 treatment, we performed qPCR for genes related to fibrosis, lipid metabolism, insulin resistance, and glucose metabolism in the liver. Total RNA was extracted using Trizol (Life Technologies, Carlsbad, CA) and was reverse transcribed to cDNA with the High-Capacity cDNA Reverse Transcription kit (Applied Biosystems, Foster City, CA). Real-time PCR was performed in a QuantStudio 12K Flex Real Time PCR System (Thermofisher Scientific, Waltham, MA) using TaqMan Gene Expression Master Mix (Applied Biosystems/Thermofisher Scientific, Waltham, MA) and predesigned gene expression assays with FAM probes from Integrated DNA Technologies (Skokie, Illinois). Target gene expression was expressed as 2<sup>−ΔΔCT</sup> by the comparative CT method (<xref ref-type="bibr" rid="bib70">Livak and Schmittgen, 2001</xref>) and normalized to the expression of TATA-Box Binding Protein (TBP) in liver.</p></sec><sec id="s4-14"><title>Western blotting</title><p>To determine if 17α-E2 altered hepatic insulin sensitivity, we evaluated phosphorylation status of AKT and FOXO1 following an insulin bolus. Liver was homogenized in RIPA Buffer (Cell Signaling, Danvers, MA) with protease and phosphatase inhibitors (Boston Bioproducts, Boston, MA). Total protein was quantified using BCA Protein Assay Reagent Kit (Pierce, Rockford, IL). Proteins were separated on an Any kD Criterion TGX Stain-Free Protein Gel (Biorad, Hercules, CA) at 75V for 150 min in Running Buffer (Cell Signaling, Danvers, MA) and transferred to a 0.2 µm pore size nitrocellulose membrane, (Biorad, Hercules, CA) at 75V for 90 min on ice. Primary antibodies used were pS256 FOX01 (Abcam ab131339, 1:1000), FOX01a (Abcam ab52857, 1:1000), pS473 AKT (Abcam ab81283, 1:3000), pan-AKT (Abcam ab179463, 1:10000), GAPDH (Abcam ab9485, 1:2500). Primary antibody detection was performed with IRDye 800CW Infrared Rabbit (LI-COR Biotechnology, Lincoln, NE) at 1:15,000 concentration. GAPDH was diluted in 5% dry milk (Cell Signaling, Danvers, MA), all other antibodies were diluted in 5% BSA (Cell Signaling, Danvers, MA). Blot imaging was done on Odyssey Fc Imaging System (LI-COR Biotechnology, Lincoln, NE) with a two-minute exposure time at 800λ, and protein detection and quantification were performed using Image Studio Software (LI-COR Biotechnology, Lincoln, NE).</p></sec><sec id="s4-15"><title>Statistical analyses</title><p>Results are presented as mean ± SEM unless otherwise stated with <italic>p</italic> values less than 0.05 considered to be significant unless otherwise specified. Analyses of differences between groups were performed by two-way ANOVA, two-way repeated measures ANOVA, or Student’s t-test where appropriate using SigmaPlot 12.5 Software. A Benjamini-Hochberg multiple testing correction was applied to the F test result to correct for the number of transcripts, proteins, and fatty acids analyzed.</p></sec></sec></body><back><ack id="ack"><title>Acknowledgements</title><p>We thank Dr. Kenneth Korach at the National Institute of Environmental Health Sciences for providing ERα KO and WT littermate mice. We also thank Dr. Lora Bailey-Downs, Richard Brush, and Michael Sullivan for technical support. This work was supported by the National Institutes of Health (R00 AG51661 and R01 AG069742 to MBS, T32 AG052363 to SNM, R01 EY030513 to M-PA, and R01 AG059430 to WMF), Veterans Affairs (I01B × 003906 to WMF) and pilot research funding from the Harold Hamm Diabetes Center (MBS and SNM), Einstein Nathan Shock Center (P30 AG038072) of Excellence in the Basic Biology of Aging (MBS), and OUHSC Lipidomics Core (P30 EY012190).</p></ack><sec id="s5" sec-type="additional-information"><title>Additional information</title><fn-group content-type="competing-interest"><title>Competing interests</title><fn fn-type="COI-statement" id="conf1"><p>No competing interests declared</p></fn></fn-group><fn-group content-type="author-contribution"><title>Author contributions</title><fn fn-type="con" id="con1"><p>Conceptualization, Formal analysis, Funding acquisition, Investigation, Methodology, Writing - original draft, Project administration, Writing - review and editing</p></fn><fn fn-type="con" id="con2"><p>Software, Formal analysis, Validation, Investigation, Visualization, Methodology, Writing - review and editing</p></fn><fn fn-type="con" id="con3"><p>Formal analysis, Validation, Methodology</p></fn><fn fn-type="con" id="con4"><p>Formal analysis, Validation, Writing - review and editing</p></fn><fn fn-type="con" id="con5"><p>Formal analysis, Investigation, Methodology</p></fn><fn fn-type="con" id="con6"><p>Formal analysis, Investigation, Writing - review and editing</p></fn><fn fn-type="con" id="con7"><p>Formal analysis, Investigation, Methodology, Writing - review and editing</p></fn><fn fn-type="con" id="con8"><p>Formal analysis, Investigation, Methodology, Writing - review and editing</p></fn><fn fn-type="con" id="con9"><p>Formal analysis, Supervision, Investigation, Methodology, Writing - review and editing</p></fn><fn fn-type="con" id="con10"><p>Formal analysis, Supervision, Validation, Investigation, Methodology, Writing - review and editing</p></fn><fn fn-type="con" id="con11"><p>Data curation, Formal analysis, Validation, Investigation, Visualization, Methodology, Writing - review and editing</p></fn><fn fn-type="con" id="con12"><p>Data curation, Software, Formal analysis, Supervision, Investigation, Visualization, Writing - review and editing</p></fn><fn fn-type="con" id="con13"><p>Conceptualization, Resources, Data curation, Formal analysis, Supervision, Funding acquisition, Validation, Investigation, Visualization, Methodology, Writing - original draft, Project administration, Writing - review and editing</p></fn></fn-group><fn-group content-type="ethics-information"><title>Ethics</title><fn fn-type="other"><p>Animal experimentation: This study was performed in strict accordance with the recommendations in the Guide for the Care and Use of Laboratory Animals of the National Institutes of Health. All of the animals were handled according to approved institutional animal care and use committee (IACUC) protocols (#19-063-SEAHI) of the University of Oklahoma Health Science Center.</p></fn></fn-group></sec><sec id="s6" sec-type="supplementary-material"><title>Additional files</title><supplementary-material id="supp1"><label>Supplementary file 1.</label><caption><title>Pairwise statistical comparisons of ERα binding.</title><p>Negative binomial regression Wald post-hoc comparison test, FDR &lt; 0.05. n = 3/group.</p></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-59616-supp1-v2.xlsx"/></supplementary-material><supplementary-material id="supp2"><label>Supplementary file 2.</label><caption><title>ERα binding motif analysis.</title><p>Motif analysis was performed using HOMER with standard settings with the significance threshold set to FDR corrected p&lt;0.05. Peak regions called for each treatment group were analyzed to identify enriched motifs relative to the entire genome. Hypergeometric test was used to test enrichment. Only motifs with FDR corrected p&lt;0.05 were reported as significant. For pairwise differential motif enrichment or depletion across experimental groups, we utilized the hypergeometric test by using the number of sequences with motif from each group and total number of peaks as total sample size. Motifs that appear in less than five sequences between both test groups were removed. Benjamini-Hochberg multiple testing correction was utilized to control for false discovery rate (FDR &lt; 0.05).</p></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-59616-supp2-v2.xlsx"/></supplementary-material><supplementary-material id="supp3"><label>Supplementary file 3.</label><caption><title>Circulating eicosanoid levels (pmol/ml).</title><p>17α-E2 mildly alters the circulating eicosanoid profile in obese middle-aged male mice. WT mice were provided 45% HFD (TestDiet 58V8)±17α-E2 (14.4ppm) for 14 weeks. Age-matched, male WT, chow-fed (TestDiet 58YP) mice were also evaluated as a normal-weight reference group. All data are presented as mean ± SEM and were analyzed by Student’s t-test with the WT Chow group being excluded from statistical comparisons. n = 5–7.</p></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-59616-supp3-v2.xlsx"/></supplementary-material><supplementary-material id="transrepform"><label>Transparent reporting form</label><media mime-subtype="docx" mimetype="application" xlink:href="elife-59616-transrepform-v2.docx"/></supplementary-material></sec><sec id="s7" sec-type="data-availability"><title>Data availability</title><p>Sequencing data has been deposited in GEO under accession code GSE151039.</p><p>The following dataset was generated:</p><p><element-citation id="dataset1" publication-type="data" specific-use="isSupplementedBy"><person-group person-group-type="author"><name><surname>Stout</surname><given-names>M</given-names></name><name><surname>Hawse</surname><given-names>J</given-names></name><name><surname>Freeman</surname><given-names>W</given-names></name><name><surname>Hadad</surname><given-names>N</given-names></name><name><surname>Mann</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2020">2020</year><data-title>Assessment of transcriptional ERa activity following exposure to 17a-E2 and 17b-E2</data-title><source>NCBI Gene Expression Omnibus</source><pub-id assigning-authority="NCBI" pub-id-type="accession" xlink:href="https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE151039">GSE151039</pub-id></element-citation></p></sec><ref-list><title>References</title><ref id="bib1"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Acosta-Martinez</surname> <given-names>M</given-names></name><name><surname>Horton</surname> <given-names>T</given-names></name><name><surname>Levine</surname> <given-names>JE</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>Estrogen receptors in neuropeptide Y neurons: at the crossroads of feeding and reproduction</article-title><source>Trends in Endocrinology &amp; Metabolism</source><volume>18</volume><fpage>48</fpage><lpage>50</lpage><pub-id pub-id-type="doi">10.1016/j.tem.2006.12.001</pub-id><pub-id pub-id-type="pmid">17174101</pub-id></element-citation></ref><ref id="bib2"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Agbaga</surname> <given-names>MP</given-names></name><name><surname>Merriman</surname> <given-names>DK</given-names></name><name><surname>Brush</surname> <given-names>RS</given-names></name><name><surname>Lydic</surname> <given-names>TA</given-names></name><name><surname>Conley</surname> <given-names>SM</given-names></name><name><surname>Naash</surname> <given-names>MI</given-names></name><name><surname>Jackson</surname> <given-names>S</given-names></name><name><surname>Woods</surname> <given-names>AS</given-names></name><name><surname>Reid</surname> <given-names>GE</given-names></name><name><surname>Busik</surname> <given-names>JV</given-names></name><name><surname>Anderson</surname> <given-names>RE</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Differential composition of DHA and very-long-chain PUFAs in rod and cone photoreceptors</article-title><source>Journal of Lipid Research</source><volume>59</volume><fpage>1586</fpage><lpage>1596</lpage><pub-id pub-id-type="doi">10.1194/jlr.M082495</pub-id><pub-id pub-id-type="pmid">29986998</pub-id></element-citation></ref><ref id="bib3"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Allard</surname> <given-names>C</given-names></name><name><surname>Morford</surname> <given-names>JJ</given-names></name><name><surname>Xu</surname> <given-names>B</given-names></name><name><surname>Salwen</surname> <given-names>B</given-names></name><name><surname>Xu</surname> <given-names>W</given-names></name><name><surname>Desmoulins</surname> <given-names>L</given-names></name><name><surname>Zsombok</surname> <given-names>A</given-names></name><name><surname>Kim</surname> <given-names>JK</given-names></name><name><surname>Levin</surname> <given-names>ER</given-names></name><name><surname>Mauvais-Jarvis</surname> <given-names>F</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Loss of nuclear and membrane estrogen Receptor-α differentially impairs insulin secretion and action in male and female mice</article-title><source>Diabetes</source><volume>68</volume><fpage>490</fpage><lpage>501</lpage><pub-id pub-id-type="doi">10.2337/db18-0293</pub-id><pub-id pub-id-type="pmid">30305367</pub-id></element-citation></ref><ref id="bib4"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Anstead</surname> <given-names>GM</given-names></name><name><surname>Carlson</surname> <given-names>KE</given-names></name><name><surname>Katzenellenbogen</surname> <given-names>JA</given-names></name></person-group><year iso-8601-date="1997">1997</year><article-title>The estradiol pharmacophore: ligand structure-estrogen receptor binding affinity relationships and a model for the receptor binding site</article-title><source>Steroids</source><volume>62</volume><fpage>268</fpage><lpage>303</lpage><pub-id pub-id-type="doi">10.1016/S0039-128X(96)00242-5</pub-id><pub-id pub-id-type="pmid">9071738</pub-id></element-citation></ref><ref id="bib5"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ayala</surname> <given-names>JE</given-names></name><name><surname>Samuel</surname> <given-names>VT</given-names></name><name><surname>Morton</surname> <given-names>GJ</given-names></name><name><surname>Obici</surname> <given-names>S</given-names></name><name><surname>Croniger</surname> <given-names>CM</given-names></name><name><surname>Shulman</surname> <given-names>GI</given-names></name><name><surname>Wasserman</surname> <given-names>DH</given-names></name><name><surname>McGuinness</surname> <given-names>OP</given-names></name><collab>NIH Mouse Metabolic Phenotyping Center Consortium</collab></person-group><year iso-8601-date="2010">2010</year><article-title>Standard operating procedures for describing and performing metabolic tests of glucose homeostasis in mice</article-title><source>Disease Models &amp; Mechanisms</source><volume>3</volume><fpage>525</fpage><lpage>534</lpage><pub-id pub-id-type="doi">10.1242/dmm.006239</pub-id><pub-id pub-id-type="pmid">20713647</pub-id></element-citation></ref><ref id="bib6"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Baeck</surname> <given-names>C</given-names></name><name><surname>Wehr</surname> <given-names>A</given-names></name><name><surname>Karlmark</surname> <given-names>KR</given-names></name><name><surname>Heymann</surname> <given-names>F</given-names></name><name><surname>Vucur</surname> <given-names>M</given-names></name><name><surname>Gassler</surname> <given-names>N</given-names></name><name><surname>Huss</surname> <given-names>S</given-names></name><name><surname>Klussmann</surname> <given-names>S</given-names></name><name><surname>Eulberg</surname> <given-names>D</given-names></name><name><surname>Luedde</surname> <given-names>T</given-names></name><name><surname>Trautwein</surname> <given-names>C</given-names></name><name><surname>Tacke</surname> <given-names>F</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Pharmacological inhibition of the chemokine CCL2 (MCP-1) diminishes liver macrophage infiltration and steatohepatitis in chronic hepatic injury</article-title><source>Gut</source><volume>61</volume><fpage>416</fpage><lpage>426</lpage><pub-id pub-id-type="doi">10.1136/gutjnl-2011-300304</pub-id><pub-id pub-id-type="pmid">21813474</pub-id></element-citation></ref><ref id="bib7"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Barros</surname> <given-names>RP</given-names></name><name><surname>Gustafsson</surname> <given-names>JÅ</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Estrogen receptors and the metabolic network</article-title><source>Cell Metabolism</source><volume>14</volume><fpage>289</fpage><lpage>299</lpage><pub-id pub-id-type="doi">10.1016/j.cmet.2011.08.005</pub-id><pub-id pub-id-type="pmid">21907136</pub-id></element-citation></ref><ref id="bib8"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Benedusi</surname> <given-names>V</given-names></name><name><surname>Martini</surname> <given-names>E</given-names></name><name><surname>Kallikourdis</surname> <given-names>M</given-names></name><name><surname>Villa</surname> <given-names>A</given-names></name><name><surname>Meda</surname> <given-names>C</given-names></name><name><surname>Maggi</surname> <given-names>A</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Ovariectomy shortens the life span of female mice</article-title><source>Oncotarget</source><volume>6</volume><fpage>10801</fpage><lpage>10811</lpage><pub-id pub-id-type="doi">10.18632/oncotarget.2984</pub-id><pub-id pub-id-type="pmid">25719423</pub-id></element-citation></ref><ref id="bib9"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bischof</surname> <given-names>GN</given-names></name><name><surname>Park</surname> <given-names>DC</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Obesity and aging: consequences for cognition, brain structure, and brain function</article-title><source>Psychosomatic Medicine</source><volume>77</volume><fpage>697</fpage><lpage>709</lpage><pub-id pub-id-type="doi">10.1097/PSY.0000000000000212</pub-id><pub-id pub-id-type="pmid">26107577</pub-id></element-citation></ref><ref id="bib10"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bligh</surname> <given-names>EG</given-names></name><name><surname>Dyer</surname> <given-names>WJ</given-names></name></person-group><year iso-8601-date="1959">1959</year><article-title>A rapid method of total lipid extraction and purification</article-title><source>Canadian Journal of Biochemistry and Physiology</source><volume>37</volume><fpage>911</fpage><lpage>917</lpage><pub-id pub-id-type="doi">10.1139/o59-099</pub-id><pub-id pub-id-type="pmid">13671378</pub-id></element-citation></ref><ref id="bib11"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bolduc</surname> <given-names>C</given-names></name><name><surname>Larose</surname> <given-names>M</given-names></name><name><surname>Yoshioka</surname> <given-names>M</given-names></name><name><surname>Ye</surname> <given-names>P</given-names></name><name><surname>Belleau</surname> <given-names>P</given-names></name><name><surname>Labrie</surname> <given-names>C</given-names></name><name><surname>Morissette</surname> <given-names>J</given-names></name><name><surname>Raymond</surname> <given-names>V</given-names></name><name><surname>Labrie</surname> <given-names>F</given-names></name><name><surname>St-Amand</surname> <given-names>J</given-names></name></person-group><year iso-8601-date="2004">2004</year><article-title>Effects of dihydrotestosterone on adipose tissue measured by serial analysis of gene expression</article-title><source>Journal of Molecular Endocrinology</source><volume>33</volume><fpage>429</fpage><lpage>444</lpage><pub-id pub-id-type="doi">10.1677/jme.1.01503</pub-id><pub-id pub-id-type="pmid">15525599</pub-id></element-citation></ref><ref id="bib12"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brandt</surname> <given-names>C</given-names></name><name><surname>Nolte</surname> <given-names>H</given-names></name><name><surname>Henschke</surname> <given-names>S</given-names></name><name><surname>Engström Ruud</surname> <given-names>L</given-names></name><name><surname>Awazawa</surname> <given-names>M</given-names></name><name><surname>Morgan</surname> <given-names>DA</given-names></name><name><surname>Gabel</surname> <given-names>P</given-names></name><name><surname>Sprenger</surname> <given-names>HG</given-names></name><name><surname>Hess</surname> <given-names>ME</given-names></name><name><surname>Günther</surname> <given-names>S</given-names></name><name><surname>Langer</surname> <given-names>T</given-names></name><name><surname>Rahmouni</surname> <given-names>K</given-names></name><name><surname>Fenselau</surname> <given-names>H</given-names></name><name><surname>Krüger</surname> <given-names>M</given-names></name><name><surname>Brüning</surname> <given-names>JC</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Food perception primes hepatic ER homeostasis via Melanocortin-Dependent control of mTOR activation</article-title><source>Cell</source><volume>175</volume><fpage>1321</fpage><lpage>1335</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2018.10.015</pub-id><pub-id pub-id-type="pmid">30445039</pub-id></element-citation></ref><ref id="bib13"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brussaard</surname> <given-names>HE</given-names></name><name><surname>Gevers Leuven</surname> <given-names>JA</given-names></name><name><surname>Frölich</surname> <given-names>M</given-names></name><name><surname>Kluft</surname> <given-names>C</given-names></name><name><surname>Krans</surname> <given-names>HM</given-names></name></person-group><year iso-8601-date="1997">1997</year><article-title>Short-term oestrogen replacement therapy improves insulin resistance, lipids and fibrinolysis in postmenopausal women with NIDDM</article-title><source>Diabetologia</source><volume>40</volume><fpage>843</fpage><lpage>849</lpage><pub-id pub-id-type="doi">10.1007/s001250050758</pub-id><pub-id pub-id-type="pmid">9243107</pub-id></element-citation></ref><ref id="bib14"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Camporez</surname> <given-names>JP</given-names></name><name><surname>Jornayvaz</surname> <given-names>FR</given-names></name><name><surname>Lee</surname> <given-names>HY</given-names></name><name><surname>Kanda</surname> <given-names>S</given-names></name><name><surname>Guigni</surname> <given-names>BA</given-names></name><name><surname>Kahn</surname> <given-names>M</given-names></name><name><surname>Samuel</surname> <given-names>VT</given-names></name><name><surname>Carvalho</surname> <given-names>CR</given-names></name><name><surname>Petersen</surname> <given-names>KF</given-names></name><name><surname>Jurczak</surname> <given-names>MJ</given-names></name><name><surname>Shulman</surname> <given-names>GI</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Cellular mechanism by which estradiol protects female ovariectomized mice from high-fat diet-induced hepatic and muscle insulin resistance</article-title><source>Endocrinology</source><volume>154</volume><fpage>1021</fpage><lpage>1028</lpage><pub-id pub-id-type="doi">10.1210/en.2012-1989</pub-id><pub-id pub-id-type="pmid">23364948</pub-id></element-citation></ref><ref id="bib15"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cherrington</surname> <given-names>AD</given-names></name><name><surname>Wasserman</surname> <given-names>DH</given-names></name><name><surname>McGinness</surname> <given-names>OP</given-names></name></person-group><year iso-8601-date="1994">1994</year><article-title>Renal contribution to glucose production after a brief fast: fact or fancy?</article-title><source>The Journal of Clinical Investigation</source><volume>93</volume><elocation-id>2303</elocation-id><pub-id pub-id-type="doi">10.1172/JCI117232</pub-id><pub-id pub-id-type="pmid">8200961</pub-id></element-citation></ref><ref id="bib16"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Crary</surname> <given-names>GS</given-names></name><name><surname>Albrecht</surname> <given-names>JH</given-names></name></person-group><year iso-8601-date="1998">1998</year><article-title>Expression of cyclin-dependent kinase inhibitor p21 in human liver</article-title><source>Hepatology</source><volume>28</volume><fpage>738</fpage><lpage>743</lpage><pub-id pub-id-type="doi">10.1002/hep.510280320</pub-id><pub-id pub-id-type="pmid">9731566</pub-id></element-citation></ref><ref id="bib17"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>D'Amato</surname> <given-names>NC</given-names></name><name><surname>Gordon</surname> <given-names>MA</given-names></name><name><surname>Babbs</surname> <given-names>B</given-names></name><name><surname>Spoelstra</surname> <given-names>NS</given-names></name><name><surname>Carson Butterfield</surname> <given-names>KT</given-names></name><name><surname>Torkko</surname> <given-names>KC</given-names></name><name><surname>Phan</surname> <given-names>VT</given-names></name><name><surname>Barton</surname> <given-names>VN</given-names></name><name><surname>Rogers</surname> <given-names>TJ</given-names></name><name><surname>Sartorius</surname> <given-names>CA</given-names></name><name><surname>Elias</surname> <given-names>A</given-names></name><name><surname>Gertz</surname> <given-names>J</given-names></name><name><surname>Jacobsen</surname> <given-names>BM</given-names></name><name><surname>Richer</surname> <given-names>JK</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Cooperative dynamics of AR and ER activity in breast Cancer</article-title><source>Molecular Cancer Research : MCR</source><volume>14</volume><fpage>1054</fpage><lpage>1067</lpage><pub-id pub-id-type="doi">10.1158/1541-7786.MCR-16-0167</pub-id><pub-id pub-id-type="pmid">27565181</pub-id></element-citation></ref><ref id="bib18"><element-citation publication-type="preprint"><person-group person-group-type="author"><name><surname>Debarba</surname> <given-names>LK</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Sex hormones underlying 17a-estradiol effects on neuroinflammation</article-title><source>bioRxiv</source><pub-id pub-id-type="doi">10.1101/2020.05.26.117689</pub-id></element-citation></ref><ref id="bib19"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Della Torre</surname> <given-names>S</given-names></name><name><surname>Mitro</surname> <given-names>N</given-names></name><name><surname>Fontana</surname> <given-names>R</given-names></name><name><surname>Gomaraschi</surname> <given-names>M</given-names></name><name><surname>Favari</surname> <given-names>E</given-names></name><name><surname>Recordati</surname> <given-names>C</given-names></name><name><surname>Lolli</surname> <given-names>F</given-names></name><name><surname>Quagliarini</surname> <given-names>F</given-names></name><name><surname>Meda</surname> <given-names>C</given-names></name><name><surname>Ohlsson</surname> <given-names>C</given-names></name><name><surname>Crestani</surname> <given-names>M</given-names></name><name><surname>Uhlenhaut</surname> <given-names>NH</given-names></name><name><surname>Calabresi</surname> <given-names>L</given-names></name><name><surname>Maggi</surname> <given-names>A</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>An essential role for liver erα in coupling hepatic metabolism to the reproductive cycle</article-title><source>Cell Reports</source><volume>15</volume><fpage>360</fpage><lpage>371</lpage><pub-id pub-id-type="doi">10.1016/j.celrep.2016.03.019</pub-id><pub-id pub-id-type="pmid">27050513</pub-id></element-citation></ref><ref id="bib20"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dirks</surname> <given-names>AJ</given-names></name><name><surname>Leeuwenburgh</surname> <given-names>C</given-names></name></person-group><year iso-8601-date="2006">2006</year><article-title>Caloric restriction in humans: potential pitfalls and health concerns</article-title><source>Mechanisms of Ageing and Development</source><volume>127</volume><fpage>1</fpage><lpage>7</lpage><pub-id pub-id-type="doi">10.1016/j.mad.2005.09.001</pub-id><pub-id pub-id-type="pmid">16226298</pub-id></element-citation></ref><ref id="bib21"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dobin</surname> <given-names>A</given-names></name><name><surname>Davis</surname> <given-names>CA</given-names></name><name><surname>Schlesinger</surname> <given-names>F</given-names></name><name><surname>Drenkow</surname> <given-names>J</given-names></name><name><surname>Zaleski</surname> <given-names>C</given-names></name><name><surname>Jha</surname> <given-names>S</given-names></name><name><surname>Batut</surname> <given-names>P</given-names></name><name><surname>Chaisson</surname> <given-names>M</given-names></name><name><surname>Gingeras</surname> <given-names>TR</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>STAR: ultrafast universal RNA-seq aligner</article-title><source>Bioinformatics</source><volume>29</volume><fpage>15</fpage><lpage>21</lpage><pub-id pub-id-type="doi">10.1093/bioinformatics/bts635</pub-id><pub-id pub-id-type="pmid">23104886</pub-id></element-citation></ref><ref id="bib22"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dodd</surname> <given-names>GT</given-names></name><name><surname>Michael</surname> <given-names>NJ</given-names></name><name><surname>Lee-Young</surname> <given-names>RS</given-names></name><name><surname>Mangiafico</surname> <given-names>SP</given-names></name><name><surname>Pryor</surname> <given-names>JT</given-names></name><name><surname>Munder</surname> <given-names>AC</given-names></name><name><surname>Simonds</surname> <given-names>SE</given-names></name><name><surname>Brüning</surname> <given-names>JC</given-names></name><name><surname>Zhang</surname> <given-names>ZY</given-names></name><name><surname>Cowley</surname> <given-names>MA</given-names></name><name><surname>Andrikopoulos</surname> <given-names>S</given-names></name><name><surname>Horvath</surname> <given-names>TL</given-names></name><name><surname>Spanswick</surname> <given-names>D</given-names></name><name><surname>Tiganis</surname> <given-names>T</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Insulin regulates POMC neuronal plasticity to control glucose metabolism</article-title><source>eLife</source><volume>7</volume><elocation-id>e38704</elocation-id><pub-id pub-id-type="doi">10.7554/eLife.38704</pub-id><pub-id pub-id-type="pmid">30230471</pub-id></element-citation></ref><ref id="bib23"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dowman</surname> <given-names>JK</given-names></name><name><surname>Hopkins</surname> <given-names>LJ</given-names></name><name><surname>Reynolds</surname> <given-names>GM</given-names></name><name><surname>Armstrong</surname> <given-names>MJ</given-names></name><name><surname>Nasiri</surname> <given-names>M</given-names></name><name><surname>Nikolaou</surname> <given-names>N</given-names></name><name><surname>van Houten</surname> <given-names>EL</given-names></name><name><surname>Visser</surname> <given-names>JA</given-names></name><name><surname>Morgan</surname> <given-names>SA</given-names></name><name><surname>Lavery</surname> <given-names>GG</given-names></name><name><surname>Oprescu</surname> <given-names>A</given-names></name><name><surname>Hübscher</surname> <given-names>SG</given-names></name><name><surname>Newsome</surname> <given-names>PN</given-names></name><name><surname>Tomlinson</surname> <given-names>JW</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Loss of 5α-reductase type 1 accelerates the development of hepatic steatosis but protects against hepatocellular carcinoma in male mice</article-title><source>Endocrinology</source><volume>154</volume><fpage>4536</fpage><lpage>4547</lpage><pub-id pub-id-type="doi">10.1210/en.2013-1592</pub-id><pub-id pub-id-type="pmid">24080367</pub-id></element-citation></ref><ref id="bib24"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dye</surname> <given-names>L</given-names></name><name><surname>Boyle</surname> <given-names>NB</given-names></name><name><surname>Champ</surname> <given-names>C</given-names></name><name><surname>Lawton</surname> <given-names>C</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>The relationship between obesity and cognitive health and decline</article-title><source>The Proceedings of the Nutrition Society</source><volume>76</volume><fpage>443</fpage><lpage>454</lpage><pub-id pub-id-type="doi">10.1017/S0029665117002014</pub-id><pub-id pub-id-type="pmid">28889822</pub-id></element-citation></ref><ref id="bib25"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Edwards</surname> <given-names>DP</given-names></name><name><surname>McGUIRE</surname> <given-names>WL</given-names></name></person-group><year iso-8601-date="1980">1980</year><article-title>17α-estradiol is a biologically active estrogen in human breast Cancer cells in tissue culture*</article-title><source>Endocrinology</source><volume>107</volume><fpage>884</fpage><lpage>891</lpage><pub-id pub-id-type="doi">10.1210/endo-107-4-884</pub-id></element-citation></ref><ref id="bib26"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Einstein</surname> <given-names>FH</given-names></name><name><surname>Huffman</surname> <given-names>DM</given-names></name><name><surname>Fishman</surname> <given-names>S</given-names></name><name><surname>Jerschow</surname> <given-names>E</given-names></name><name><surname>Heo</surname> <given-names>HJ</given-names></name><name><surname>Atzmon</surname> <given-names>G</given-names></name><name><surname>Schechter</surname> <given-names>C</given-names></name><name><surname>Barzilai</surname> <given-names>N</given-names></name><name><surname>Muzumdar</surname> <given-names>RH</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Aging per se increases the susceptibility to free fatty Acid-Induced insulin resistance</article-title><source>The Journals of Gerontology Series A: Biological Sciences and Medical Sciences</source><volume>65A</volume><fpage>800</fpage><lpage>808</lpage><pub-id pub-id-type="doi">10.1093/gerona/glq078</pub-id></element-citation></ref><ref id="bib27"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Engler-Chiurazzi</surname> <given-names>EB</given-names></name><name><surname>Covey</surname> <given-names>DF</given-names></name><name><surname>Simpkins</surname> <given-names>JW</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>A novel mechanism of non-feminizing estrogens in neuroprotection</article-title><source>Experimental Gerontology</source><volume>94</volume><fpage>99</fpage><lpage>102</lpage><pub-id pub-id-type="doi">10.1016/j.exger.2016.10.013</pub-id><pub-id pub-id-type="pmid">27818250</pub-id></element-citation></ref><ref id="bib28"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Flegal</surname> <given-names>KM</given-names></name><name><surname>Carroll</surname> <given-names>MD</given-names></name><name><surname>Ogden</surname> <given-names>CL</given-names></name><name><surname>Curtin</surname> <given-names>LR</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Prevalence and trends in obesity among US adults, 1999-2008</article-title><source>Jama</source><volume>303</volume><fpage>235</fpage><lpage>241</lpage><pub-id pub-id-type="doi">10.1001/jama.2009.2014</pub-id><pub-id pub-id-type="pmid">20071471</pub-id></element-citation></ref><ref id="bib29"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Flegal</surname> <given-names>KM</given-names></name><name><surname>Kruszon-Moran</surname> <given-names>D</given-names></name><name><surname>Carroll</surname> <given-names>MD</given-names></name><name><surname>Fryar</surname> <given-names>CD</given-names></name><name><surname>Ogden</surname> <given-names>CL</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Trends in obesity among adults in the united states, 2005 to 2014</article-title><source>Jama</source><volume>315</volume><fpage>2284</fpage><lpage>2291</lpage><pub-id pub-id-type="doi">10.1001/jama.2016.6458</pub-id><pub-id pub-id-type="pmid">27272580</pub-id></element-citation></ref><ref id="bib30"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Flouriot</surname> <given-names>G</given-names></name><name><surname>Griffin</surname> <given-names>C</given-names></name><name><surname>Kenealy</surname> <given-names>M</given-names></name><name><surname>Sonntag-Buck</surname> <given-names>V</given-names></name><name><surname>Gannon</surname> <given-names>F</given-names></name></person-group><year iso-8601-date="1998">1998</year><article-title>Differentially expressed messenger RNA isoforms of the human estrogen receptor-alpha gene are generated by alternative splicing and promoter usage</article-title><source>Molecular Endocrinology</source><volume>12</volume><fpage>1939</fpage><lpage>1954</lpage><pub-id pub-id-type="doi">10.1210/mend.12.12.0209</pub-id><pub-id pub-id-type="pmid">9849967</pub-id></element-citation></ref><ref id="bib31"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Folch</surname> <given-names>J</given-names></name><name><surname>Lees</surname> <given-names>M</given-names></name><name><surname>Sloane Stanley</surname> <given-names>GH</given-names></name></person-group><year iso-8601-date="1957">1957</year><article-title>A simple method for the isolation and purification of total lipides from animal tissues</article-title><source>The Journal of Biological Chemistry</source><volume>226</volume><fpage>497</fpage><lpage>509</lpage><pub-id pub-id-type="pmid">13428781</pub-id></element-citation></ref><ref id="bib32"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Garratt</surname> <given-names>M</given-names></name><name><surname>Bower</surname> <given-names>B</given-names></name><name><surname>Garcia</surname> <given-names>GG</given-names></name><name><surname>Miller</surname> <given-names>RA</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Sex differences in lifespan extension with acarbose and 17-α estradiol: gonadal hormones underlie male-specific improvements in glucose tolerance and mTORC2 signaling</article-title><source>Aging Cell</source><volume>16</volume><fpage>1256</fpage><lpage>1266</lpage><pub-id pub-id-type="doi">10.1111/acel.12656</pub-id><pub-id pub-id-type="pmid">28834262</pub-id></element-citation></ref><ref id="bib33"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Garratt</surname> <given-names>M</given-names></name><name><surname>Lagerborg</surname> <given-names>KA</given-names></name><name><surname>Tsai</surname> <given-names>YM</given-names></name><name><surname>Galecki</surname> <given-names>A</given-names></name><name><surname>Jain</surname> <given-names>M</given-names></name><name><surname>Miller</surname> <given-names>RA</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title><italic>Male lifespan extension with</italic> 17<italic>-α estradiol is linked to a sex-specific metabolomic response modulated by gonadal hormones in mice</italic></article-title><source>Aging Cell</source><volume>17</volume><elocation-id>e12786</elocation-id><pub-id pub-id-type="doi">10.1111/acel.12786</pub-id><pub-id pub-id-type="pmid">29806096</pub-id></element-citation></ref><ref id="bib34"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Garratt</surname> <given-names>M</given-names></name><name><surname>Stout</surname> <given-names>MB</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Hormone actions controlling sex-specific life-extension</article-title><source>Aging</source><volume>10</volume><fpage>293</fpage><lpage>294</lpage><pub-id pub-id-type="doi">10.18632/aging.101396</pub-id><pub-id pub-id-type="pmid">29514132</pub-id></element-citation></ref><ref id="bib35"><element-citation publication-type="journal"><person-group person-group-type="author"><collab>GBD 2017 Cirrhosis Collaborators</collab><name><surname>Collaborators</surname> <given-names>G</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>The global, regional, and national burden of cirrhosis by cause in 195 countries and territories, 1990-2017: a systematic analysis for the global burden of disease study 2017</article-title><source>The Lancet. Gastroenterology &amp; Hepatology</source><volume>5</volume><fpage>245</fpage><lpage>266</lpage><pub-id pub-id-type="doi">10.1016/S2468-1253(19)30349-8</pub-id><pub-id pub-id-type="pmid">31981519</pub-id></element-citation></ref><ref id="bib36"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gilroy</surname> <given-names>DW</given-names></name><name><surname>Edin</surname> <given-names>ML</given-names></name><name><surname>De Maeyer</surname> <given-names>RP</given-names></name><name><surname>Bystrom</surname> <given-names>J</given-names></name><name><surname>Newson</surname> <given-names>J</given-names></name><name><surname>Lih</surname> <given-names>FB</given-names></name><name><surname>Stables</surname> <given-names>M</given-names></name><name><surname>Zeldin</surname> <given-names>DC</given-names></name><name><surname>Bishop-Bailey</surname> <given-names>D</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>CYP450-derived oxylipins mediate inflammatory resolution</article-title><source>PNAS</source><volume>113</volume><fpage>E3240</fpage><lpage>E3249</lpage><pub-id pub-id-type="doi">10.1073/pnas.1521453113</pub-id><pub-id pub-id-type="pmid">27226306</pub-id></element-citation></ref><ref id="bib37"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Glass</surname> <given-names>O</given-names></name><name><surname>Henao</surname> <given-names>R</given-names></name><name><surname>Patel</surname> <given-names>K</given-names></name><name><surname>Guy</surname> <given-names>CD</given-names></name><name><surname>Gruss</surname> <given-names>HJ</given-names></name><name><surname>Syn</surname> <given-names>WK</given-names></name><name><surname>Moylan</surname> <given-names>CA</given-names></name><name><surname>Streilein</surname> <given-names>R</given-names></name><name><surname>Hall</surname> <given-names>R</given-names></name><name><surname>Mae Diehl</surname> <given-names>A</given-names></name><name><surname>Abdelmalek</surname> <given-names>MF</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Serum Interleukin-8, osteopontin, and monocyte chemoattractant protein 1 are associated with hepatic fibrosis in patients with nonalcoholic fatty liver disease</article-title><source>Hepatology Communications</source><volume>2</volume><fpage>1344</fpage><lpage>1355</lpage><pub-id pub-id-type="doi">10.1002/hep4.1237</pub-id><pub-id pub-id-type="pmid">30411081</pub-id></element-citation></ref><ref id="bib38"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gould</surname> <given-names>ML</given-names></name><name><surname>Hurst</surname> <given-names>PR</given-names></name><name><surname>Nicholson</surname> <given-names>HD</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>The effects of oestrogen receptors alpha and beta on testicular cell number and steroidogenesis in mice</article-title><source>Reproduction</source><volume>134</volume><fpage>271</fpage><lpage>279</lpage><pub-id pub-id-type="doi">10.1530/REP-07-0025</pub-id><pub-id pub-id-type="pmid">17660237</pub-id></element-citation></ref><ref id="bib39"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Grattagliano</surname> <given-names>I</given-names></name><name><surname>Montezinho</surname> <given-names>LP</given-names></name><name><surname>Oliveira</surname> <given-names>PJ</given-names></name><name><surname>Frühbeck</surname> <given-names>G</given-names></name><name><surname>Gómez-Ambrosi</surname> <given-names>J</given-names></name><name><surname>Montecucco</surname> <given-names>F</given-names></name><name><surname>Carbone</surname> <given-names>F</given-names></name><name><surname>Wieckowski</surname> <given-names>MR</given-names></name><name><surname>Wang</surname> <given-names>DQ</given-names></name><name><surname>Portincasa</surname> <given-names>P</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Targeting mitochondria to oppose the progression of nonalcoholic fatty liver disease</article-title><source>Biochemical Pharmacology</source><volume>160</volume><fpage>34</fpage><lpage>45</lpage><pub-id pub-id-type="doi">10.1016/j.bcp.2018.11.020</pub-id><pub-id pub-id-type="pmid">30508523</pub-id></element-citation></ref><ref id="bib40"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Green</surname> <given-names>PS</given-names></name><name><surname>Simpkins</surname> <given-names>JW</given-names></name></person-group><year iso-8601-date="2000">2000</year><article-title>Estrogens and estrogen-like non-feminizing compounds their role in the prevention and treatment of alzheimer's disease</article-title><source>Annals of the New York Academy of Sciences</source><volume>924</volume><fpage>93</fpage><lpage>98</lpage><pub-id pub-id-type="doi">10.1111/j.1749-6632.2000.tb05566.x</pub-id><pub-id pub-id-type="pmid">11193809</pub-id></element-citation></ref><ref id="bib41"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Guillaume</surname> <given-names>M</given-names></name><name><surname>Riant</surname> <given-names>E</given-names></name><name><surname>Fabre</surname> <given-names>A</given-names></name><name><surname>Raymond-Letron</surname> <given-names>I</given-names></name><name><surname>Buscato</surname> <given-names>M</given-names></name><name><surname>Davezac</surname> <given-names>M</given-names></name><name><surname>Tramunt</surname> <given-names>B</given-names></name><name><surname>Montagner</surname> <given-names>A</given-names></name><name><surname>Smati</surname> <given-names>S</given-names></name><name><surname>Zahreddine</surname> <given-names>R</given-names></name><name><surname>Palierne</surname> <given-names>G</given-names></name><name><surname>Valera</surname> <given-names>MC</given-names></name><name><surname>Guillou</surname> <given-names>H</given-names></name><name><surname>Lenfant</surname> <given-names>F</given-names></name><name><surname>Unsicker</surname> <given-names>K</given-names></name><name><surname>Metivier</surname> <given-names>R</given-names></name><name><surname>Fontaine</surname> <given-names>C</given-names></name><name><surname>Arnal</surname> <given-names>JF</given-names></name><name><surname>Gourdy</surname> <given-names>P</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title><italic>Selective liver estrogen receptor α modulation prevents steatosis</italic>, Diabetes<italic>, and Obesity Through the Anorectic Growth Differentiation Factor 15 Hepatokine in Mice</italic></article-title><source>Hepatology Communications</source><volume>3</volume><fpage>908</fpage><lpage>924</lpage><pub-id pub-id-type="doi">10.1002/hep4.1363</pub-id><pub-id pub-id-type="pmid">31304450</pub-id></element-citation></ref><ref id="bib42"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Guy</surname> <given-names>J</given-names></name><name><surname>Peters</surname> <given-names>MG</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Liver disease in women: the influence of gender on epidemiology, natural history, and patient outcomes</article-title><source>Gastroenterología Y HepatologíA</source><volume>9</volume><fpage>633</fpage><lpage>639</lpage></element-citation></ref><ref id="bib43"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hadad</surname> <given-names>N</given-names></name><name><surname>Masser</surname> <given-names>DR</given-names></name><name><surname>Blanco-Berdugo</surname> <given-names>L</given-names></name><name><surname>Stanford</surname> <given-names>DR</given-names></name><name><surname>Freeman</surname> <given-names>WM</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Early-life DNA methylation profiles are indicative of age-related transcriptome changes</article-title><source>Epigenetics &amp; Chromatin</source><volume>12</volume><elocation-id>58</elocation-id><pub-id pub-id-type="doi">10.1186/s13072-019-0306-5</pub-id><pub-id pub-id-type="pmid">31594536</pub-id></element-citation></ref><ref id="bib44"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Harrison</surname> <given-names>DE</given-names></name><name><surname>Strong</surname> <given-names>R</given-names></name><name><surname>Allison</surname> <given-names>DB</given-names></name><name><surname>Ames</surname> <given-names>BN</given-names></name><name><surname>Astle</surname> <given-names>CM</given-names></name><name><surname>Atamna</surname> <given-names>H</given-names></name><name><surname>Fernandez</surname> <given-names>E</given-names></name><name><surname>Flurkey</surname> <given-names>K</given-names></name><name><surname>Javors</surname> <given-names>MA</given-names></name><name><surname>Nadon</surname> <given-names>NL</given-names></name><name><surname>Nelson</surname> <given-names>JF</given-names></name><name><surname>Pletcher</surname> <given-names>S</given-names></name><name><surname>Simpkins</surname> <given-names>JW</given-names></name><name><surname>Smith</surname> <given-names>D</given-names></name><name><surname>Wilkinson</surname> <given-names>JE</given-names></name><name><surname>Miller</surname> <given-names>RA</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Acarbose, 17-α-estradiol, and nordihydroguaiaretic acid extend mouse lifespan preferentially in males</article-title><source>Aging Cell</source><volume>13</volume><fpage>273</fpage><lpage>282</lpage><pub-id pub-id-type="doi">10.1111/acel.12170</pub-id><pub-id pub-id-type="pmid">24245565</pub-id></element-citation></ref><ref id="bib45"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hayashi</surname> <given-names>M</given-names></name><name><surname>Nomoto</surname> <given-names>S</given-names></name><name><surname>Hishida</surname> <given-names>M</given-names></name><name><surname>Inokawa</surname> <given-names>Y</given-names></name><name><surname>Kanda</surname> <given-names>M</given-names></name><name><surname>Okamura</surname> <given-names>Y</given-names></name><name><surname>Nishikawa</surname> <given-names>Y</given-names></name><name><surname>Tanaka</surname> <given-names>C</given-names></name><name><surname>Kobayashi</surname> <given-names>D</given-names></name><name><surname>Yamada</surname> <given-names>S</given-names></name><name><surname>Nakayama</surname> <given-names>G</given-names></name><name><surname>Fujii</surname> <given-names>T</given-names></name><name><surname>Sugimoto</surname> <given-names>H</given-names></name><name><surname>Koike</surname> <given-names>M</given-names></name><name><surname>Fujiwara</surname> <given-names>M</given-names></name><name><surname>Takeda</surname> <given-names>S</given-names></name><name><surname>Kodera</surname> <given-names>Y</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Identification of the collagen type 1 α 1 gene (COL1A1) as a candidate survival-related factor associated with hepatocellular carcinoma</article-title><source>BMC Cancer</source><volume>14</volume><elocation-id>108</elocation-id><pub-id pub-id-type="doi">10.1186/1471-2407-14-108</pub-id><pub-id pub-id-type="pmid">24552139</pub-id></element-citation></ref><ref id="bib46"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Heine</surname> <given-names>PA</given-names></name><name><surname>Taylor</surname> <given-names>JA</given-names></name><name><surname>Iwamoto</surname> <given-names>GA</given-names></name><name><surname>Lubahn</surname> <given-names>DB</given-names></name><name><surname>Cooke</surname> <given-names>PS</given-names></name></person-group><year iso-8601-date="2000">2000</year><article-title>Increased adipose tissue in male and female estrogen receptor-alpha knockout mice</article-title><source>PNAS</source><volume>97</volume><fpage>12729</fpage><lpage>12734</lpage><pub-id pub-id-type="doi">10.1073/pnas.97.23.12729</pub-id><pub-id pub-id-type="pmid">11070086</pub-id></element-citation></ref><ref id="bib47"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Horvath</surname> <given-names>S</given-names></name><name><surname>Erhart</surname> <given-names>W</given-names></name><name><surname>Brosch</surname> <given-names>M</given-names></name><name><surname>Ammerpohl</surname> <given-names>O</given-names></name><name><surname>von Schönfels</surname> <given-names>W</given-names></name><name><surname>Ahrens</surname> <given-names>M</given-names></name><name><surname>Heits</surname> <given-names>N</given-names></name><name><surname>Bell</surname> <given-names>JT</given-names></name><name><surname>Tsai</surname> <given-names>PC</given-names></name><name><surname>Spector</surname> <given-names>TD</given-names></name><name><surname>Deloukas</surname> <given-names>P</given-names></name><name><surname>Siebert</surname> <given-names>R</given-names></name><name><surname>Sipos</surname> <given-names>B</given-names></name><name><surname>Becker</surname> <given-names>T</given-names></name><name><surname>Röcken</surname> <given-names>C</given-names></name><name><surname>Schafmayer</surname> <given-names>C</given-names></name><name><surname>Hampe</surname> <given-names>J</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Obesity accelerates epigenetic aging of human liver</article-title><source>PNAS</source><volume>111</volume><fpage>15538</fpage><lpage>15543</lpage><pub-id pub-id-type="doi">10.1073/pnas.1412759111</pub-id><pub-id pub-id-type="pmid">25313081</pub-id></element-citation></ref><ref id="bib48"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Huffman</surname> <given-names>DM</given-names></name><name><surname>Farias Quipildor</surname> <given-names>G</given-names></name><name><surname>Mao</surname> <given-names>K</given-names></name><name><surname>Zhang</surname> <given-names>X</given-names></name><name><surname>Wan</surname> <given-names>J</given-names></name><name><surname>Apontes</surname> <given-names>P</given-names></name><name><surname>Cohen</surname> <given-names>P</given-names></name><name><surname>Barzilai</surname> <given-names>N</given-names></name></person-group><year iso-8601-date="2016">2016a</year><article-title>Central insulin-like growth factor-1 (IGF-1) restores whole-body insulin action in a model of age-related insulin resistance and IGF-1 decline</article-title><source>Aging Cell</source><volume>15</volume><fpage>181</fpage><lpage>186</lpage><pub-id pub-id-type="doi">10.1111/acel.12415</pub-id><pub-id pub-id-type="pmid">26534869</pub-id></element-citation></ref><ref id="bib49"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Huffman</surname> <given-names>DM</given-names></name><name><surname>Justice</surname> <given-names>JN</given-names></name><name><surname>Stout</surname> <given-names>MB</given-names></name><name><surname>Kirkland</surname> <given-names>JL</given-names></name><name><surname>Barzilai</surname> <given-names>N</given-names></name><name><surname>Austad</surname> <given-names>SN</given-names></name></person-group><year iso-8601-date="2016">2016b</year><article-title>Evaluating health span in preclinical models of aging and disease: guidelines, challenges, and opportunities for geroscience</article-title><source>The Journals of Gerontology Series A: Biological Sciences and Medical Sciences</source><volume>71</volume><fpage>1395</fpage><lpage>1406</lpage><pub-id pub-id-type="doi">10.1093/gerona/glw106</pub-id></element-citation></ref><ref id="bib50"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hunt</surname> <given-names>NJ</given-names></name><name><surname>Kang</surname> <given-names>SWS</given-names></name><name><surname>Lockwood</surname> <given-names>GP</given-names></name><name><surname>Le Couteur</surname> <given-names>DG</given-names></name><name><surname>Cogger</surname> <given-names>VC</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Hallmarks of aging in the liver</article-title><source>Computational and Structural Biotechnology Journal</source><volume>17</volume><fpage>1151</fpage><lpage>1161</lpage><pub-id pub-id-type="doi">10.1016/j.csbj.2019.07.021</pub-id><pub-id pub-id-type="pmid">31462971</pub-id></element-citation></ref><ref id="bib51"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Iñigo</surname> <given-names>MR</given-names></name><name><surname>Amorese</surname> <given-names>AJ</given-names></name><name><surname>Tarpey</surname> <given-names>MD</given-names></name><name><surname>Balestrieri</surname> <given-names>NP</given-names></name><name><surname>Jones</surname> <given-names>KG</given-names></name><name><surname>Patteson</surname> <given-names>DJ</given-names></name><name><surname>Jackson</surname> <given-names>KC</given-names></name><name><surname>Torres</surname> <given-names>MJ</given-names></name><name><surname>Lin</surname> <given-names>CT</given-names></name><name><surname>Smith</surname> <given-names>CD</given-names></name><name><surname>Heden</surname> <given-names>TD</given-names></name><name><surname>McMillin</surname> <given-names>SL</given-names></name><name><surname>Weyrauch</surname> <given-names>LA</given-names></name><name><surname>Stanley</surname> <given-names>EC</given-names></name><name><surname>Schmidt</surname> <given-names>CA</given-names></name><name><surname>Kilburg-Basnyat</surname> <given-names>BB</given-names></name><name><surname>Reece</surname> <given-names>SW</given-names></name><name><surname>Psaltis</surname> <given-names>CE</given-names></name><name><surname>Leinwand</surname> <given-names>LA</given-names></name><name><surname>Funai</surname> <given-names>K</given-names></name><name><surname>McClung</surname> <given-names>JM</given-names></name><name><surname>Gowdy</surname> <given-names>KM</given-names></name><name><surname>Witczak</surname> <given-names>CA</given-names></name><name><surname>Lowe</surname> <given-names>DA</given-names></name><name><surname>Neufer</surname> <given-names>PD</given-names></name><name><surname>Spangenburg</surname> <given-names>EE</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Estrogen receptor-α in female skeletal muscle is not required for regulation of muscle insulin sensitivity and mitochondrial regulation</article-title><source>Molecular Metabolism</source><volume>34</volume><fpage>1</fpage><lpage>15</lpage><pub-id pub-id-type="doi">10.1016/j.molmet.2019.12.010</pub-id><pub-id pub-id-type="pmid">32180550</pub-id></element-citation></ref><ref id="bib52"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jensen</surname> <given-names>MD</given-names></name><name><surname>Ryan</surname> <given-names>DH</given-names></name><name><surname>Apovian</surname> <given-names>CM</given-names></name><name><surname>Ard</surname> <given-names>JD</given-names></name><name><surname>Comuzzie</surname> <given-names>AG</given-names></name><name><surname>Donato</surname> <given-names>KA</given-names></name><name><surname>Hu</surname> <given-names>FB</given-names></name><name><surname>Hubbard</surname> <given-names>VS</given-names></name><name><surname>Jakicic</surname> <given-names>JM</given-names></name><name><surname>Kushner</surname> <given-names>RF</given-names></name><name><surname>Loria</surname> <given-names>CM</given-names></name><name><surname>Millen</surname> <given-names>BE</given-names></name><name><surname>Nonas</surname> <given-names>CA</given-names></name><name><surname>Pi-Sunyer</surname> <given-names>FX</given-names></name><name><surname>Stevens</surname> <given-names>J</given-names></name><name><surname>Stevens</surname> <given-names>VJ</given-names></name><name><surname>Wadden</surname> <given-names>TA</given-names></name><name><surname>Wolfe</surname> <given-names>BM</given-names></name><name><surname>Yanovski</surname> <given-names>SZ</given-names></name><name><surname>Jordan</surname> <given-names>HS</given-names></name><name><surname>Kendall</surname> <given-names>KA</given-names></name><name><surname>Lux</surname> <given-names>LJ</given-names></name><name><surname>Mentor-Marcel</surname> <given-names>R</given-names></name><name><surname>Morgan</surname> <given-names>LC</given-names></name><name><surname>Trisolini</surname> <given-names>MG</given-names></name><name><surname>Wnek</surname> <given-names>J</given-names></name><name><surname>Anderson</surname> <given-names>JL</given-names></name><name><surname>Halperin</surname> <given-names>JL</given-names></name><name><surname>Albert</surname> <given-names>NM</given-names></name><name><surname>Bozkurt</surname> <given-names>B</given-names></name><name><surname>Brindis</surname> <given-names>RG</given-names></name><name><surname>Curtis</surname> <given-names>LH</given-names></name><name><surname>DeMets</surname> <given-names>D</given-names></name><name><surname>Hochman</surname> <given-names>JS</given-names></name><name><surname>Kovacs</surname> <given-names>RJ</given-names></name><name><surname>Ohman</surname> <given-names>EM</given-names></name><name><surname>Pressler</surname> <given-names>SJ</given-names></name><name><surname>Sellke</surname> <given-names>FW</given-names></name><name><surname>Shen</surname> <given-names>WK</given-names></name><name><surname>Smith</surname> <given-names>SC</given-names></name><name><surname>Tomaselli</surname> <given-names>GF</given-names></name><collab>American College of Cardiology/American Heart Association Task Force on Practice Guidelines</collab><collab>Obesity Society</collab></person-group><year iso-8601-date="2014">2014</year><article-title>AHA/ACC/TOS guideline for the management of overweight and obesity in adults: a report of the American college of cardiology/American heart association task force on practice guidelines and the obesity society</article-title><source>Circulation</source><volume>129</volume><fpage>S102</fpage><lpage>S138</lpage><pub-id pub-id-type="doi">10.1161/01.cir.0000437739.71477.ee</pub-id><pub-id pub-id-type="pmid">24222017</pub-id></element-citation></ref><ref id="bib53"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kaur</surname> <given-names>SP</given-names></name><name><surname>Bansal</surname> <given-names>S</given-names></name><name><surname>Chopra</surname> <given-names>K</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>17α-estradiol: a candidate neuroserm and non-feminizing estrogen for postmenopausal neuronal complications</article-title><source>Steroids</source><volume>96</volume><fpage>7</fpage><lpage>15</lpage><pub-id pub-id-type="doi">10.1016/j.steroids.2015.01.004</pub-id><pub-id pub-id-type="pmid">25595449</pub-id></element-citation></ref><ref id="bib54"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kelly</surname> <given-names>MJ</given-names></name><name><surname>Rønnekleiv</surname> <given-names>OK</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Minireview: neural signaling of estradiol in the hypothalamus</article-title><source>Molecular Endocrinology</source><volume>29</volume><fpage>645</fpage><lpage>657</lpage><pub-id pub-id-type="doi">10.1210/me.2014-1397</pub-id><pub-id pub-id-type="pmid">25751314</pub-id></element-citation></ref><ref id="bib55"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Khosla</surname> <given-names>S</given-names></name><name><surname>Monroe</surname> <given-names>DG</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Regulation of bone metabolism by sex steroids</article-title><source>Cold Spring Harbor Perspectives in Medicine</source><volume>8</volume><elocation-id>a031211</elocation-id><pub-id pub-id-type="doi">10.1101/cshperspect.a031211</pub-id><pub-id pub-id-type="pmid">28710257</pub-id></element-citation></ref><ref id="bib56"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname> <given-names>IH</given-names></name><name><surname>Kisseleva</surname> <given-names>T</given-names></name><name><surname>Brenner</surname> <given-names>DA</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Aging and liver disease</article-title><source>Current Opinion in Gastroenterology</source><volume>31</volume><fpage>184</fpage><lpage>191</lpage><pub-id pub-id-type="doi">10.1097/MOG.0000000000000176</pub-id><pub-id pub-id-type="pmid">25850346</pub-id></element-citation></ref><ref id="bib57"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kiss</surname> <given-names>L</given-names></name><name><surname>Schütte</surname> <given-names>H</given-names></name><name><surname>Padberg</surname> <given-names>W</given-names></name><name><surname>Weissmann</surname> <given-names>N</given-names></name><name><surname>Mayer</surname> <given-names>K</given-names></name><name><surname>Gessler</surname> <given-names>T</given-names></name><name><surname>Voswinckel</surname> <given-names>R</given-names></name><name><surname>Seeger</surname> <given-names>W</given-names></name><name><surname>Grimminger</surname> <given-names>F</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Epoxyeicosatrienoates are the dominant eicosanoids in human lungs upon microbial challenge</article-title><source>European Respiratory Journal</source><volume>36</volume><fpage>1088</fpage><lpage>1098</lpage><pub-id pub-id-type="doi">10.1183/09031936.00000309</pub-id><pub-id pub-id-type="pmid">20378604</pub-id></element-citation></ref><ref id="bib58"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kohli</surname> <given-names>P</given-names></name><name><surname>Levy</surname> <given-names>BD</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>Resolvins and protectins: mediating solutions to inflammation</article-title><source>British Journal of Pharmacology</source><volume>158</volume><fpage>960</fpage><lpage>971</lpage><pub-id pub-id-type="doi">10.1111/j.1476-5381.2009.00290.x</pub-id><pub-id pub-id-type="pmid">19594757</pub-id></element-citation></ref><ref id="bib59"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Könner</surname> <given-names>AC</given-names></name><name><surname>Janoschek</surname> <given-names>R</given-names></name><name><surname>Plum</surname> <given-names>L</given-names></name><name><surname>Jordan</surname> <given-names>SD</given-names></name><name><surname>Rother</surname> <given-names>E</given-names></name><name><surname>Ma</surname> <given-names>X</given-names></name><name><surname>Xu</surname> <given-names>C</given-names></name><name><surname>Enriori</surname> <given-names>P</given-names></name><name><surname>Hampel</surname> <given-names>B</given-names></name><name><surname>Barsh</surname> <given-names>GS</given-names></name><name><surname>Kahn</surname> <given-names>CR</given-names></name><name><surname>Cowley</surname> <given-names>MA</given-names></name><name><surname>Ashcroft</surname> <given-names>FM</given-names></name><name><surname>Brüning</surname> <given-names>JC</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>Insulin action in AgRP-expressing neurons is required for suppression of hepatic glucose production</article-title><source>Cell Metabolism</source><volume>5</volume><fpage>438</fpage><lpage>449</lpage><pub-id pub-id-type="doi">10.1016/j.cmet.2007.05.004</pub-id><pub-id pub-id-type="pmid">17550779</pub-id></element-citation></ref><ref id="bib60"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Koo</surname> <given-names>BK</given-names></name><name><surname>Um</surname> <given-names>SH</given-names></name><name><surname>Seo</surname> <given-names>DS</given-names></name><name><surname>Joo</surname> <given-names>SK</given-names></name><name><surname>Bae</surname> <given-names>JM</given-names></name><name><surname>Park</surname> <given-names>JH</given-names></name><name><surname>Chang</surname> <given-names>MS</given-names></name><name><surname>Kim</surname> <given-names>JH</given-names></name><name><surname>Lee</surname> <given-names>J</given-names></name><name><surname>Jeong</surname> <given-names>WI</given-names></name><name><surname>Kim</surname> <given-names>W</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Growth differentiation factor 15 predicts advanced fibrosis in biopsy-proven non-alcoholic fatty liver disease</article-title><source>Liver International</source><volume>38</volume><fpage>695</fpage><lpage>705</lpage><pub-id pub-id-type="doi">10.1111/liv.13587</pub-id><pub-id pub-id-type="pmid">28898507</pub-id></element-citation></ref><ref id="bib61"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Korenman</surname> <given-names>SG</given-names></name></person-group><year iso-8601-date="1969">1969</year><article-title>Comparative binding affinity of estrogens and its relation to estrogenic potency</article-title><source>Steroids</source><volume>13</volume><fpage>163</fpage><lpage>177</lpage><pub-id pub-id-type="doi">10.1016/0039-128X(69)90004-X</pub-id><pub-id pub-id-type="pmid">5773887</pub-id></element-citation></ref><ref id="bib62"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Langmead</surname> <given-names>B</given-names></name><name><surname>Salzberg</surname> <given-names>SL</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Fast gapped-read alignment with bowtie 2</article-title><source>Nature Methods</source><volume>9</volume><fpage>357</fpage><lpage>359</lpage><pub-id pub-id-type="doi">10.1038/nmeth.1923</pub-id><pub-id pub-id-type="pmid">22388286</pub-id></element-citation></ref><ref id="bib63"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname> <given-names>SK</given-names></name><name><surname>Choi</surname> <given-names>HS</given-names></name><name><surname>Song</surname> <given-names>MR</given-names></name><name><surname>Lee</surname> <given-names>MO</given-names></name><name><surname>Lee</surname> <given-names>JW</given-names></name></person-group><year iso-8601-date="1998">1998</year><article-title>Estrogen receptor, a common interaction partner for a subset of nuclear receptors</article-title><source>Molecular Endocrinology</source><volume>12</volume><fpage>1184</fpage><lpage>1192</lpage><pub-id pub-id-type="doi">10.1210/mend.12.8.0146</pub-id><pub-id pub-id-type="pmid">9717844</pub-id></element-citation></ref><ref id="bib64"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Leonard</surname> <given-names>AK</given-names></name><name><surname>Loughran</surname> <given-names>EA</given-names></name><name><surname>Klymenko</surname> <given-names>Y</given-names></name><name><surname>Liu</surname> <given-names>Y</given-names></name><name><surname>Kim</surname> <given-names>O</given-names></name><name><surname>Asem</surname> <given-names>M</given-names></name><name><surname>McAbee</surname> <given-names>K</given-names></name><name><surname>Ravosa</surname> <given-names>MJ</given-names></name><name><surname>Stack</surname> <given-names>MS</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Methods for the visualization and analysis of extracellular matrix protein structure and degradation</article-title><source>Methods in Cell Biology</source><volume>143</volume><fpage>79</fpage><lpage>95</lpage><pub-id pub-id-type="doi">10.1016/bs.mcb.2017.08.005</pub-id><pub-id pub-id-type="pmid">29310793</pub-id></element-citation></ref><ref id="bib65"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname> <given-names>H</given-names></name><name><surname>Handsaker</surname> <given-names>B</given-names></name><name><surname>Wysoker</surname> <given-names>A</given-names></name><name><surname>Fennell</surname> <given-names>T</given-names></name><name><surname>Ruan</surname> <given-names>J</given-names></name><name><surname>Homer</surname> <given-names>N</given-names></name><name><surname>Marth</surname> <given-names>G</given-names></name><name><surname>Abecasis</surname> <given-names>G</given-names></name><name><surname>Durbin</surname> <given-names>R</given-names></name><collab>1000 Genome Project Data Processing Subgroup</collab></person-group><year iso-8601-date="2009">2009</year><article-title>The sequence alignment/Map format and SAMtools</article-title><source>Bioinformatics</source><volume>25</volume><fpage>2078</fpage><lpage>2079</lpage><pub-id pub-id-type="doi">10.1093/bioinformatics/btp352</pub-id><pub-id pub-id-type="pmid">19505943</pub-id></element-citation></ref><ref id="bib66"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lichtinghagen</surname> <given-names>R</given-names></name><name><surname>Bahr</surname> <given-names>MJ</given-names></name><name><surname>Wehmeier</surname> <given-names>M</given-names></name><name><surname>MichelsI</surname> <given-names>D</given-names></name><name><surname>Haberkorn</surname> <given-names>CI</given-names></name><name><surname>Arndt</surname> <given-names>B</given-names></name><name><surname>Flemming</surname> <given-names>P</given-names></name><name><surname>Manns</surname> <given-names>MP</given-names></name><name><surname>Boeker</surname> <given-names>KHW</given-names></name></person-group><year iso-8601-date="2003">2003</year><article-title>Expression and coordinated regulation of matrix metalloproteinases in chronic hepatitis C and hepatitis C virus-induced liver cirrhosis</article-title><source>Clinical Science</source><volume>105</volume><fpage>373</fpage><lpage>382</lpage><pub-id pub-id-type="doi">10.1042/CS20030098</pub-id></element-citation></ref><ref id="bib67"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lin</surname> <given-names>CY</given-names></name><name><surname>Vega</surname> <given-names>VB</given-names></name><name><surname>Thomsen</surname> <given-names>JS</given-names></name><name><surname>Zhang</surname> <given-names>T</given-names></name><name><surname>Kong</surname> <given-names>SL</given-names></name><name><surname>Xie</surname> <given-names>M</given-names></name><name><surname>Chiu</surname> <given-names>KP</given-names></name><name><surname>Lipovich</surname> <given-names>L</given-names></name><name><surname>Barnett</surname> <given-names>DH</given-names></name><name><surname>Stossi</surname> <given-names>F</given-names></name><name><surname>Yeo</surname> <given-names>A</given-names></name><name><surname>George</surname> <given-names>J</given-names></name><name><surname>Kuznetsov</surname> <given-names>VA</given-names></name><name><surname>Lee</surname> <given-names>YK</given-names></name><name><surname>Charn</surname> <given-names>TH</given-names></name><name><surname>Palanisamy</surname> <given-names>N</given-names></name><name><surname>Miller</surname> <given-names>LD</given-names></name><name><surname>Cheung</surname> <given-names>E</given-names></name><name><surname>Katzenellenbogen</surname> <given-names>BS</given-names></name><name><surname>Ruan</surname> <given-names>Y</given-names></name><name><surname>Bourque</surname> <given-names>G</given-names></name><name><surname>Wei</surname> <given-names>CL</given-names></name><name><surname>Liu</surname> <given-names>ET</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>Whole-genome cartography of estrogen receptor alpha binding sites</article-title><source>PLOS Genetics</source><volume>3</volume><elocation-id>e87</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pgen.0030087</pub-id><pub-id pub-id-type="pmid">17542648</pub-id></element-citation></ref><ref id="bib68"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lin</surname> <given-names>AH</given-names></name><name><surname>Li</surname> <given-names>RW</given-names></name><name><surname>Ho</surname> <given-names>EY</given-names></name><name><surname>Leung</surname> <given-names>GP</given-names></name><name><surname>Leung</surname> <given-names>SW</given-names></name><name><surname>Vanhoutte</surname> <given-names>PM</given-names></name><name><surname>Man</surname> <given-names>RY</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Differential ligand binding affinities of human estrogen Receptor-α isoforms</article-title><source>PLOS ONE</source><volume>8</volume><elocation-id>e63199</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0063199</pub-id><pub-id pub-id-type="pmid">23646196</pub-id></element-citation></ref><ref id="bib69"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Littlefield</surname> <given-names>BA</given-names></name><name><surname>Gurpide</surname> <given-names>E</given-names></name><name><surname>Markiewicz</surname> <given-names>L</given-names></name><name><surname>McKinley</surname> <given-names>B</given-names></name><name><surname>Hochberg</surname> <given-names>RB</given-names></name></person-group><year iso-8601-date="1990">1990</year><article-title>A simple and sensitive microtiter plate estrogen bioassay based on stimulation of alkaline phosphatase in Ishikawa cells: estrogenic action of Delta <sup>5</sup>adrenal steroids</article-title><source>Endocrinology</source><volume>127</volume><fpage>2757</fpage><lpage>2762</lpage><pub-id pub-id-type="doi">10.1210/endo-127-6-2757</pub-id><pub-id pub-id-type="pmid">2249627</pub-id></element-citation></ref><ref id="bib70"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Livak</surname> <given-names>KJ</given-names></name><name><surname>Schmittgen</surname> <given-names>TD</given-names></name></person-group><year iso-8601-date="2001">2001</year><article-title>Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta delta C(T)) Method</article-title><source>Methods</source><volume>25</volume><fpage>402</fpage><lpage>408</lpage><pub-id pub-id-type="doi">10.1006/meth.2001.1262</pub-id><pub-id pub-id-type="pmid">11846609</pub-id></element-citation></ref><ref id="bib71"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Livingstone</surname> <given-names>DE</given-names></name><name><surname>Barat</surname> <given-names>P</given-names></name><name><surname>Di Rollo</surname> <given-names>EM</given-names></name><name><surname>Rees</surname> <given-names>GA</given-names></name><name><surname>Weldin</surname> <given-names>BA</given-names></name><name><surname>Rog-Zielinska</surname> <given-names>EA</given-names></name><name><surname>MacFarlane</surname> <given-names>DP</given-names></name><name><surname>Walker</surname> <given-names>BR</given-names></name><name><surname>Andrew</surname> <given-names>R</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>5α-Reductase type 1 deficiency or inhibition predisposes to insulin resistance, hepatic Steatosis, and liver fibrosis in rodents</article-title><source>Diabetes</source><volume>64</volume><fpage>447</fpage><lpage>458</lpage><pub-id pub-id-type="doi">10.2337/db14-0249</pub-id><pub-id pub-id-type="pmid">25239636</pub-id></element-citation></ref><ref id="bib72"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>López</surname> <given-names>M</given-names></name><name><surname>Tena-Sempere</surname> <given-names>M</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Estrogens and the control of energy homeostasis: a brain perspective</article-title><source>Trends in Endocrinology &amp; Metabolism</source><volume>26</volume><fpage>411</fpage><lpage>421</lpage><pub-id pub-id-type="doi">10.1016/j.tem.2015.06.003</pub-id><pub-id pub-id-type="pmid">26126705</pub-id></element-citation></ref><ref id="bib73"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>López-Otín</surname> <given-names>C</given-names></name><name><surname>Blasco</surname> <given-names>MA</given-names></name><name><surname>Partridge</surname> <given-names>L</given-names></name><name><surname>Serrano</surname> <given-names>M</given-names></name><name><surname>Kroemer</surname> <given-names>G</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>The hallmarks of aging</article-title><source>Cell</source><volume>153</volume><fpage>1194</fpage><lpage>1217</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2013.05.039</pub-id><pub-id pub-id-type="pmid">23746838</pub-id></element-citation></ref><ref id="bib74"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Love</surname> <given-names>MI</given-names></name><name><surname>Huber</surname> <given-names>W</given-names></name><name><surname>Anders</surname> <given-names>S</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2</article-title><source>Genome Biology</source><volume>15</volume><elocation-id>550</elocation-id><pub-id pub-id-type="doi">10.1186/s13059-014-0550-8</pub-id><pub-id pub-id-type="pmid">25516281</pub-id></element-citation></ref><ref id="bib75"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lu</surname> <given-names>M</given-names></name><name><surname>Wan</surname> <given-names>M</given-names></name><name><surname>Leavens</surname> <given-names>KF</given-names></name><name><surname>Chu</surname> <given-names>Q</given-names></name><name><surname>Monks</surname> <given-names>BR</given-names></name><name><surname>Fernandez</surname> <given-names>S</given-names></name><name><surname>Ahima</surname> <given-names>RS</given-names></name><name><surname>Ueki</surname> <given-names>K</given-names></name><name><surname>Kahn</surname> <given-names>CR</given-names></name><name><surname>Birnbaum</surname> <given-names>MJ</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Insulin regulates liver metabolism in vivo in the absence of hepatic akt and Foxo1</article-title><source>Nature Medicine</source><volume>18</volume><fpage>388</fpage><lpage>395</lpage><pub-id pub-id-type="doi">10.1038/nm.2686</pub-id><pub-id pub-id-type="pmid">22344295</pub-id></element-citation></ref><ref id="bib76"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lua</surname> <given-names>I</given-names></name><name><surname>Li</surname> <given-names>Y</given-names></name><name><surname>Zagory</surname> <given-names>JA</given-names></name><name><surname>Wang</surname> <given-names>KS</given-names></name><name><surname>French</surname> <given-names>SW</given-names></name><name><surname>Sévigny</surname> <given-names>J</given-names></name><name><surname>Asahina</surname> <given-names>K</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Characterization of hepatic stellate cells, portal fibroblasts, and mesothelial cells in normal and fibrotic livers</article-title><source>Journal of Hepatology</source><volume>64</volume><fpage>1137</fpage><lpage>1146</lpage><pub-id pub-id-type="doi">10.1016/j.jhep.2016.01.010</pub-id><pub-id pub-id-type="pmid">26806818</pub-id></element-citation></ref><ref id="bib77"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Madala</surname> <given-names>SK</given-names></name><name><surname>Pesce</surname> <given-names>JT</given-names></name><name><surname>Ramalingam</surname> <given-names>TR</given-names></name><name><surname>Wilson</surname> <given-names>MS</given-names></name><name><surname>Minnicozzi</surname> <given-names>S</given-names></name><name><surname>Cheever</surname> <given-names>AW</given-names></name><name><surname>Thompson</surname> <given-names>RW</given-names></name><name><surname>Mentink-Kane</surname> <given-names>MM</given-names></name><name><surname>Wynn</surname> <given-names>TA</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Matrix metalloproteinase 12-deficiency augments extracellular matrix degrading metalloproteinases and attenuates IL-13-dependent fibrosis</article-title><source>The Journal of Immunology</source><volume>184</volume><fpage>3955</fpage><lpage>3963</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.0903008</pub-id><pub-id pub-id-type="pmid">20181883</pub-id></element-citation></ref><ref id="bib78"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mann</surname> <given-names>SN</given-names></name><name><surname>Pitel</surname> <given-names>KS</given-names></name><name><surname>Nelson-Holte</surname> <given-names>MH</given-names></name><name><surname>Iwaniec</surname> <given-names>UT</given-names></name><name><surname>Turner</surname> <given-names>RT</given-names></name><name><surname>Sathiaseelan</surname> <given-names>R</given-names></name><name><surname>Kirkland</surname> <given-names>JL</given-names></name><name><surname>Schneider</surname> <given-names>A</given-names></name><name><surname>Morris</surname> <given-names>KT</given-names></name><name><surname>Malayannan</surname> <given-names>S</given-names></name><name><surname>Hawse</surname> <given-names>JR</given-names></name><name><surname>Stout</surname> <given-names>MB</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>17α-estradiol prevents ovariectomy-mediated obesity and bone loss</article-title><source>Experimental Gerontology</source><volume>142</volume><elocation-id>111113</elocation-id><pub-id pub-id-type="doi">10.1016/j.exger.2020.111113</pub-id><pub-id pub-id-type="pmid">33065227</pub-id></element-citation></ref><ref id="bib79"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Manrique</surname> <given-names>C</given-names></name><name><surname>Lastra</surname> <given-names>G</given-names></name><name><surname>Habibi</surname> <given-names>J</given-names></name><name><surname>Mugerfeld</surname> <given-names>I</given-names></name><name><surname>Garro</surname> <given-names>M</given-names></name><name><surname>Sowers</surname> <given-names>JR</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Loss of estrogen receptor α signaling leads to insulin resistance and obesity in young and adult female mice</article-title><source>Cardiorenal Medicine</source><volume>2</volume><fpage>200</fpage><lpage>210</lpage><pub-id pub-id-type="doi">10.1159/000339563</pub-id><pub-id pub-id-type="pmid">22969776</pub-id></element-citation></ref><ref id="bib80"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Meda</surname> <given-names>C</given-names></name><name><surname>Barone</surname> <given-names>M</given-names></name><name><surname>Mitro</surname> <given-names>N</given-names></name><name><surname>Lolli</surname> <given-names>F</given-names></name><name><surname>Pedretti</surname> <given-names>S</given-names></name><name><surname>Caruso</surname> <given-names>D</given-names></name><name><surname>Maggi</surname> <given-names>A</given-names></name><name><surname>Della Torre</surname> <given-names>S</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Hepatic erα accounts for sex differences in the ability to cope with an excess of dietary lipids</article-title><source>Molecular Metabolism</source><volume>32</volume><fpage>97</fpage><lpage>108</lpage><pub-id pub-id-type="doi">10.1016/j.molmet.2019.12.009</pub-id><pub-id pub-id-type="pmid">32029233</pub-id></element-citation></ref><ref id="bib81"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mehlem</surname> <given-names>A</given-names></name><name><surname>Hagberg</surname> <given-names>CE</given-names></name><name><surname>Muhl</surname> <given-names>L</given-names></name><name><surname>Eriksson</surname> <given-names>U</given-names></name><name><surname>Falkevall</surname> <given-names>A</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Imaging of neutral lipids by oil red O for analyzing the metabolic status in health and disease</article-title><source>Nature Protocols</source><volume>8</volume><fpage>1149</fpage><lpage>1154</lpage><pub-id pub-id-type="doi">10.1038/nprot.2013.055</pub-id><pub-id pub-id-type="pmid">23702831</pub-id></element-citation></ref><ref id="bib82"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Miller</surname> <given-names>BF</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Short-term calorie restriction and 17α-estradiol administration elicit divergent effects on proteostatic processes and protein content in metabolically active tissues</article-title><source>The Journals of Gerontology: Series A</source><volume>75 </volume><fpage>849</fpage><lpage>857</lpage><pub-id pub-id-type="doi">10.1093/gerona/glz113</pub-id></element-citation></ref><ref id="bib83"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Monroe</surname> <given-names>DG</given-names></name><name><surname>Getz</surname> <given-names>BJ</given-names></name><name><surname>Johnsen</surname> <given-names>SA</given-names></name><name><surname>Riggs</surname> <given-names>BL</given-names></name><name><surname>Khosla</surname> <given-names>S</given-names></name><name><surname>Spelsberg</surname> <given-names>TC</given-names></name></person-group><year iso-8601-date="2003">2003</year><article-title>Estrogen receptor isoform-specific regulation of endogenous gene expression in human osteoblastic cell lines expressing either ERalpha or ERbeta</article-title><source>Journal of Cellular Biochemistry</source><volume>90</volume><fpage>315</fpage><lpage>326</lpage><pub-id pub-id-type="doi">10.1002/jcb.10633</pub-id><pub-id pub-id-type="pmid">14505348</pub-id></element-citation></ref><ref id="bib84"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Monroe</surname> <given-names>DG</given-names></name><name><surname>Secreto</surname> <given-names>FJ</given-names></name><name><surname>Subramaniam</surname> <given-names>M</given-names></name><name><surname>Getz</surname> <given-names>BJ</given-names></name><name><surname>Khosla</surname> <given-names>S</given-names></name><name><surname>Spelsberg</surname> <given-names>TC</given-names></name></person-group><year iso-8601-date="2005">2005</year><article-title>Estrogen receptor alpha and beta heterodimers exert unique effects on estrogen- and tamoxifen-dependent gene expression in human U2OS osteosarcoma cells</article-title><source>Molecular Endocrinology</source><volume>19</volume><fpage>1555</fpage><lpage>1568</lpage><pub-id pub-id-type="doi">10.1210/me.2004-0381</pub-id><pub-id pub-id-type="pmid">15802376</pub-id></element-citation></ref><ref id="bib85"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Movérare-Skrtic</surname> <given-names>S</given-names></name><name><surname>Venken</surname> <given-names>K</given-names></name><name><surname>Andersson</surname> <given-names>N</given-names></name><name><surname>Lindberg</surname> <given-names>MK</given-names></name><name><surname>Svensson</surname> <given-names>J</given-names></name><name><surname>Swanson</surname> <given-names>C</given-names></name><name><surname>Vanderschueren</surname> <given-names>D</given-names></name><name><surname>Oscarsson</surname> <given-names>J</given-names></name><name><surname>Gustafsson</surname> <given-names>JA</given-names></name><name><surname>Ohlsson</surname> <given-names>C</given-names></name></person-group><year iso-8601-date="2006">2006</year><article-title>Dihydrotestosterone treatment results in obesity and altered lipid metabolism in orchidectomized mice</article-title><source>Obesity</source><volume>14</volume><fpage>662</fpage><lpage>672</lpage><pub-id pub-id-type="doi">10.1038/oby.2006.75</pub-id><pub-id pub-id-type="pmid">16741268</pub-id></element-citation></ref><ref id="bib86"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Murray</surname> <given-names>SA</given-names></name><name><surname>Eppig</surname> <given-names>JT</given-names></name><name><surname>Smedley</surname> <given-names>D</given-names></name><name><surname>Simpson</surname> <given-names>EM</given-names></name><name><surname>Rosenthal</surname> <given-names>N</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Beyond knockouts: cre resources for conditional mutagenesis</article-title><source>Mammalian Genome</source><volume>23</volume><fpage>587</fpage><lpage>599</lpage><pub-id pub-id-type="doi">10.1007/s00335-012-9430-2</pub-id><pub-id pub-id-type="pmid">22926223</pub-id></element-citation></ref><ref id="bib87"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nelson</surname> <given-names>JD</given-names></name><name><surname>Denisenko</surname> <given-names>O</given-names></name><name><surname>Sova</surname> <given-names>P</given-names></name><name><surname>Bomsztyk</surname> <given-names>K</given-names></name></person-group><year iso-8601-date="2006">2006</year><article-title>Fast chromatin immunoprecipitation assay</article-title><source>Nucleic Acids Research</source><volume>34</volume><elocation-id>e2</elocation-id><pub-id pub-id-type="doi">10.1093/nar/gnj004</pub-id><pub-id pub-id-type="pmid">16397291</pub-id></element-citation></ref><ref id="bib88"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nevalainen</surname> <given-names>T</given-names></name><name><surname>Kananen</surname> <given-names>L</given-names></name><name><surname>Marttila</surname> <given-names>S</given-names></name><name><surname>Jylhävä</surname> <given-names>J</given-names></name><name><surname>Mononen</surname> <given-names>N</given-names></name><name><surname>Kähönen</surname> <given-names>M</given-names></name><name><surname>Raitakari</surname> <given-names>OT</given-names></name><name><surname>Hervonen</surname> <given-names>A</given-names></name><name><surname>Jylhä</surname> <given-names>M</given-names></name><name><surname>Lehtimäki</surname> <given-names>T</given-names></name><name><surname>Hurme</surname> <given-names>M</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Obesity accelerates epigenetic aging in middle-aged but not in elderly individuals</article-title><source>Clinical Epigenetics</source><volume>9</volume><elocation-id>20</elocation-id><pub-id pub-id-type="doi">10.1186/s13148-016-0301-7</pub-id><pub-id pub-id-type="pmid">28289477</pub-id></element-citation></ref><ref id="bib89"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ogrodnik</surname> <given-names>M</given-names></name><name><surname>Miwa</surname> <given-names>S</given-names></name><name><surname>Tchkonia</surname> <given-names>T</given-names></name><name><surname>Tiniakos</surname> <given-names>D</given-names></name><name><surname>Wilson</surname> <given-names>CL</given-names></name><name><surname>Lahat</surname> <given-names>A</given-names></name><name><surname>Day</surname> <given-names>CP</given-names></name><name><surname>Burt</surname> <given-names>A</given-names></name><name><surname>Palmer</surname> <given-names>A</given-names></name><name><surname>Anstee</surname> <given-names>QM</given-names></name><name><surname>Grellscheid</surname> <given-names>SN</given-names></name><name><surname>Hoeijmakers</surname> <given-names>JHJ</given-names></name><name><surname>Barnhoorn</surname> <given-names>S</given-names></name><name><surname>Mann</surname> <given-names>DA</given-names></name><name><surname>Bird</surname> <given-names>TG</given-names></name><name><surname>Vermeij</surname> <given-names>WP</given-names></name><name><surname>Kirkland</surname> <given-names>JL</given-names></name><name><surname>Passos</surname> <given-names>JF</given-names></name><name><surname>von Zglinicki</surname> <given-names>T</given-names></name><name><surname>Jurk</surname> <given-names>D</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Cellular senescence drives age-dependent hepatic steatosis</article-title><source>Nature Communications</source><volume>8</volume><elocation-id>15691</elocation-id><pub-id pub-id-type="doi">10.1038/ncomms15691</pub-id><pub-id pub-id-type="pmid">28608850</pub-id></element-citation></ref><ref id="bib90"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Orfanos</surname> <given-names>CE</given-names></name><name><surname>Vogels</surname> <given-names>L</given-names></name></person-group><year iso-8601-date="1980">1980</year><article-title>[Local therapy of androgenetic alopecia with 17 alpha-estradiol A controlled, randomized double-blind study (author's transl)]</article-title><source>Dermatologica</source><volume>161</volume><fpage>124</fpage><lpage>132</lpage><pub-id pub-id-type="pmid">7398983</pub-id></element-citation></ref><ref id="bib91"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Panet-Raymond</surname> <given-names>V</given-names></name><name><surname>Gottlieb</surname> <given-names>B</given-names></name><name><surname>Beitel</surname> <given-names>LK</given-names></name><name><surname>Pinsky</surname> <given-names>L</given-names></name><name><surname>Trifiro</surname> <given-names>MA</given-names></name></person-group><year iso-8601-date="2000">2000</year><article-title>Interactions between androgen and estrogen receptors and the effects on their transactivational properties</article-title><source>Molecular and Cellular Endocrinology</source><volume>167</volume><fpage>139</fpage><lpage>150</lpage><pub-id pub-id-type="doi">10.1016/S0303-7207(00)00279-3</pub-id><pub-id pub-id-type="pmid">11000528</pub-id></element-citation></ref><ref id="bib92"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Parks</surname> <given-names>BW</given-names></name><name><surname>Sallam</surname> <given-names>T</given-names></name><name><surname>Mehrabian</surname> <given-names>M</given-names></name><name><surname>Psychogios</surname> <given-names>N</given-names></name><name><surname>Hui</surname> <given-names>ST</given-names></name><name><surname>Norheim</surname> <given-names>F</given-names></name><name><surname>Castellani</surname> <given-names>LW</given-names></name><name><surname>Rau</surname> <given-names>CD</given-names></name><name><surname>Pan</surname> <given-names>C</given-names></name><name><surname>Phun</surname> <given-names>J</given-names></name><name><surname>Zhou</surname> <given-names>Z</given-names></name><name><surname>Yang</surname> <given-names>WP</given-names></name><name><surname>Neuhaus</surname> <given-names>I</given-names></name><name><surname>Gargalovic</surname> <given-names>PS</given-names></name><name><surname>Kirchgessner</surname> <given-names>TG</given-names></name><name><surname>Graham</surname> <given-names>M</given-names></name><name><surname>Lee</surname> <given-names>R</given-names></name><name><surname>Tontonoz</surname> <given-names>P</given-names></name><name><surname>Gerszten</surname> <given-names>RE</given-names></name><name><surname>Hevener</surname> <given-names>AL</given-names></name><name><surname>Lusis</surname> <given-names>AJ</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Genetic architecture of insulin resistance in the mouse</article-title><source>Cell Metabolism</source><volume>21</volume><fpage>334</fpage><lpage>347</lpage><pub-id pub-id-type="doi">10.1016/j.cmet.2015.01.002</pub-id><pub-id pub-id-type="pmid">25651185</pub-id></element-citation></ref><ref id="bib93"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pedram</surname> <given-names>A</given-names></name><name><surname>Razandi</surname> <given-names>M</given-names></name><name><surname>Blumberg</surname> <given-names>B</given-names></name><name><surname>Levin</surname> <given-names>ER</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Membrane and nuclear estrogen receptor α collaborate to suppress adipogenesis but not triglyceride content</article-title><source>The FASEB Journal</source><volume>30</volume><fpage>230</fpage><lpage>240</lpage><pub-id pub-id-type="doi">10.1096/fj.15-274878</pub-id><pub-id pub-id-type="pmid">26373802</pub-id></element-citation></ref><ref id="bib94"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pérez</surname> <given-names>LM</given-names></name><name><surname>Pareja-Galeano</surname> <given-names>H</given-names></name><name><surname>Sanchis-Gomar</surname> <given-names>F</given-names></name><name><surname>Emanuele</surname> <given-names>E</given-names></name><name><surname>Lucia</surname> <given-names>A</given-names></name><name><surname>Gálvez</surname> <given-names>BG</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>'Adipaging': ageing and obesity share biological hallmarks related to a dysfunctional adipose tissue</article-title><source>The Journal of Physiology</source><volume>594</volume><fpage>3187</fpage><lpage>3207</lpage><pub-id pub-id-type="doi">10.1113/JP271691</pub-id><pub-id pub-id-type="pmid">26926488</pub-id></element-citation></ref><ref id="bib95"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Peters</surname> <given-names>AA</given-names></name><name><surname>Buchanan</surname> <given-names>G</given-names></name><name><surname>Ricciardelli</surname> <given-names>C</given-names></name><name><surname>Bianco-Miotto</surname> <given-names>T</given-names></name><name><surname>Centenera</surname> <given-names>MM</given-names></name><name><surname>Harris</surname> <given-names>JM</given-names></name><name><surname>Jindal</surname> <given-names>S</given-names></name><name><surname>Segara</surname> <given-names>D</given-names></name><name><surname>Jia</surname> <given-names>L</given-names></name><name><surname>Moore</surname> <given-names>NL</given-names></name><name><surname>Henshall</surname> <given-names>SM</given-names></name><name><surname>Birrell</surname> <given-names>SN</given-names></name><name><surname>Coetzee</surname> <given-names>GA</given-names></name><name><surname>Sutherland</surname> <given-names>RL</given-names></name><name><surname>Butler</surname> <given-names>LM</given-names></name><name><surname>Tilley</surname> <given-names>WD</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>Androgen receptor inhibits estrogen receptor-alpha activity and is prognostic in breast Cancer</article-title><source>Cancer Research</source><volume>69</volume><fpage>6131</fpage><lpage>6140</lpage><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-09-0452</pub-id><pub-id pub-id-type="pmid">19638585</pub-id></element-citation></ref><ref id="bib96"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pocai</surname> <given-names>A</given-names></name><name><surname>Obici</surname> <given-names>S</given-names></name><name><surname>Schwartz</surname> <given-names>GJ</given-names></name><name><surname>Rossetti</surname> <given-names>L</given-names></name></person-group><year iso-8601-date="2005">2005a</year><article-title>A brain-liver circuit regulates glucose homeostasis</article-title><source>Cell Metabolism</source><volume>1</volume><fpage>53</fpage><lpage>61</lpage><pub-id pub-id-type="doi">10.1016/j.cmet.2004.11.001</pub-id><pub-id pub-id-type="pmid">16054044</pub-id></element-citation></ref><ref id="bib97"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pocai</surname> <given-names>A</given-names></name><name><surname>Lam</surname> <given-names>TK</given-names></name><name><surname>Gutierrez-Juarez</surname> <given-names>R</given-names></name><name><surname>Obici</surname> <given-names>S</given-names></name><name><surname>Schwartz</surname> <given-names>GJ</given-names></name><name><surname>Bryan</surname> <given-names>J</given-names></name><name><surname>Aguilar-Bryan</surname> <given-names>L</given-names></name><name><surname>Rossetti</surname> <given-names>L</given-names></name></person-group><year iso-8601-date="2005">2005b</year><article-title>Hypothalamic K(ATP) channels control hepatic glucose production</article-title><source>Nature</source><volume>434</volume><fpage>1026</fpage><lpage>1031</lpage><pub-id pub-id-type="doi">10.1038/nature03439</pub-id><pub-id pub-id-type="pmid">15846348</pub-id></element-citation></ref><ref id="bib98"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Qiu</surname> <given-names>S</given-names></name><name><surname>Vazquez</surname> <given-names>JT</given-names></name><name><surname>Boulger</surname> <given-names>E</given-names></name><name><surname>Liu</surname> <given-names>H</given-names></name><name><surname>Xue</surname> <given-names>P</given-names></name><name><surname>Hussain</surname> <given-names>MA</given-names></name><name><surname>Wolfe</surname> <given-names>A</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Hepatic estrogen receptor α is critical for regulation of gluconeogenesis and lipid metabolism in males</article-title><source>Scientific Reports</source><volume>7</volume><elocation-id>1661</elocation-id><pub-id pub-id-type="doi">10.1038/s41598-017-01937-4</pub-id><pub-id pub-id-type="pmid">28490809</pub-id></element-citation></ref><ref id="bib99"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Quehenberger</surname> <given-names>O</given-names></name><name><surname>Armando</surname> <given-names>AM</given-names></name><name><surname>Brown</surname> <given-names>AH</given-names></name><name><surname>Milne</surname> <given-names>SB</given-names></name><name><surname>Myers</surname> <given-names>DS</given-names></name><name><surname>Merrill</surname> <given-names>AH</given-names></name><name><surname>Bandyopadhyay</surname> <given-names>S</given-names></name><name><surname>Jones</surname> <given-names>KN</given-names></name><name><surname>Kelly</surname> <given-names>S</given-names></name><name><surname>Shaner</surname> <given-names>RL</given-names></name><name><surname>Sullards</surname> <given-names>CM</given-names></name><name><surname>Wang</surname> <given-names>E</given-names></name><name><surname>Murphy</surname> <given-names>RC</given-names></name><name><surname>Barkley</surname> <given-names>RM</given-names></name><name><surname>Leiker</surname> <given-names>TJ</given-names></name><name><surname>Raetz</surname> <given-names>CR</given-names></name><name><surname>Guan</surname> <given-names>Z</given-names></name><name><surname>Laird</surname> <given-names>GM</given-names></name><name><surname>Six</surname> <given-names>DA</given-names></name><name><surname>Russell</surname> <given-names>DW</given-names></name><name><surname>McDonald</surname> <given-names>JG</given-names></name><name><surname>Subramaniam</surname> <given-names>S</given-names></name><name><surname>Fahy</surname> <given-names>E</given-names></name><name><surname>Dennis</surname> <given-names>EA</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Lipidomics reveals a remarkable diversity of lipids in human plasma</article-title><source>Journal of Lipid Research</source><volume>51</volume><fpage>3299</fpage><lpage>3305</lpage><pub-id pub-id-type="doi">10.1194/jlr.M009449</pub-id><pub-id pub-id-type="pmid">20671299</pub-id></element-citation></ref><ref id="bib100"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Reese</surname> <given-names>JM</given-names></name><name><surname>Bruinsma</surname> <given-names>ES</given-names></name><name><surname>Nelson</surname> <given-names>AW</given-names></name><name><surname>Chernukhin</surname> <given-names>I</given-names></name><name><surname>Carroll</surname> <given-names>JS</given-names></name><name><surname>Li</surname> <given-names>Y</given-names></name><name><surname>Subramaniam</surname> <given-names>M</given-names></name><name><surname>Suman</surname> <given-names>VJ</given-names></name><name><surname>Negron</surname> <given-names>V</given-names></name><name><surname>Monroe</surname> <given-names>DG</given-names></name><name><surname>Ingle</surname> <given-names>JN</given-names></name><name><surname>Goetz</surname> <given-names>MP</given-names></name><name><surname>Hawse</surname> <given-names>JR</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>ERβ-mediated induction of cystatins results in suppression of tgfβ signaling and inhibition of triple-negative breast Cancer metastasis</article-title><source>PNAS</source><volume>115</volume><fpage>E9580</fpage><lpage>E9589</lpage><pub-id pub-id-type="doi">10.1073/pnas.1807751115</pub-id><pub-id pub-id-type="pmid">30257941</pub-id></element-citation></ref><ref id="bib101"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rosenfeld</surname> <given-names>CS</given-names></name><name><surname>Ganjam</surname> <given-names>VK</given-names></name><name><surname>Taylor</surname> <given-names>JA</given-names></name><name><surname>Yuan</surname> <given-names>X</given-names></name><name><surname>Stiehr</surname> <given-names>JR</given-names></name><name><surname>Hardy</surname> <given-names>MP</given-names></name><name><surname>Lubahn</surname> <given-names>DB</given-names></name></person-group><year iso-8601-date="1998">1998</year><article-title>Transcription and translation of estrogen receptor-beta in the male reproductive tract of estrogen receptor-alpha knock-out and wild-type mice</article-title><source>Endocrinology</source><volume>139</volume><fpage>2982</fpage><lpage>2987</lpage><pub-id pub-id-type="doi">10.1210/endo.139.6.6028</pub-id><pub-id pub-id-type="pmid">9607809</pub-id></element-citation></ref><ref id="bib102"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ross-Innes</surname> <given-names>CS</given-names></name><name><surname>Stark</surname> <given-names>R</given-names></name><name><surname>Teschendorff</surname> <given-names>AE</given-names></name><name><surname>Holmes</surname> <given-names>KA</given-names></name><name><surname>Ali</surname> <given-names>HR</given-names></name><name><surname>Dunning</surname> <given-names>MJ</given-names></name><name><surname>Brown</surname> <given-names>GD</given-names></name><name><surname>Gojis</surname> <given-names>O</given-names></name><name><surname>Ellis</surname> <given-names>IO</given-names></name><name><surname>Green</surname> <given-names>AR</given-names></name><name><surname>Ali</surname> <given-names>S</given-names></name><name><surname>Chin</surname> <given-names>SF</given-names></name><name><surname>Palmieri</surname> <given-names>C</given-names></name><name><surname>Caldas</surname> <given-names>C</given-names></name><name><surname>Carroll</surname> <given-names>JS</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Differential oestrogen receptor binding is associated with clinical outcome in breast cancer</article-title><source>Nature</source><volume>481</volume><fpage>389</fpage><lpage>393</lpage><pub-id pub-id-type="doi">10.1038/nature10730</pub-id><pub-id pub-id-type="pmid">22217937</pub-id></element-citation></ref><ref id="bib103"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rossi</surname> <given-names>R</given-names></name><name><surname>Origliani</surname> <given-names>G</given-names></name><name><surname>Modena</surname> <given-names>MG</given-names></name></person-group><year iso-8601-date="2004">2004</year><article-title>Transdermal 17-beta-estradiol and risk of developing type 2 diabetes in a population of healthy, nonobese postmenopausal women</article-title><source>Diabetes Care</source><volume>27</volume><fpage>645</fpage><lpage>649</lpage><pub-id pub-id-type="doi">10.2337/diacare.27.3.645</pub-id><pub-id pub-id-type="pmid">14988279</pub-id></element-citation></ref><ref id="bib104"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rubinow</surname> <given-names>KB</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Estrogens and body weight regulation in men</article-title><source>Advances in Experimental Medicine and Biology</source><volume>1043</volume><fpage>285</fpage><lpage>313</lpage><pub-id pub-id-type="doi">10.1007/978-3-319-70178-3_14</pub-id><pub-id pub-id-type="pmid">29224100</pub-id></element-citation></ref><ref id="bib105"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ruud</surname> <given-names>J</given-names></name><name><surname>Steculorum</surname> <given-names>SM</given-names></name><name><surname>Brüning</surname> <given-names>JC</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Neuronal control of peripheral insulin sensitivity and glucose metabolism</article-title><source>Nature Communications</source><volume>8</volume><elocation-id>15259</elocation-id><pub-id pub-id-type="doi">10.1038/ncomms15259</pub-id><pub-id pub-id-type="pmid">28469281</pub-id></element-citation></ref><ref id="bib106"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Salvestrini</surname> <given-names>V</given-names></name><name><surname>Sell</surname> <given-names>C</given-names></name><name><surname>Lorenzini</surname> <given-names>A</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Obesity may accelerate the aging process</article-title><source>Frontiers in Endocrinology</source><volume>10</volume><elocation-id>266</elocation-id><pub-id pub-id-type="doi">10.3389/fendo.2019.00266</pub-id><pub-id pub-id-type="pmid">31130916</pub-id></element-citation></ref><ref id="bib107"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sánchez-Criado</surname> <given-names>JE</given-names></name><name><surname>Trudgen</surname> <given-names>K</given-names></name><name><surname>Millán</surname> <given-names>Y</given-names></name><name><surname>Blanco</surname> <given-names>A</given-names></name><name><surname>Monterde</surname> <given-names>J</given-names></name><name><surname>Garrido-Gracia</surname> <given-names>JC</given-names></name><name><surname>Gordon</surname> <given-names>A</given-names></name><name><surname>Aguilar</surname> <given-names>R</given-names></name><name><surname>de Las Mulas</surname> <given-names>JM</given-names></name><name><surname>Ko</surname> <given-names>C</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Estrogen receptor (ESR) 2 partially offsets the absence of ESR1 in gonadotropes of pituitary-specific Esr1 knockout female mice</article-title><source>Reproduction</source><volume>143</volume><fpage>549</fpage><lpage>558</lpage><pub-id pub-id-type="doi">10.1530/REP-11-0214</pub-id><pub-id pub-id-type="pmid">22367588</pub-id></element-citation></ref><ref id="bib108"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sar</surname> <given-names>M</given-names></name><name><surname>Sahu</surname> <given-names>A</given-names></name><name><surname>Crowley</surname> <given-names>WR</given-names></name><name><surname>Kalra</surname> <given-names>SP</given-names></name></person-group><year iso-8601-date="1990">1990</year><article-title>Localization of neuropeptide-Y immunoreactivity in estradiol-concentrating cells in the hypothalamus</article-title><source>Endocrinology</source><volume>127</volume><fpage>2752</fpage><lpage>2756</lpage><pub-id pub-id-type="doi">10.1210/endo-127-6-2752</pub-id><pub-id pub-id-type="pmid">2249626</pub-id></element-citation></ref><ref id="bib109"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schriefers</surname> <given-names>H</given-names></name><name><surname>Wright</surname> <given-names>MC</given-names></name><name><surname>Rozman</surname> <given-names>T</given-names></name><name><surname>Hevert</surname> <given-names>F</given-names></name></person-group><year iso-8601-date="1991">1991</year><article-title>Inhibition of testosterone metabolism by 17-alpha-estradiol in rat liver slices]</article-title><source>Arzneimittel-Forschung</source><volume>41</volume><fpage>1186</fpage><lpage>1189</lpage><pub-id pub-id-type="pmid">1810267</pub-id></element-citation></ref><ref id="bib110"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sidhom</surname> <given-names>S</given-names></name><name><surname>Schneider</surname> <given-names>A</given-names></name><name><surname>Fang</surname> <given-names>Y</given-names></name><name><surname>McFadden</surname> <given-names>S</given-names></name><name><surname>Darcy</surname> <given-names>J</given-names></name><name><surname>Sathiaseelan</surname> <given-names>R</given-names></name><name><surname>Palmer</surname> <given-names>AK</given-names></name><name><surname>Steyn</surname> <given-names>FJ</given-names></name><name><surname>Grillari</surname> <given-names>J</given-names></name><name><surname>Kopchick</surname> <given-names>JJ</given-names></name><name><surname>Bartke</surname> <given-names>A</given-names></name><name><surname>Siddiqi</surname> <given-names>S</given-names></name><name><surname>Masternak</surname> <given-names>MM</given-names></name><name><surname>Stout</surname> <given-names>MB</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title><italic>17α-estradiol</italic> modulates IGF1 <italic>and hepatic gene expression in a Sex-Specific</italic> manner</article-title><source>The Journals of Gerontology: Series A</source><volume>28</volume><elocation-id>glaa215</elocation-id><pub-id pub-id-type="doi">10.1093/gerona/glaa215</pub-id></element-citation></ref><ref id="bib111"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Skinner</surname> <given-names>DC</given-names></name><name><surname>Herbison</surname> <given-names>AE</given-names></name></person-group><year iso-8601-date="1997">1997</year><article-title>Effects of photoperiod on estrogen receptor, tyrosine hydroxylase, neuropeptide Y, and beta-endorphin immunoreactivity in the ewe hypothalamus</article-title><source>Endocrinology</source><volume>138</volume><fpage>2585</fpage><lpage>2595</lpage><pub-id pub-id-type="doi">10.1210/endo.138.6.5208</pub-id><pub-id pub-id-type="pmid">9165052</pub-id></element-citation></ref><ref id="bib112"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Smith</surname> <given-names>AW</given-names></name><name><surname>Bosch</surname> <given-names>MA</given-names></name><name><surname>Wagner</surname> <given-names>EJ</given-names></name><name><surname>Rønnekleiv</surname> <given-names>OK</given-names></name><name><surname>Kelly</surname> <given-names>MJ</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>The membrane estrogen receptor ligand STX rapidly enhances GABAergic signaling in NPY/AgRP neurons: role in mediating the anorexigenic effects of 17β-estradiol</article-title><source>American Journal of Physiology-Endocrinology and Metabolism</source><volume>305</volume><fpage>E632</fpage><lpage>E640</lpage><pub-id pub-id-type="doi">10.1152/ajpendo.00281.2013</pub-id><pub-id pub-id-type="pmid">23820624</pub-id></element-citation></ref><ref id="bib113"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Smith</surname> <given-names>AW</given-names></name><name><surname>Rønnekleiv</surname> <given-names>OK</given-names></name><name><surname>Kelly</surname> <given-names>MJ</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Gq-mER signaling has opposite effects on hypothalamic orexigenic and anorexigenic neurons</article-title><source>Steroids</source><volume>81</volume><fpage>31</fpage><lpage>35</lpage><pub-id pub-id-type="doi">10.1016/j.steroids.2013.11.007</pub-id><pub-id pub-id-type="pmid">24269736</pub-id></element-citation></ref><ref id="bib114"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stefanska</surname> <given-names>A</given-names></name><name><surname>Bergmann</surname> <given-names>K</given-names></name><name><surname>Sypniewska</surname> <given-names>G</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Metabolic syndrome and menopause: pathophysiology, clinical and diagnostic significance</article-title><source>Advances in Clinical Chemistry</source><volume>72</volume><fpage>1</fpage><lpage>75</lpage><pub-id pub-id-type="doi">10.1016/bs.acc.2015.07.001</pub-id><pub-id pub-id-type="pmid">26471080</pub-id></element-citation></ref><ref id="bib115"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Steyn</surname> <given-names>FJ</given-names></name><name><surname>Ngo</surname> <given-names>ST</given-names></name><name><surname>Chen</surname> <given-names>VP</given-names></name><name><surname>Bailey-Downs</surname> <given-names>LC</given-names></name><name><surname>Xie</surname> <given-names>TY</given-names></name><name><surname>Ghadami</surname> <given-names>M</given-names></name><name><surname>Brimijoin</surname> <given-names>S</given-names></name><name><surname>Freeman</surname> <given-names>WM</given-names></name><name><surname>Rubinstein</surname> <given-names>M</given-names></name><name><surname>Low</surname> <given-names>MJ</given-names></name><name><surname>Stout</surname> <given-names>MB</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>17α-estradiol acts through hypothalamic pro-opiomelanocortin expressing neurons to reduce feeding behavior</article-title><source>Aging Cell</source><volume>17</volume><elocation-id>e12703</elocation-id><pub-id pub-id-type="doi">10.1111/acel.12703</pub-id></element-citation></ref><ref id="bib116"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stincic</surname> <given-names>TL</given-names></name><name><surname>Rønnekleiv</surname> <given-names>OK</given-names></name><name><surname>Kelly</surname> <given-names>MJ</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Diverse actions of estradiol on anorexigenic and orexigenic hypothalamic arcuate neurons</article-title><source>Hormones and Behavior</source><volume>104</volume><fpage>146</fpage><lpage>155</lpage><pub-id pub-id-type="doi">10.1016/j.yhbeh.2018.04.001</pub-id><pub-id pub-id-type="pmid">29626486</pub-id></element-citation></ref><ref id="bib117"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stout</surname> <given-names>MB</given-names></name><name><surname>Liu</surname> <given-names>LF</given-names></name><name><surname>Belury</surname> <given-names>MA</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Hepatic steatosis by dietary-conjugated linoleic acid is accompanied by accumulation of diacylglycerol and increased membrane-associated protein kinase C ε in mice</article-title><source>Molecular Nutrition &amp; Food Research</source><volume>55</volume><fpage>1010</fpage><lpage>1017</lpage><pub-id pub-id-type="doi">10.1002/mnfr.201000413</pub-id><pub-id pub-id-type="pmid">21480517</pub-id></element-citation></ref><ref id="bib118"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stout</surname> <given-names>MB</given-names></name><name><surname>Justice</surname> <given-names>JN</given-names></name><name><surname>Nicklas</surname> <given-names>BJ</given-names></name><name><surname>Kirkland</surname> <given-names>JL</given-names></name></person-group><year iso-8601-date="2017">2017a</year><article-title><italic>Physiological aging: links among adipose tissue dysfunction</italic>, Diabetes<italic>, and Frailty</italic></article-title><source>Physiology</source><volume>32</volume><fpage>9</fpage><lpage>19</lpage><pub-id pub-id-type="doi">10.1152/physiol.00012.2016</pub-id><pub-id pub-id-type="pmid">27927801</pub-id></element-citation></ref><ref id="bib119"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stout</surname> <given-names>MB</given-names></name><name><surname>Steyn</surname> <given-names>FJ</given-names></name><name><surname>Jurczak</surname> <given-names>MJ</given-names></name><name><surname>Camporez</surname> <given-names>J-PG</given-names></name><name><surname>Zhu</surname> <given-names>Y</given-names></name><name><surname>Hawse</surname> <given-names>JR</given-names></name><name><surname>Jurk</surname> <given-names>D</given-names></name><name><surname>Palmer</surname> <given-names>AK</given-names></name><name><surname>Xu</surname> <given-names>M</given-names></name><name><surname>Pirtskhalava</surname> <given-names>T</given-names></name><name><surname>Evans</surname> <given-names>GL</given-names></name><name><surname>de Souza Santos</surname> <given-names>R</given-names></name><name><surname>Frank</surname> <given-names>AP</given-names></name><name><surname>White</surname> <given-names>TA</given-names></name><name><surname>Monroe</surname> <given-names>DG</given-names></name><name><surname>Singh</surname> <given-names>RJ</given-names></name><name><surname>Casaclang-Verzosa</surname> <given-names>G</given-names></name><name><surname>Miller</surname> <given-names>JD</given-names></name><name><surname>Clegg</surname> <given-names>DJ</given-names></name><name><surname>LeBrasseur</surname> <given-names>NK</given-names></name><name><surname>von Zglinicki</surname> <given-names>T</given-names></name><name><surname>Shulman</surname> <given-names>GI</given-names></name><name><surname>Tchkonia</surname> <given-names>T</given-names></name><name><surname>Kirkland</surname> <given-names>JL</given-names></name></person-group><year iso-8601-date="2017">2017b</year><article-title>17α-estradiol alleviates Age-related metabolic and inflammatory dysfunction in male mice without inducing feminization</article-title><source>The Journals of Gerontology Series A: Biological Sciences and Medical Sciences</source><volume>72</volume><fpage>3</fpage><lpage>15</lpage><pub-id pub-id-type="doi">10.1093/gerona/glv309</pub-id></element-citation></ref><ref id="bib120"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Strong</surname> <given-names>R</given-names></name><name><surname>Miller</surname> <given-names>RA</given-names></name><name><surname>Antebi</surname> <given-names>A</given-names></name><name><surname>Astle</surname> <given-names>CM</given-names></name><name><surname>Bogue</surname> <given-names>M</given-names></name><name><surname>Denzel</surname> <given-names>MS</given-names></name><name><surname>Fernandez</surname> <given-names>E</given-names></name><name><surname>Flurkey</surname> <given-names>K</given-names></name><name><surname>Hamilton</surname> <given-names>KL</given-names></name><name><surname>Lamming</surname> <given-names>DW</given-names></name><name><surname>Javors</surname> <given-names>MA</given-names></name><name><surname>de Magalhães</surname> <given-names>JP</given-names></name><name><surname>Martinez</surname> <given-names>PA</given-names></name><name><surname>McCord</surname> <given-names>JM</given-names></name><name><surname>Miller</surname> <given-names>BF</given-names></name><name><surname>Müller</surname> <given-names>M</given-names></name><name><surname>Nelson</surname> <given-names>JF</given-names></name><name><surname>Ndukum</surname> <given-names>J</given-names></name><name><surname>Rainger</surname> <given-names>GE</given-names></name><name><surname>Richardson</surname> <given-names>A</given-names></name><name><surname>Sabatini</surname> <given-names>DM</given-names></name><name><surname>Salmon</surname> <given-names>AB</given-names></name><name><surname>Simpkins</surname> <given-names>JW</given-names></name><name><surname>Steegenga</surname> <given-names>WT</given-names></name><name><surname>Nadon</surname> <given-names>NL</given-names></name><name><surname>Harrison</surname> <given-names>DE</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Longer lifespan in male mice treated with a weakly estrogenic agonist, an antioxidant, an α-glucosidase inhibitor or a Nrf2-inducer</article-title><source>Aging Cell</source><volume>15</volume><fpage>872</fpage><lpage>884</lpage><pub-id pub-id-type="doi">10.1111/acel.12496</pub-id><pub-id pub-id-type="pmid">27312235</pub-id></element-citation></ref><ref id="bib121"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stubbins</surname> <given-names>RE</given-names></name><name><surname>Holcomb</surname> <given-names>VB</given-names></name><name><surname>Hong</surname> <given-names>J</given-names></name><name><surname>Núñez</surname> <given-names>NP</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Estrogen modulates abdominal adiposity and protects female mice from obesity and impaired glucose tolerance</article-title><source>European Journal of Nutrition</source><volume>51</volume><fpage>861</fpage><lpage>870</lpage><pub-id pub-id-type="doi">10.1007/s00394-011-0266-4</pub-id><pub-id pub-id-type="pmid">22042005</pub-id></element-citation></ref><ref id="bib122"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Szefel</surname> <given-names>J</given-names></name><name><surname>Kruszewski</surname> <given-names>WJ</given-names></name><name><surname>Sobczak</surname> <given-names>E</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Factors influencing the eicosanoids synthesis in vivo</article-title><source>BioMed Research International</source><volume>2015</volume><elocation-id>690692</elocation-id><pub-id pub-id-type="doi">10.1155/2015/690692</pub-id><pub-id pub-id-type="pmid">25861641</pub-id></element-citation></ref><ref id="bib123"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tao</surname> <given-names>R</given-names></name><name><surname>Wang</surname> <given-names>C</given-names></name><name><surname>Stöhr</surname> <given-names>O</given-names></name><name><surname>Qiu</surname> <given-names>W</given-names></name><name><surname>Hu</surname> <given-names>Y</given-names></name><name><surname>Miao</surname> <given-names>J</given-names></name><name><surname>Dong</surname> <given-names>XC</given-names></name><name><surname>Leng</surname> <given-names>S</given-names></name><name><surname>Stefater</surname> <given-names>M</given-names></name><name><surname>Stylopoulos</surname> <given-names>N</given-names></name><name><surname>Lin</surname> <given-names>L</given-names></name><name><surname>Copps</surname> <given-names>KD</given-names></name><name><surname>White</surname> <given-names>MF</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Inactivating hepatic follistatin alleviates hyperglycemia</article-title><source>Nature Medicine</source><volume>24</volume><fpage>1058</fpage><lpage>1069</lpage><pub-id pub-id-type="doi">10.1038/s41591-018-0048-0</pub-id><pub-id pub-id-type="pmid">29867232</pub-id></element-citation></ref><ref id="bib124"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Taylor</surname> <given-names>SE</given-names></name><name><surname>Martin-Hirsch</surname> <given-names>PL</given-names></name><name><surname>Martin</surname> <given-names>FL</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Oestrogen receptor splice variants in the pathogenesis of disease</article-title><source>Cancer Letters</source><volume>288</volume><fpage>133</fpage><lpage>148</lpage><pub-id pub-id-type="doi">10.1016/j.canlet.2009.06.017</pub-id><pub-id pub-id-type="pmid">19608332</pub-id></element-citation></ref><ref id="bib125"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tchkonia</surname> <given-names>T</given-names></name><name><surname>Morbeck</surname> <given-names>DE</given-names></name><name><surname>Von Zglinicki</surname> <given-names>T</given-names></name><name><surname>Van Deursen</surname> <given-names>J</given-names></name><name><surname>Lustgarten</surname> <given-names>J</given-names></name><name><surname>Scrable</surname> <given-names>H</given-names></name><name><surname>Khosla</surname> <given-names>S</given-names></name><name><surname>Jensen</surname> <given-names>MD</given-names></name><name><surname>Kirkland</surname> <given-names>JL</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Fat tissue, aging, and cellular senescence</article-title><source>Aging Cell</source><volume>9</volume><fpage>667</fpage><lpage>684</lpage><pub-id pub-id-type="doi">10.1111/j.1474-9726.2010.00608.x</pub-id><pub-id pub-id-type="pmid">20701600</pub-id></element-citation></ref><ref id="bib126"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Timper</surname> <given-names>K</given-names></name><name><surname>Brüning</surname> <given-names>JC</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Hypothalamic circuits regulating appetite and energy homeostasis: pathways to obesity</article-title><source>Disease Models &amp; Mechanisms</source><volume>10</volume><fpage>679</fpage><lpage>689</lpage><pub-id pub-id-type="doi">10.1242/dmm.026609</pub-id><pub-id pub-id-type="pmid">28592656</pub-id></element-citation></ref><ref id="bib127"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Toran-Allerand</surname> <given-names>CD</given-names></name><name><surname>Guan</surname> <given-names>X</given-names></name><name><surname>MacLusky</surname> <given-names>NJ</given-names></name><name><surname>Horvath</surname> <given-names>TL</given-names></name><name><surname>Diano</surname> <given-names>S</given-names></name><name><surname>Singh</surname> <given-names>M</given-names></name><name><surname>Connolly</surname> <given-names>ES</given-names></name><name><surname>Nethrapalli</surname> <given-names>IS</given-names></name><name><surname>Tinnikov</surname> <given-names>AA</given-names></name></person-group><year iso-8601-date="2002">2002</year><article-title>ER-X: a novel, plasma membrane-associated, putative estrogen receptor that is regulated during development and after ischemic brain injury</article-title><source>The Journal of Neuroscience</source><volume>22</volume><fpage>8391</fpage><lpage>8401</lpage><pub-id pub-id-type="doi">10.1523/JNEUROSCI.22-19-08391.2002</pub-id><pub-id pub-id-type="pmid">12351713</pub-id></element-citation></ref><ref id="bib128"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Toran-Allerand</surname> <given-names>CD</given-names></name></person-group><year iso-8601-date="2005">2005</year><article-title>Estrogen and the brain: beyond ER-alpha, ER-beta, and 17beta-estradiol</article-title><source>Annals of the New York Academy of Sciences</source><volume>1052</volume><fpage>136</fpage><lpage>144</lpage><pub-id pub-id-type="doi">10.1196/annals.1347.009</pub-id><pub-id pub-id-type="pmid">16024756</pub-id></element-citation></ref><ref id="bib129"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Toran-Allerand</surname> <given-names>CD</given-names></name><name><surname>Tinnikov</surname> <given-names>AA</given-names></name><name><surname>Singh</surname> <given-names>RJ</given-names></name><name><surname>Nethrapalli</surname> <given-names>IS</given-names></name></person-group><year iso-8601-date="2005">2005</year><article-title>17alpha-estradiol: a brain-active estrogen?</article-title><source>Endocrinology</source><volume>146</volume><fpage>3843</fpage><lpage>3850</lpage><pub-id pub-id-type="doi">10.1210/en.2004-1616</pub-id><pub-id pub-id-type="pmid">15947006</pub-id></element-citation></ref><ref id="bib130"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Torre</surname> <given-names>D</given-names></name><name><surname>Lolli</surname> <given-names>F</given-names></name><name><surname>Ciana</surname> <given-names>P</given-names></name><name><surname>Maggi</surname> <given-names>A</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Sexual dimorphism and estrogen action in mouse liver</article-title><source>Advances in Experimental Medicine and Biology</source><volume>1043</volume><fpage>141</fpage><lpage>151</lpage><pub-id pub-id-type="doi">10.1007/978-3-319-70178-3_8</pub-id><pub-id pub-id-type="pmid">29224094</pub-id></element-citation></ref><ref id="bib131"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tyshkovskiy</surname> <given-names>A</given-names></name><name><surname>Bozaykut</surname> <given-names>P</given-names></name><name><surname>Borodinova</surname> <given-names>AA</given-names></name><name><surname>Gerashchenko</surname> <given-names>MV</given-names></name><name><surname>Ables</surname> <given-names>GP</given-names></name><name><surname>Garratt</surname> <given-names>M</given-names></name><name><surname>Khaitovich</surname> <given-names>P</given-names></name><name><surname>Clish</surname> <given-names>CB</given-names></name><name><surname>Miller</surname> <given-names>RA</given-names></name><name><surname>Gladyshev</surname> <given-names>VN</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Identification and application of gene expression signatures associated with lifespan extension</article-title><source>Cell Metabolism</source><volume>30</volume><fpage>573</fpage><lpage>593</lpage><pub-id pub-id-type="doi">10.1016/j.cmet.2019.06.018</pub-id><pub-id pub-id-type="pmid">31353263</pub-id></element-citation></ref><ref id="bib132"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tzanetakou</surname> <given-names>IP</given-names></name><name><surname>Katsilambros</surname> <given-names>NL</given-names></name><name><surname>Benetos</surname> <given-names>A</given-names></name><name><surname>Mikhailidis</surname> <given-names>DP</given-names></name><name><surname>Perrea</surname> <given-names>DN</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>&quot;Is obesity linked to aging?&quot;: adipose tissue and the role of telomeres</article-title><source>Ageing Research Reviews</source><volume>11</volume><fpage>220</fpage><lpage>229</lpage><pub-id pub-id-type="doi">10.1016/j.arr.2011.12.003</pub-id><pub-id pub-id-type="pmid">22186032</pub-id></element-citation></ref><ref id="bib133"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Veldhuis</surname> <given-names>JD</given-names></name><name><surname>Mielke</surname> <given-names>KL</given-names></name><name><surname>Cosma</surname> <given-names>M</given-names></name><name><surname>Soares-Welch</surname> <given-names>C</given-names></name><name><surname>Paulo</surname> <given-names>R</given-names></name><name><surname>Miles</surname> <given-names>JM</given-names></name><name><surname>Bowers</surname> <given-names>CY</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>Aromatase and 5alpha-reductase inhibition during an exogenous testosterone clamp unveils selective sex steroid modulation of somatostatin and growth hormone secretagogue actions in healthy older men</article-title><source>The Journal of Clinical Endocrinology &amp; Metabolism</source><volume>94</volume><fpage>973</fpage><lpage>981</lpage><pub-id pub-id-type="doi">10.1210/jc.2008-2108</pub-id><pub-id pub-id-type="pmid">19088159</pub-id></element-citation></ref><ref id="bib134"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vidal</surname> <given-names>O</given-names></name><name><surname>Lindberg</surname> <given-names>M</given-names></name><name><surname>Sävendahl</surname> <given-names>L</given-names></name><name><surname>Lubahn</surname> <given-names>DB</given-names></name><name><surname>Ritzen</surname> <given-names>EM</given-names></name><name><surname>Gustafsson</surname> <given-names>JA</given-names></name><name><surname>Ohlsson</surname> <given-names>C</given-names></name></person-group><year iso-8601-date="1999">1999</year><article-title>Disproportional body growth in female estrogen receptor-alpha-inactivated mice</article-title><source>Biochemical and Biophysical Research Communications</source><volume>265</volume><fpage>569</fpage><lpage>571</lpage><pub-id pub-id-type="doi">10.1006/bbrc.1999.1711</pub-id><pub-id pub-id-type="pmid">10558910</pub-id></element-citation></ref><ref id="bib135"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Villareal</surname> <given-names>DT</given-names></name><name><surname>Apovian</surname> <given-names>CM</given-names></name><name><surname>Kushner</surname> <given-names>RF</given-names></name><name><surname>Klein</surname> <given-names>S</given-names></name><collab>American Society for Nutrition</collab><collab>NAASO, The Obesity Society</collab></person-group><year iso-8601-date="2005">2005</year><article-title>Obesity in older adults: technical review and position statement of the american society for nutrition and NAASO, the obesity society</article-title><source>Obesity Research</source><volume>13</volume><fpage>1849</fpage><lpage>1863</lpage><pub-id pub-id-type="doi">10.1038/oby.2005.228</pub-id><pub-id pub-id-type="pmid">16339115</pub-id></element-citation></ref><ref id="bib136"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname> <given-names>Z</given-names></name><name><surname>Zhang</surname> <given-names>X</given-names></name><name><surname>Shen</surname> <given-names>P</given-names></name><name><surname>Loggie</surname> <given-names>BW</given-names></name><name><surname>Chang</surname> <given-names>Y</given-names></name><name><surname>Deuel</surname> <given-names>TF</given-names></name></person-group><year iso-8601-date="2005">2005</year><article-title>Identification, cloning, and expression of human estrogen receptor-alpha36, a novel variant of human estrogen receptor-alpha66</article-title><source>Biochemical and Biophysical Research Communications</source><volume>336</volume><fpage>1023</fpage><lpage>1027</lpage><pub-id pub-id-type="doi">10.1016/j.bbrc.2005.08.226</pub-id><pub-id pub-id-type="pmid">16165085</pub-id></element-citation></ref><ref id="bib137"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Waters</surname> <given-names>DL</given-names></name><name><surname>Ward</surname> <given-names>AL</given-names></name><name><surname>Villareal</surname> <given-names>DT</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Weight loss in obese adults 65years and older: a review of the controversy</article-title><source>Experimental Gerontology</source><volume>48</volume><fpage>1054</fpage><lpage>1061</lpage><pub-id pub-id-type="doi">10.1016/j.exger.2013.02.005</pub-id><pub-id pub-id-type="pmid">23403042</pub-id></element-citation></ref><ref id="bib138"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wei</surname> <given-names>L</given-names></name><name><surname>Lai</surname> <given-names>EC</given-names></name><name><surname>Kao-Yang</surname> <given-names>YH</given-names></name><name><surname>Walker</surname> <given-names>BR</given-names></name><name><surname>MacDonald</surname> <given-names>TM</given-names></name><name><surname>Andrew</surname> <given-names>R</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Incidence of type 2 diabetes mellitus in men receiving steroid 5alpha-reductase inhibitors: population based cohort study</article-title><source>BMJ</source><volume>365</volume><elocation-id>l1204</elocation-id><pub-id pub-id-type="doi">10.1136/bmj.l1204</pub-id><pub-id pub-id-type="pmid">30971393</pub-id></element-citation></ref><ref id="bib139"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Whitmer</surname> <given-names>RA</given-names></name><name><surname>Gunderson</surname> <given-names>EP</given-names></name><name><surname>Barrett-Connor</surname> <given-names>E</given-names></name><name><surname>Quesenberry</surname> <given-names>CP</given-names></name><name><surname>Yaffe</surname> <given-names>K</given-names></name></person-group><year iso-8601-date="2005">2005a</year><article-title>Obesity in middle age and future risk of dementia: a 27 year longitudinal population based study</article-title><source>BMJ</source><volume>330</volume><elocation-id>1360</elocation-id><pub-id pub-id-type="doi">10.1136/bmj.38446.466238.E0</pub-id><pub-id pub-id-type="pmid">15863436</pub-id></element-citation></ref><ref id="bib140"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Whitmer</surname> <given-names>RA</given-names></name><name><surname>Sidney</surname> <given-names>S</given-names></name><name><surname>Selby</surname> <given-names>J</given-names></name><name><surname>Johnston</surname> <given-names>SC</given-names></name><name><surname>Yaffe</surname> <given-names>K</given-names></name></person-group><year iso-8601-date="2005">2005b</year><article-title>Midlife cardiovascular risk factors and risk of dementia in late life</article-title><source>Neurology</source><volume>64</volume><fpage>277</fpage><lpage>281</lpage><pub-id pub-id-type="doi">10.1212/01.WNL.0000149519.47454.F2</pub-id><pub-id pub-id-type="pmid">15668425</pub-id></element-citation></ref><ref id="bib141"><element-citation publication-type="confproc"><person-group person-group-type="author"><name><surname>Xiong</surname> <given-names>Y</given-names></name><name><surname>Lei</surname> <given-names>QY</given-names></name><name><surname>Zhao</surname> <given-names>S</given-names></name><name><surname>Guan</surname> <given-names>KL</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Regulation of glycolysis and gluconeogenesis by acetylation of PKM and PEPCK</article-title><conf-name>Cold Spring Harbor Symposia on Quantitative Biology</conf-name><fpage>285</fpage><lpage>289</lpage></element-citation></ref><ref id="bib142"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xu</surname> <given-names>Y</given-names></name><name><surname>Nedungadi</surname> <given-names>TP</given-names></name><name><surname>Zhu</surname> <given-names>L</given-names></name><name><surname>Sobhani</surname> <given-names>N</given-names></name><name><surname>Irani</surname> <given-names>BG</given-names></name><name><surname>Davis</surname> <given-names>KE</given-names></name><name><surname>Zhang</surname> <given-names>X</given-names></name><name><surname>Zou</surname> <given-names>F</given-names></name><name><surname>Gent</surname> <given-names>LM</given-names></name><name><surname>Hahner</surname> <given-names>LD</given-names></name><name><surname>Khan</surname> <given-names>SA</given-names></name><name><surname>Elias</surname> <given-names>CF</given-names></name><name><surname>Elmquist</surname> <given-names>JK</given-names></name><name><surname>Clegg</surname> <given-names>DJ</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Distinct hypothalamic neurons mediate estrogenic effects on energy homeostasis and reproduction</article-title><source>Cell Metabolism</source><volume>14</volume><fpage>453</fpage><lpage>465</lpage><pub-id pub-id-type="doi">10.1016/j.cmet.2011.08.009</pub-id><pub-id pub-id-type="pmid">21982706</pub-id></element-citation></ref><ref id="bib143"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yan</surname> <given-names>H</given-names></name><name><surname>Yang</surname> <given-names>W</given-names></name><name><surname>Zhou</surname> <given-names>F</given-names></name><name><surname>Li</surname> <given-names>X</given-names></name><name><surname>Pan</surname> <given-names>Q</given-names></name><name><surname>Shen</surname> <given-names>Z</given-names></name><name><surname>Han</surname> <given-names>G</given-names></name><name><surname>Newell-Fugate</surname> <given-names>A</given-names></name><name><surname>Tian</surname> <given-names>Y</given-names></name><name><surname>Majeti</surname> <given-names>R</given-names></name><name><surname>Liu</surname> <given-names>W</given-names></name><name><surname>Xu</surname> <given-names>Y</given-names></name><name><surname>Wu</surname> <given-names>C</given-names></name><name><surname>Allred</surname> <given-names>K</given-names></name><name><surname>Allred</surname> <given-names>C</given-names></name><name><surname>Sun</surname> <given-names>Y</given-names></name><name><surname>Guo</surname> <given-names>S</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Estrogen improves insulin sensitivity and suppresses gluconeogenesis via the transcription factor Foxo1</article-title><source>Diabetes</source><volume>68</volume><fpage>291</fpage><lpage>304</lpage><pub-id pub-id-type="doi">10.2337/db18-0638</pub-id><pub-id pub-id-type="pmid">30487265</pub-id></element-citation></ref><ref id="bib144"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yang</surname> <given-names>H</given-names></name><name><surname>Youm</surname> <given-names>YH</given-names></name><name><surname>Vandanmagsar</surname> <given-names>B</given-names></name><name><surname>Rood</surname> <given-names>J</given-names></name><name><surname>Kumar</surname> <given-names>KG</given-names></name><name><surname>Butler</surname> <given-names>AA</given-names></name><name><surname>Dixit</surname> <given-names>VD</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>Obesity accelerates thymic aging</article-title><source>Blood</source><volume>114</volume><fpage>3803</fpage><lpage>3812</lpage><pub-id pub-id-type="doi">10.1182/blood-2009-03-213595</pub-id><pub-id pub-id-type="pmid">19721009</pub-id></element-citation></ref><ref id="bib145"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yang</surname> <given-names>L</given-names></name><name><surname>Miura</surname> <given-names>K</given-names></name><name><surname>Zhang</surname> <given-names>B</given-names></name><name><surname>Matsushita</surname> <given-names>H</given-names></name><name><surname>Yang</surname> <given-names>YM</given-names></name><name><surname>Liang</surname> <given-names>S</given-names></name><name><surname>Song</surname> <given-names>J</given-names></name><name><surname>Roh</surname> <given-names>YS</given-names></name><name><surname>Seki</surname> <given-names>E</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>TRIF differentially regulates hepatic steatosis and inflammation/Fibrosis in mice</article-title><source>Cellular and Molecular Gastroenterology and Hepatology</source><volume>3</volume><fpage>469</fpage><lpage>483</lpage><pub-id pub-id-type="doi">10.1016/j.jcmgh.2016.12.004</pub-id><pub-id pub-id-type="pmid">28462384</pub-id></element-citation></ref><ref id="bib146"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yang</surname> <given-names>L</given-names></name><name><surname>Fu</surname> <given-names>WL</given-names></name><name><surname>Zhu</surname> <given-names>Y</given-names></name><name><surname>Wang</surname> <given-names>XG</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Tβ4 suppresses lincRNA-p21-mediated hepatic apoptosis and fibrosis by inhibiting PI3K-AKT-NF-κB pathway</article-title><source>Gene</source><volume>758</volume><elocation-id>144946</elocation-id><pub-id pub-id-type="doi">10.1016/j.gene.2020.144946</pub-id><pub-id pub-id-type="pmid">32649978</pub-id></element-citation></ref><ref id="bib147"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yu</surname> <given-names>M</given-names></name><name><surname>Benham</surname> <given-names>A</given-names></name><name><surname>Logan</surname> <given-names>S</given-names></name><name><surname>Brush</surname> <given-names>RS</given-names></name><name><surname>Mandal</surname> <given-names>MN</given-names></name><name><surname>Anderson</surname> <given-names>RE</given-names></name><name><surname>Agbaga</surname> <given-names>MP</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>ELOVL4 protein preferentially elongates 20:5n3 to very long chain PUFAs over 20:4n6 and 22:6n3</article-title><source>Journal of Lipid Research</source><volume>53</volume><fpage>494</fpage><lpage>504</lpage><pub-id pub-id-type="doi">10.1194/jlr.M021386</pub-id><pub-id pub-id-type="pmid">22158834</pub-id></element-citation></ref><ref id="bib148"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname> <given-names>Y</given-names></name><name><surname>Liu</surname> <given-names>T</given-names></name><name><surname>Meyer</surname> <given-names>CA</given-names></name><name><surname>Eeckhoute</surname> <given-names>J</given-names></name><name><surname>Johnson</surname> <given-names>DS</given-names></name><name><surname>Bernstein</surname> <given-names>BE</given-names></name><name><surname>Nusbaum</surname> <given-names>C</given-names></name><name><surname>Myers</surname> <given-names>RM</given-names></name><name><surname>Brown</surname> <given-names>M</given-names></name><name><surname>Li</surname> <given-names>W</given-names></name><name><surname>Liu</surname> <given-names>XS</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>Model-based analysis of ChIP-Seq (MACS)</article-title><source>Genome Biology</source><volume>9</volume><elocation-id>R137</elocation-id><pub-id pub-id-type="doi">10.1186/gb-2008-9-9-r137</pub-id><pub-id pub-id-type="pmid">18798982</pub-id></element-citation></ref><ref id="bib149"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname> <given-names>H</given-names></name><name><surname>Liu</surname> <given-names>Y</given-names></name><name><surname>Wang</surname> <given-names>L</given-names></name><name><surname>Li</surname> <given-names>Z</given-names></name><name><surname>Zhang</surname> <given-names>H</given-names></name><name><surname>Wu</surname> <given-names>J</given-names></name><name><surname>Rahman</surname> <given-names>N</given-names></name><name><surname>Guo</surname> <given-names>Y</given-names></name><name><surname>Li</surname> <given-names>D</given-names></name><name><surname>Li</surname> <given-names>N</given-names></name><name><surname>Huhtaniemi</surname> <given-names>I</given-names></name><name><surname>Tsang</surname> <given-names>SY</given-names></name><name><surname>Gao</surname> <given-names>GF</given-names></name><name><surname>Li</surname> <given-names>X</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Differential effects of estrogen/androgen on the prevention of nonalcoholic fatty liver disease in the male rat</article-title><source>Journal of Lipid Research</source><volume>54</volume><fpage>345</fpage><lpage>357</lpage><pub-id pub-id-type="doi">10.1194/jlr.M028969</pub-id><pub-id pub-id-type="pmid">23175777</pub-id></element-citation></ref><ref id="bib150"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname> <given-names>J</given-names></name><name><surname>Ren</surname> <given-names>J</given-names></name><name><surname>Wei</surname> <given-names>J</given-names></name><name><surname>Chong</surname> <given-names>CC</given-names></name><name><surname>Yang</surname> <given-names>D</given-names></name><name><surname>He</surname> <given-names>Y</given-names></name><name><surname>Chen</surname> <given-names>GG</given-names></name><name><surname>Lai</surname> <given-names>PB</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Alternative splicing of estrogen receptor alpha in hepatocellular carcinoma</article-title><source>BMC Cancer</source><volume>16</volume><elocation-id>926</elocation-id><pub-id pub-id-type="doi">10.1186/s12885-016-2928-3</pub-id><pub-id pub-id-type="pmid">27899088</pub-id></element-citation></ref><ref id="bib151"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname> <given-names>X</given-names></name><name><surname>Yang</surname> <given-names>S</given-names></name><name><surname>Chen</surname> <given-names>J</given-names></name><name><surname>Su</surname> <given-names>Z</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Unraveling the regulation of hepatic gluconeogenesis</article-title><source>Frontiers in Endocrinology</source><volume>9</volume><elocation-id>802</elocation-id><pub-id pub-id-type="doi">10.3389/fendo.2018.00802</pub-id><pub-id pub-id-type="pmid">30733709</pub-id></element-citation></ref><ref id="bib152"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhu</surname> <given-names>L</given-names></name><name><surname>Brown</surname> <given-names>WC</given-names></name><name><surname>Cai</surname> <given-names>Q</given-names></name><name><surname>Krust</surname> <given-names>A</given-names></name><name><surname>Chambon</surname> <given-names>P</given-names></name><name><surname>McGuinness</surname> <given-names>OP</given-names></name><name><surname>Stafford</surname> <given-names>JM</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Estrogen treatment after ovariectomy protects against fatty liver and may improve pathway-selective insulin resistance</article-title><source>Diabetes</source><volume>62</volume><fpage>424</fpage><lpage>434</lpage><pub-id pub-id-type="doi">10.2337/db11-1718</pub-id><pub-id pub-id-type="pmid">22966069</pub-id></element-citation></ref><ref id="bib153"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhu</surname> <given-names>L</given-names></name><name><surname>Martinez</surname> <given-names>MN</given-names></name><name><surname>Emfinger</surname> <given-names>CH</given-names></name><name><surname>Palmisano</surname> <given-names>BT</given-names></name><name><surname>Stafford</surname> <given-names>JM</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Estrogen signaling prevents diet-induced hepatic insulin resistance in male mice with obesity</article-title><source>American Journal of Physiology-Endocrinology and Metabolism</source><volume>306</volume><fpage>E1188</fpage><lpage>E1197</lpage><pub-id pub-id-type="doi">10.1152/ajpendo.00579.2013</pub-id><pub-id pub-id-type="pmid">24691030</pub-id></element-citation></ref></ref-list></back><sub-article article-type="decision-letter" id="sa1"><front-stub><article-id pub-id-type="doi">10.7554/eLife.59616.sa1</article-id><title-group><article-title>Decision letter</article-title></title-group><contrib-group><contrib contrib-type="editor"><name><surname>Buffenstein</surname><given-names>Rochelle</given-names></name><role>Reviewing Editor</role><aff><institution>Calico Life Sciences, LLC</institution><country>United States</country></aff></contrib></contrib-group><contrib-group><contrib contrib-type="reviewer"><name><surname>Kimmel</surname><given-names>Jacob C</given-names></name><role>Reviewer</role><aff><institution>University of California, San Francisco</institution><country>United States</country></aff></contrib></contrib-group></front-stub><body><boxed-text><p>In the interests of transparency, eLife publishes the most substantive revision requests and the accompanying author responses.</p></boxed-text><p><bold>Acceptance summary:</bold></p><p>This manuscript expands upon and provides an important mechanistic explanation for previous published studies reporting that treatment with 17α-estradiol (17α-E2), extends lifespan in male mice and also reverses the harmful metabolic changes associated with obesity. The authors confirm through genomic and knock out studies that this effect is dependent upon the presence of the estrogen receptor a rather than a novel receptor as was previously speculated. Moreover, they elucidate a potential mechanism that contributes to the longevity extending effects of 17α-E2 by life extending effects primarily to modulating hypothalamic and hepatic glucose metabolism.</p><p><bold>Decision letter after peer review:</bold></p><p>Thank you for submitting your article &quot;Health benefits attributed to 17α-estradiol, a lifespan-extending compound, are mediated through estrogen receptor α&quot; for consideration by <italic>eLife</italic>. Your article has been reviewed by four peer reviewers, one of whom is a member of our Board of Reviewing Editors, and the evaluation has been overseen Jessica Tyler as the Senior Editor. The following individual involved in review of your submission has agreed to reveal their identity: Jacob C Kimmel (Reviewer #3).</p><p>The reviewers have discussed the reviews with one another and the Reviewing Editor has drafted this decision to help you prepare a revised submission.</p><p>As the editors have judged that your manuscript is of interest, but as described below that additional experiments are required before it is published, we would like to draw your attention to changes in our revision policy that we have made in response to COVID-19 (https://elifesciences.org/articles/57162). First, because many researchers have temporarily lost access to the labs, we will give authors as much time as they need to submit revised manuscripts. We are also offering, if you choose, to post the manuscript to bioRxiv (if it is not already there) along with this decision letter and a formal designation that the manuscript is &quot;in revision at <italic>eLife</italic>&quot;. Please let us know if you would like to pursue this option. (If your work is more suitable for medRxiv, you will need to post the preprint yourself, as the mechanisms for us to do so are still in development.)</p><p>Summary:</p><p>This work has the potential to make an important original contribution to the aging biology literature and includes interesting new findings regarding the role of 17α-E2 in lifespan extension. The authors provide persuasive evidence of the role of classic estradiol receptor ERα in 17α-E2 signaling and mediating the metabolic effects of 17α-E2. However, far reaching and unsupported claims are made regarding the central tenets of this manuscript as is stated in their Abstract – namely sex-specific differences and that of tissue specific mediation of 17α-E2 effects facilitating the therapeutic benefit. While the tissue specific data are suggestive that the liver and hypothalamus facilitate the beneficial effects of 17α-E2, these data do not appear to have been appropriately statistically analyzed. These need to be addressed prior to publication.</p><p>The authors need to provide additional evidence for the tissue-specific nature of 17α-E2s effects on metabolism and lifespan, as well as correct/redo/undertake their statistical analyses using appropriate methods. Moreover, the experimental design needs to be more clearly documented and the data presented in a legible and interpretable manner. As such, the manuscript requires a complete reanalysis of current data and a complete rewrite, before we could consider its publication in <italic>eLife</italic>.</p><p>Essential revisions:</p><p>1) The experimental design needs to be more clearly documented, and the data presented in legible figures with detailed legends that alert the reader to the salient methods and findings. The authors should include a brief rational for each of the experiments used and their choice of cells and provide a concise description of the methods used, and sample size. The authors need to articulate how the significance for RNA-seq and ChIP-seq data was assessed.</p><p>2) If the authors already have the complementary data on female mice on a high fat diet (rather than on normal chow) to facilitate a direct comparison with the male mice on a high fat diet and, thereby, support their sex-specific claims, it would strengthen the paper considerably, if not their claims on sex specificity should be removed from this paper as one cannot directly compare females on normal chow with males on a HFD.</p><p>3) The authors state that their ChIP-seq data reveal nearly identical ERα binding patterns with17α-E2 and 17β-E2, however these have not been rigorously analyzed. The authors need to undertake actual statistical comparisons across groups rather than rely solely on qualitative assessments.</p><p>4) The authors need to provide additional evidence for the tissue-specific nature of 17α-E2s effects on metabolism and lifespan. While they present convincing data that administration of 17α-E2 has direct effects on liver and hypothalamus, they have not provided definitive evidence that these tissues are directly responsible for the beneficial effects on metabolism and lifespan. The Abstract and Results section should be appropriately tempered.</p><p>5) The authors claim that 17α-E2 reverses cellular senescence in the liver but provide limited conclusive supporting data. The authors need to provide additional evidence to support these claims.</p><p>6) The motif comparison for the ChIP-seq data in Figure 1B is not described sufficiently to allow for evaluation by readers. Moreover, the authors do not appear to have employed appropriate statistical analyses. Please describe the statistical tests employed.</p><p>[Editors' note: further revisions were suggested prior to acceptance, as described below.]</p><p>Thank you for resubmitting your article &quot;Health benefits attributed to 17α-estradiol, a lifespan-extending compound, are mediated through estrogen receptor α&quot; for consideration by <italic>eLife</italic>. Your article has been reviewed by Jessica Tyler as the Senior Editor, a Reviewing Editor, and three reviewers. The following individual involved in review of your submission this round has agreed to reveal their identity: Rozalyn Anderson (Reviewer #6).</p><p>The reviewers have discussed the reviews with one another and the Reviewing Editor has drafted this decision to help you prepare a revised submission. Overall, all agree the manuscript has been vastly improved, however several key concerns were ignored in your revision and still need to be addressed before this article can be accepted for publication.</p><p>The genomics analyses remain difficult to interpret and the prior request for clearer, more interpretable figures was ignored. Please redo these figures, as per the comments from the first set of reviewers.</p><p>Moreover, the Materials and methods are insufficient for reproduction, and some relevant statistical tests are omitted. These statistical information should be included within the body of the manuscript adjacent to the specific results in which they were used.</p><p>The female data remain problematic and while there are understandable issues with KO females; given the differing experimental designs and the fact that the bulk of the data are exclusively in males, we believe that the paper would be considerably stronger if these inconclusive data on females given their different treatments/diet were excluded from the paper and the Abstract as well. as the paper modified accordingly. We are not asking for additional data.</p><p>The text should be tightened up, removing speculative conclusions not based. upon the data presented. The manuscript and in particular the Abstract still contains unsupported claims that 17α-E2 acts through liver and hypothalamus, despite the authors pointing out that this claim is &quot;speculation&quot; later in the Discussion.</p><p>Below please find the reviewer's comments.</p><p><italic>Reviewer #3:</italic></p><p>The authors have made considerable improvements to the original manuscript. However, some concerns remain that should be addressed. While the descriptions are improved, the authors' genomics analyses remain difficult to interpret from the unchanged figures, the Materials and methods are insufficient for reproduction, and some relevant statistical tests are omitted. The authors have appropriately moderated their claims of tissue-specific mediators of 17-E2 benefit, but the original, unqualified claims nonetheless remain in the Abstract.</p><p>Essential revisions:</p><p>1) The p-values presented in Figure 1B are still much smaller than those present in the supplementary data (Supplementary file 1). For instance, the first motif listed in Figure 1B shows p-values at log10(p) = -5000, but the lowest in the table is ~-2000. What accounts for this discrepancy?</p><p>2) The claim that there are &quot;no differences in the binding motifs identified between treatment groups&quot; suggests a statistical comparison was performed across all pairwise combinations of treatment groups. Is this the case? If so, the tests should be specified in the Figure legend and explicitly described in the Materials and methods (e.g. We performed pairwise comparisons between treatment groups…). It also seems plausible that there may be differences in the enrichment of ERα among its motifs depending on the ligand. Rather than making binary calls for motif identification/non-identification, the authors should compare the enrichment levels across treatment groups (hypergeometric would again be appropriate).</p><p>3) The manuscript still contains prominent claims that 17α-E2 acts through liver and hypothalamus, despite the authors pointing out that this claim is &quot;speculation&quot; later in the manuscript. The Abstract contains &quot;that 17α-E2 acts primarily through the liver and hypothalamus to improve metabolic parameters&quot; while the later Introduction states &quot;we speculate that 17α-E2 acts through ERα in the liver and/or hypothalamus to improve metabolic homeostasis in male mammals&quot; and the Results state &quot;…suggests that the liver and hypothalamus are two primary sites of action for the regulation of metabolic parameters by 17α-E2.&quot; The authors should adopt the latter qualifications for all such statements. As agreed in their response to reviewers, they do not present evidence to support the former, stronger claim that remains prominently in the Abstract.</p><p><italic>Reviewer #6:</italic></p><p>The manuscript is much improved, the central message is certainly of interest and the genetic component adds pretty convincing evidence that the 17-α-E2 is indeed working through or at least requires the ERα receptor to improve metabolic indices in male mice on a high fat diet.</p><p>The authors have been very responsive to the concerns raised – I think it would be no harm at all to name the statistical tests used in the body of the paper not just to have them better described in the Materials and methods which they have done as per the Editor's suggestion.</p><p>The Discussion is a little redundant in places with the Result section – the authors might want to trim out the repetition so that the major points of Discussion, context, and interpretation are not lost to the reader.</p><p><italic>Reviewer #7:</italic></p><p>Authors have nicely addressed most of the previous concerns.</p><p>The Female data are still problematic. Due to the differing design, interpretation is unknown whether difference is due to females, due to diet, etc. Understandable there are issues with the KO female, but suggest perhaps removing these data. Particularly since the remainder of data are in males exclusively.</p></body></sub-article><sub-article article-type="reply" id="sa2"><front-stub><article-id pub-id-type="doi">10.7554/eLife.59616.sa2</article-id><title-group><article-title>Author response</article-title></title-group></front-stub><body><disp-quote content-type="editor-comment"><p>Essential revisions:</p><p>1) The experimental design needs to be more clearly documented, and the data presented in legible figures with detailed legends that alert the reader to the salient methods and findings. The authors should include a brief rational for each of the experiments used and their choice of cells and provide a concise description of the methods used, and sample size. The authors need to articulate how the significance for RNA-seq and ChIP-seq data was assessed.</p></disp-quote><p>We appreciate these suggestions and apologize for our initial submission lacking appropriate detail. In response to these requests, we:</p><p>a) completely reanalyzed all of the data and rewrote several sections of the manuscript to include more detail related to the experimental design and statistical approaches employed</p><p>b) significantly expanded the figure legends by including more detail related to approach and analyses</p><p>c) added brief rationales to the Results section and Materials and methods section for each experiment undertaken</p><p>d) significantly expanded methodological and statistical sections describing how the RNA-seq and ChIP-seq experiments were performed and analysed.</p><disp-quote content-type="editor-comment"><p>2) If the authors already have the complementary data on female mice on a high fat diet (rather than on normal chow) to facilitate a direct comparison with the male mice on a high fat diet and, thereby, support their sex-specific claims, it would strengthen the paper considerably, if not their claims on sex specificity should be removed from this paper as one cannot directly compare females on normal chow with males on a HFD.</p></disp-quote><p>We understand that the decision to place male mice on high-fat diets and female mice on chow diets could be confusing, so we provided additional background on the ERα KO model and a rationale for why this was done. As is now stated in the manuscript (Discussion), “female mice present a greater phenotypic response than males to the ablation of ERα, thereby exacerbating obesity and metabolic dysfunction which makes comparisons to female WT mice as well as their male littermates problematic. For this reason, we chose not to provide HFD to female mice in these studies.” In addition to providing more detail about our rationale, we have also tempered our conclusions throughout the manuscript related to sexually dimorphic effects of 17α-E2 in our studies.&lt;bold /&gt;<italic>3) The authors state that their ChIP-seq data reveal nearly identical ERα binding patterns with 17α-E2 and 17β-E2, however these have not been rigorously analyzed. The authors need to undertake actual statistical comparisons across groups rather than rely solely on qualitative assessments.</italic></p><p>We apologize that the statistical analyses we used to compare the ChIP-seq data were poorly described in our initial submission. We have now significantly expanded the methodological and statistical sections describing how the ChIP-seq experiments were performed and analyzed.</p><disp-quote content-type="editor-comment"><p>4) The authors need to provide additional evidence for the tissue-specific nature of 17α-E2s effects on metabolism and lifespan. While they present convincing data that administration of 17α-E2 has direct effects on liver and hypothalamus, they have not provided definitive evidence that these tissues are directly responsible for the beneficial effects on metabolism and lifespan. The Abstract and Results section should be appropriately tempered.</p></disp-quote><p>We appreciate this concern and have tempered our conclusions within the manuscript to convey that our data are highly suggestive of tissue-specific effects of 17α-E2 actions, but that additional studies will be needed to definitively prove this. In the final paragraph of the Discussion we state that, “Future studies will be needed to confirm that 17α-E2 acts predominantly through ERα in a cell-type-specific manner in the liver and hypothalamus to modulate systemic metabolic homeostasis”.</p><disp-quote content-type="editor-comment"><p>5) The authors claim that 17α-E2 reverses cellular senescence in the liver but provide limited conclusive supporting data. The authors need to provide additional evidence to support these claims.</p></disp-quote><p>We agree that our data does not allow for any definitive conclusions to be drawn regarding how 17α-E2 modulates cellular senescence in the liver, therefore we removed any reference to this in the text. This portion of the manuscript and Figure 5 now focuses exclusively on markers of liver fibrosis and insulin sensitivity.</p><disp-quote content-type="editor-comment"><p>6) The motif comparison for the ChIP-seq data in Figure 1B is not described sufficiently to allow for evaluation by readers. Moreover, the authors do not appear to have employed appropriate statistical analyses. Please describe the statistical tests employed.</p></disp-quote><p>We apologize that the statistical analyses we used to analyze the ChIP-seq data were poorly described in our initial submission. We have significantly expanded the methodological and statistical sections describing how the ChIP-seq and motif enrichment analyses were performed and analyzed, and additional citations were also added.</p><p>[Editors' note: further revisions were suggested prior to acceptance, as described below.]</p><disp-quote content-type="editor-comment"><p>Reviewer #3:</p><p>The authors have made considerable improvements to the original manuscript. However, some concerns remain that should be addressed. While the descriptions are improved, the authors' genomics analyses remain difficult to interpret from the unchanged figures, the Materials and methods are insufficient for reproduction, and some relevant statistical tests are omitted. The authors have appropriately moderated their claims of tissue-specific mediators of 17-E2 benefit, but the original, unqualified claims nonetheless remain in the Abstract.</p></disp-quote><p>We thank reviewer #3 for their suggestions. We have addressed all concerns in a detailed fashion below.&lt;bold /&gt;<italic>Essential revisions:</italic></p><disp-quote content-type="editor-comment"><p>1) The p-values presented in Figure 1B are still much smaller than those present in the supplementary data (Supplementary file 1). For instance, the first motif listed in Figure 1B shows p-values at log10(p) = -5000, but the lowest in the table is ~-2000. What accounts for this discrepancy?</p></disp-quote><p>We apologize for the confusion related to this. In the revised Figure 1C the log p-value is presented which corresponds to column E in Supplementary file 2. The former Supplementary file 1 is now Supplementary file 2 because we added an additional Supplementary file that corresponds to the new Figure 1B.&lt;bold /&gt;<italic>2) The claim that there are &quot;no differences in the binding motifs identified between treatment groups&quot; suggests a statistical comparison was performed across all pairwise combinations of treatment groups. Is this the case? If so, the tests should be specified in the Figure legend and explicitly described in the Materials and methods (e.g. We performed pairwise comparisons between treatment groups…). It also seems plausible that there may be differences in the enrichment of ERα among its motifs depending on the ligand. Rather than making binary calls for motif identification/non-identification, the authors should compare the enrichment levels across treatment groups (hypergeometric would again be appropriate).</italic></p><p>The presentation of the ERα ChIP-seq data has been extensively revised. First, the Figure 1 panels have been updated to clarify axes and labels. Second, a new panel (Figure 1B) has been added to more clearly demonstrate that ERα binds to the same genomic locations and to similar magnitudes with both 17α-E2 and 17β-E2 exposure. We have also clarified our findings in the Results, Materials and methods, and figure legends while noting the specific statistical tests used. Regarding the question related to differential motif enrichment, there were no differences between 17α-E2 and 17β-E2 in the motif enrichment, which is aligned with the observation that ERα is binding to the same genomic locations following exposure to both ligands.</p><disp-quote content-type="editor-comment"><p>3) The manuscript still contains prominent claims that 17α-E2 acts through liver and hypothalamus, despite the authors pointing out that this claim is &quot;speculation&quot; later in the manuscript. The Abstract contains &quot;that 17α-E2 acts primarily through the liver and hypothalamus to improve metabolic parameters&quot; while the later Introduction states &quot;we speculate that 17α-E2 acts through ERα in the liver and/or hypothalamus to improve metabolic homeostasis in male mammals&quot; and the Results state &quot;…suggests that the liver and hypothalamus are two primary sites of action for the regulation of metabolic parameters by 17α-E2.&quot; The authors should adopt the latter qualifications for all such statements. As agreed in their response to reviewers, they do not present evidence to support the former, stronger claim that remains prominently in the Abstract.</p></disp-quote><p>We appreciate this astute observation by the reviewer and have updated the Abstract to reflect the tempered conclusions in other parts of manuscript.</p><disp-quote content-type="editor-comment"><p>Reviewer #6:</p><p>The manuscript is much improved, the central message is certainly of interest and the genetic component adds pretty convincing evidence that the 17-α-E2 is indeed working through or at least requires the ERα receptor to improve metabolic indices in male mice on a high fat diet.</p></disp-quote><p>We thank reviewer #6 for their kind words and suggestions. We have addressed all concerns in a detailed fashion below.&lt;bold /&gt;</p><disp-quote content-type="editor-comment"><p>The authors have been very responsive to the concerns raised – I think it would be no harm at all to name the statistical tests used in the body of the paper not just to have them better described in the Materials and methods which they have done as per the Editor's suggestion.</p></disp-quote><p>We have expanded the details on the statistical tests used in the Results, text, figure legends, and Materials and methods.</p><disp-quote content-type="editor-comment"><p>The Discussion is a little redundant in places with the result section – the authors might want to trim out the repetition so that the major points of discussion, context, and interpretation are not lost to the reader.</p></disp-quote><p>We appreciate this suggestion and have further refined the Discussion.</p><disp-quote content-type="editor-comment"><p>Reviewer #7:</p><p>Authors have nicely addressed most of the previous concerns.</p></disp-quote><p>We thank reviewer #7 for their kind words and suggestions. We have addressed the concerns related to the inclusion of female mice below.&lt;bold /&gt;&lt;italic /&gt;</p><disp-quote content-type="editor-comment"><p>The Female data are still problematic. Due to the differing design, interpretation is unknown whether difference is due to females, due to diet, etc. Understandable there are issues with the KO female, but suggest perhaps removing these data. Particularly since the remainder of data are in males exclusively.</p></disp-quote><p>We appreciate this suggestion, but feel the female data is sufficiently interpretable and supports other publications in the field. Additionally, since our previous resubmission to <italic>eLife</italic> we have published a report demonstrating that OVX in females engenders 17α-E2 responsiveness, which supports our contention that endogenous 17β-E2 plays a key role in rendering female mice unresponsive to exogenous 17α-E2 treatment. This new publication (Mann et al., 2020), coupled with the genomic and transcriptional data presented in the current report (Figure 1, Figure 1—figure supplement 1, Supplementary file 1, Supplementary file 2), allows for clearer interpretation of the female data from the current set of studies. Of particular relevance, we are not the first group to report that 17α-E2 has limited effectiveness on a variety of variables in intact female mice (see Strong et al., 2016, Harrison et al., 2014, Garratt et al., 2017, PMID: 30740872); therefore, our female data presented herein that demonstrates a lack of effects of 17α-E2 on metabolic variables supports previous reports. Lastly, we also explicitly describe within the manuscript our rationale for not subjecting female mice to high-fat feeding (the ERαKO naturally develops obesity) and discuss the importance of future studies evaluating the effects of 17α-E2 in female mice following diet-induced obesity (HFD), which we openly acknowledge was not done in the current set of experiments. In an effort to find common ground, we have further tempered our conclusions related to our observations in female mice in these studies.</p></body></sub-article></article>